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Summary
Summary
The switch from a petrol based economy to a biobased economy has brought
researchers to investigate how biotechnology may be utilized to create cell facto-
ries producing already known compounds, while production of new-to-nature or
designed compounds are also receiving attention. The understanding of natural
product chemistry has long been improving, especially with the application of
molecular biology to investigate the enzymatic machinery behind the biosynthesis
of natural products. The understanding of polyketide synthases, which produces
the natural products polyketides, has also brought about engineering attempts of
these complex enzymes and it has to some degree been possible to design novel
polyketide scaffolds. The goal of this PhD project was to investigate the possibility
to create a programmable platform for creation of polyketides with a given chain
length and folding pattern.
Initially, the possibility of combining type III PKSs with cyclases from type
II PKS systems with Saccharomyces cerevisiae as production organism was inves-
tigated (Chapter 3 - Manuscript I). This approach was an attempt to divide the
polyketide chain synthesis and the folding of the polyketide chain, into different
enzymes making combinatorial experiments possible. It was found that a variety
type III PKSs were functionally expressed in S. cerevisiae producing polyketide
chains of C6 to C16 depending on the expressed PKS. With the combination of
the C16 producing octaketide synthase (OKS) and two different cyclases directing
either the C7-C12 or C9-C14 folding patterns, it was shown that it was possible
to direct the folding of the type III PKS polyketide product. This was a proof-
of-concept step towards making a platform to design polyketides with a certain
chain length and folding pattern.
Next, we wanted to investigate if it was possible to utilize the knowledge gained
in the initial study to produce flavokermesic acid, which is a precursor of the indus-
trial colorant carminic acid (Chapter 4 - Manuscript II). The pathway to produce
flavokermesic acid consisting of a type III PKS and two cyclases had previously
been expressed in Nicotiana benthamiana and Aspergillus nidulans. The aim of
this study was to investigate if utilizing S. cerevisiae as a cell factory produc-
tion host was feasible, as well as investigating if fusion of biosynthetic enzymes
would limit shunt products of the pathway, and thereby improve the production
of flavokermesic acid. It was found that S. cerevisiae was able to produce 52 mg
flavokermesic acid per liter of medium if the biosynthetic enzymes were not fused,
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while all versions of the fused biosynthetic enzymes were found to have reduced
levels of flavokermesic acid, compared to the non-fused version. Two more tailoring
steps are needed in order to synthesize carminic acid from flavokermesic acid, but
the work presented here shows the potential of the platform to create a polyketide
scaffold, which can be developed into an industrially important compound.
For the platform to be fully developed the incorporation of tailoring enzymes
to alter the polyketide scaffolds are needed. To gain insight into a natural sys-
tem, evolved to generate a high chemical diversity of polyketides, investigation of
the pgl1 gene cluster in the fungal genus Fusarium was conducted (Chapter 5 -
Manuscript III). The investigation had two aims. The first being to investigate
the diversity of the biosynthetic gene cluster throughout the genus of Fusarium,
and the second being to propose a biosynthetic model for the chemical diversity
thought to be derived form the pgl1 biosynthetic cluster. The genes in the biosyn-
thetic gene cluster were found to be highly conserved across the genus while the
topology of the cluster was found to be less conserved, especially in the species
complexes solani, decemcellulare and buxicola. It was proposed that these species
within these species complexes could contain more biosynthetic activities in the
pgl1 cluster than other species in the Fusarium genus. This was an interesting
hypothesis as the biosynthetic steps needed to create the chemodiversity found in
the putative biosynthetic pathway, included many more enzymatic activities than
what is included in currently identified biosynthetic cluster. This could either
mean that more genes are implicated in the biosynthetic pathway, that some of
the needed conversions happen spontaneously, or that the biosynthetic enzymes
are promiscuous and therefore have low substrate specificity and may have several
enzymatic specificities.
In summary, this PhD project has investigated the possibilities of creating a
programmable platform for production of aromatic polyketides in S. cerevisiae,
which allow control of chain length and folding pattern. Furthermore it has in-
vestigated what enzymatic machinery is employed in nature to derivatize a given
polyketide scaffold. This work lays the foundation for further development of the
platform to expand polyketide diversity with longer polyketide chains and cyclases
to direct more of the folding of the polyketide chain, and furthermore, to attempt
introduction of tailoring enzymes to fully develop the chemodiversity, which is
possible to create with the platform.
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Sammenfatning
Sammenfatning
Overgangen fra en fossilbaseret økonomi til en biobaseret økonomi har ledt forskere
til at undersøge, hvordan bioteknologi kan udnyttes til at skabe cellefabrikker, der
producerer allerede kendte forbindelser, mens produktionen af new-to-nature eller
designede forbindelser også modtager opmærksomhed. Kendskabet til naturstofkemi
har længe været i fremgang, især via anvendelse af molekylærbiologi til at under-
søge det enzymatiske maskineri bag biosyntesen af naturstoffer. Forståelsen af
polyketidsyntaser, som producerer naturstofferne polyketider, har også medført
ingeniørmæssige tiltag for at manipulere disse komplekse enzymer, og det har i
nogen grad været muligt at designe nye polyketid afledte stoffer. Målet med dette
Ph.D.-projekt var at undersøge muligheden for at skabe en programmerbar plat-
form til dannelse af polyketider med en given kædelængde og foldemønster.
Indledningsvis blev muligheden for at kombinere type III PKS’er med cyklaser
fra type II PKS systemer, med Saccharomyces cerevisiaese som produktionsorgan-
isme, undersøgt (Kapitel 3 - Manuskript I). Denne fremgangsmåde var et forsøg på
at opdele polyketidkædesyntesen og foldningen af polyketidkæden i forskellige en-
zymer, hvilket ville muliggøre kombinatoriske eksperimenter. Det blev fundet, at
en række type III PKS’er var funktionelt udtrykt i S. cerevisiae, og producerende
polyketidkæder af C6 til C16 afhængigt af den udtrykte PKS. Ved kombination af
den C16 producerende oktaketid syntase (OKS) og to forskellige cyklaser, der styr-
erede enten C7-C12 eller C9-C14 foldemønstre, blev det vist, at det var muligt at
styre foldningen af type III PKS polyketidproduktet. Dette var et proof-of-concept
mod at skabe en platform til at designe polyketider med en given kædelængde og
foldemønster.
Dernæst ønskede vi at undersøge, om det var muligt at udnytte den viden,
der blev gundlagt i det første studie til at fremstille flavokermessyre, som er et
forstadie til det industrielle farvestof karminsyre (Kapitel 4 - Manuskript II). Den
syntetiske biosyntesevej til fremstilling af flavokermesyre bestående af en type III
PKS og to cyclaser havde tidligere blevet udtrykt i Nicotiana benthamiana og
Aspergillus nidulans. Formålet med dette studie var at undersøge, om udnyttelse
af S. cerevisiaeas som cellefabrik til netop denne biosyntesevej var muligt, samt
at undersøge, om fusion af de biosyntetiske enzymer ville begrænse side produk-
terne fra biosyntesevejen og dermed hæve produktionen af flavokermesyre. Det
blev konstateret, at S. cerevisiae producerede 52 mg flavokermesyre per liter me-
die, hvis de biosyntetiske enzymer ikke var fusioneret, imens alle versioner af de
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fusionerede biosyntetiske enzymer blev fundet til at reducere niveauet af flavok-
ermesyre sammenlignet med den ikke fusionerede version. Der er behov for to
yderligere biosyntese trin for at syntetisere karminsyre fra flavokermesyre, men
det nuværende studie viste potentialet i platformen til at producere et polyketid,
der kan udvikles til et industrielt vigtigt stof.
For at platformen kan blive fuldt udviklet, er det nødvendigt at inkorporere en-
zymer til at danne deriviater af polyketid skeletterne. For at få indsigt i et naturligt
system, der har udviklet sig til at generere en høj kemisk diversitet af polyketider,
blev en undersøgelse af pgl1 gen clusteret i svampeslægten Fusarium gennemført
(Kapitel 5 - Manuskript III). Undersøgelsen havde to formål. Det første var at
undersøge mangfoldigheden af det biosyntetiske gen cluster i Fusarium slægten,
og det andet formal var at foreslå en biosyntetisk model for den kemiske mang-
foldighed, der menes at være afledt af det biosyntetiske cluster pgl1. Generne i den
biosyntetiske cluster viste sig at være stærkt konserverede gennem hele slægten,
mens clusterens topologi viste sig at være mindre konserveret, især i artskomplek-
serne solani, decemcellulare og buxicola. Derfor blev det foreslået, at arter indenfor
disse artskomplekser kunne indeholde flere biosyntetiske gener i pgl1 gen clusteret
end andre arter i Fusarium slægten. Dette var en interessant hypotese, da de
biosyntetiske trin, der var nødvendige for at skabe den kemodiversitet, der blev
fundet i den foreslåede biosyntetiske vej, omfattede flere enzymatiske aktiviteter
end hvad der kunne forklares med det nuværende identificerede biosyntetiske clus-
ter. Dette kan enten betyde, at flere gener er impliceret i biosyntesen, at nogle af
de nødvendige trin sker spontant eller at de biosyntetiske enzymer er promiskuøse
og dermed har lav substratspecificitet og har flere enzymatiske specificiteter.
For at opsummere har dette Ph.D. projekt undersøgt mulighederne for at skabe
en programmerbar platform til produktion af aromatiske polyketider i S. cere-
visiae, som tillader kontrol af kædelængde og foldemønster. Endvidere har det
undersøgt, hvilke enzymatiske mekanismer der anvendes i naturen til at derivatis-
ere et givent polyketid skelet. Dette projekt ligger grundlaget for videreudvikling
af platformen for at udvide polyketid diversiteten med længere polyketidkæder og
flere cyclaser for at styre foldningen af polyketidkæden og endvidere at forsøge at
indføre enzymer til deriviaterere polyketid skelettet og dermed at fuldt udvikle
kemodiversiteten, det er mulig med platformen.
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1 Project motivation and aim
1.1 Project motivation
As the issues of the petrol based economy has arisen and the options of switch-
ing to a biobased economy begun to be investigated. To reach this goal many
new biological solutions have to be developed as the range of products and com-
modities derived from the petrochemical industry is large. These range from bulk
chemicals such as fuels, over commodity chemicals such as plastics to fine chemi-
cals such as pharmaceuticals [1, 2]. The development of cell factories to produce
such compounds based only on biological materials are underway from many sides
and focus is given on many different parts of the process such as diversification
of possible growth substrate for production [3, 4], increasing output of a selected
metabolic pathway by metabolic engineering [5] as well as development of the
product range to replace more of the petroleum derived compounds [6, 7]. An im-
portant compound group within the fine chemicals are polyketides of which many
are used as medicine [8] or as additives to food and cosmetics [9]. The realisation
of the biobased economy requires the development of new compounds within all
classes of chemicals and engineering efforts has created toolboxes to design specific
polyketides [10, 11, 12].
1.2 Project aim and thesis outline
The overall goal of the work presented in this thesis was to develop a platform
to produce aromatic polyketides in a programmable fashion in the industrial
workhorse Saccharomyces cerevisiae. The choice of S. cerevisiae as the organ-
ism for the platform was that it had been used for the construction of many
different biosynthetic pathways [13, 14] and amplification of a pathway of choice
to improve production titers [15, 16]. One solution for creating a programmable
biosynthetic pathway is to divide pathway product formation into distinct steps
(modules) and then attempt to control them individually. In the case of producing
aromatic polyketides the biosynthetic problem can be divided into the formation
of the backbone polyketide chain, and secondly the folding of this chain to yield
1
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the desired cyclic structure. A key concept in synthetic biology is modularity in
design, and control over the two described steps would allow for production of a
large array of polyketide backbones.
Specific aims for the given project were as follows:
1. Devise and provide proof-of-concept for a programmable platform that allows
for the production of cyclic and aromatic polyketides in S. cerevisiae
2. Evaluate the potential for the production of a relevant industrial chemical
utilizing the platform
3. Investigate how further derivation of polyketides are processed in nature
These aims have been addressed throughout the project, which have resulted
in three manuscripts. The content of the thesis is outlined here:
Chapter 2 - Theoretical background of polyketide synthesis to understand the
production of polyketides in nature, while also giving insight into past strategies
to engineer various type of polyketide producing enzymatic machineries.
Chapter 3 - Describes the proof-of-concept for a programmable platform in
S. cerevisiae to create cyclic and aromatic polyketides by combination of type III
PKSs and cyclases from type II PKS systems.
Chapter 4 - Describes the establishment an artificial biosynthetic pathway
in S. cerevisiae to produce flavokermesic acid, which is a precursor of the widely
used industrial colorant carminic acid.
Chapter 5 - Investigation of a shared biosynthetic pathway the production
of fusarubins and related compounds in the fungal genus Fusarium, and how the
metabolites isolated from individual species can be connected through few bio-
chemical conversions to create a more elaborate metabiosynthetic pathway. Fur-
thermore, the biosynthetic gene cluster producing the metabolites and its distri-
bution throughout the Fusarium genus is investigated.
Chapter 6 - Gives a general discussion of the thesis and draws the overall
conclusions as well as giving some perspectives of the work presented in the thesis.
The references given inside each chapter is referring to the reference list, which
is in the end of that particular chapter.
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2 Background
The field of natural product chemistry is broad and has been through rapid devel-
opment over the past decades as our understanding of the biosynthetic origin of
natural products. This has been aided by a mechanistic understanding of the un-
derlying genetic and enzymatic machinery, which is responsible for the production
these complex biomolecules. Especially, the application of molecular genetic tools
has sped up the elucidation of secondary metabolic pathways. The application of
molecular techniques like gene knockout in the native host [1], expression of path-
way encoding genes in heterologous hosts [2] and enzyme purification followed by
in vitro enzymatic assays [3], has been the most powerful tools in getting a grip on
natural product biosynthesis. Furthermore, chemical analysis methods have been
in a rapid development. The application of high performance chromatography
methods for better separation of complex natural samples, as well as development
of more sensitive and precise detection methods such as high resolution mass spec-
troscopy (HRMS) detection, has been pivotal to the detection and elucidation of
novel compounds [4].
Within secondary metabolism the four most important compound classes are
terpenes, non-ribosomal peptides, shikimic acid derived compounds and polyke-
tides. The vast majority of known secondary metabolites to date originate from
one or more of these compound classes [5]. The first class, terpenes, are formed
using C5 isoprene units as building blocks, which are joined in the mevalonate
pathway to form branched chains of highly reduced carbon chains. The name
terpenes refers to its discovery in turpentine oil from pine trees. The chemical
diversity of terpenes is created by the different terpene cyclase enzymes, which
fold the isoprene derived chains into complex structures. The second compound
class, non-ribosomal peptides, consist of small peptides, which are, as the name
suggest not produced by ribosomes, but rather via an mRNA independant man-
ner. Formation of the non-ribosomal peptide, are catalyzed by non-ribosomal
peptide syntethase (NRPS), which join amino acids. The substrate for NRPSs
are proteinogenic or non-proteinogenic amino acids, which are joined by peptide
bonds as with regular protein synthesis in ribosomes, but cyclisation and other
internal modifications make them unique in comparison with ribosomal peptides
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and proteins. The third class originate from the important primary metabolite
shikimic acid. The biosynthesis of aromatic amino acids depend on this metabo-
lite and shikimic acid is also found in biosynthesis of secondary metabolites, as
shikimic acid derived compounds from central metabolism can be used in sec-
ondary metabolism [5]. The fourth and final compound class, polyketides, have
much structural similarity with fatty acids. The enzymatic machinery produc-
ing polyketides are called polyketide synthases and they utilize building blocks in
the form of C2 acetate units or derivatives thereof called ketides. The repeated
joining of these building blocks yields a polyketide chain and is the foundation for
polyketides. Fatty acids are mostly saturated or with very few double bonds, while
polyketides can have many different levels of saturation [6, 7]. Even higher levels
of diversity is obtained when two or more of the compound classes are combined
to form hybrid natural products [8, 9].
These four compound classes are the foundation for production of secondary
metabolites, but the diversity of secondary metabolism is only partly due to these
four enzyme classes. After production of the basic chemical structures tailoring
enzymes can carry out a plethora of extremely specific chemical reactions leaving
organic synthesis chemists in envy. These can be reductions, oxidations, methyla-
tions or rearrangements to name a few [10].
The compound class of interest in this project has been polyketides and the en-
gineering of the enzyme responsible for formation of these. Therefore, the following
chapters will focus on introducing the mechanism of polyketides synthases in na-
ture and thereafter give a review of previous attempts of engineering of polyketide
synthases.
2.1 Production of polyketides in nature
Polyketides are an extremely diverse group of natural products. The diversity
is not only in the range of known polyketide derived metabolites but also in the
enzymes producing polyketides, namely the polyketide synthases (PKSs). There
are three types of PKSs, I, II and III. In brief, the structure of type I PKSs
consist of a single protein with a number of domains. Type II PKSs are composed
of several individual enzymes, each with a unique function, which interact to
produce the polyketide chain. Type III PKSs are homodimers consisting of only
one domain [11, 12, 13].
Polyketide synthesis proceeds via the claisen condensation reaction that forms
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C-C bonds between chain and incoming extender units. The formation of a new
polyketide is initiated by the loading of a starter unit. The starter unit can
be extremely diverse and examples include amino acids, fatty acids and many
other, but the most prominent is acetyl coenzyme A (acetyl-CoA). Thereafter,
claisen condensations, which are driven by elimination of CO2 from the incoming
extender substrate malonyl coenzyme A (malonyl-CoA) or derivatives thereof,
elongate the polyketide chain. The elongation is continued until an enzyme specific
chain length is reached, and the final product is released. The release can result
in ring formation of the polyketide chain or simply by release of the polyketide
chain from the PKS [7, 14].
The chemical diversity of polyketides are primarily determined by the bio-
chemical activity harnessed by the domains in the PKS. The ketosynthase domain
(KS) are common for all PKSs and is the only recognized domain in type III
PKSs. In type I and II PKSs the acyl-carrier protein (ACP) is also an essential
domain as it in tandem with the KS domain to accept elongation units from the
acyltransferase domain (AT) and carries the growing polyketide chain. Also, the
AT domain responsible for selection of the starter units in polyketide synthesis.
Another important feature of the ACP is the ability to allow the growing polyke-
tide chain to be modified by other domains in the PKS, which along with other
hallmarks of the different PKS systems will be described in detail in the following
sections. The general mechanism for polyketide synthesis and an overview of the
different PKS systems is depicted in figure 2.1.
2.1.1 Type I modular PKSs
Type I polyketides are split into two groups, iterative and modular PKSs. The
modular PKSs (mPKS) are almost exclusively found in bacteria and are the most
intensively studied type of PKS. The reason for this interest is the important
hallmark of these enzymes that the enzyme domain architecture and the resultant
compound, which the enzyme produce, are correlated. This makes prediction of
the final compound based on genetic information possible because each module of
domains (KS, AT and ACP) in the mPKS is only used once, and therefore, the
length and to a high degree other modifications (e.g. reductions or methylations)
of the resultant polyketide chain can be predicted from the amino acid sequence
of the mPKS alone. This principle is named colinearity [11, 13].
In between modules of the mPKS are a stretch of amino acids which have been
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Figure 2.1 Overview of overall structure and mechanism of PKSs. (A) The structure of the dif-
ferent types of PKSs and hallmarks that make them distinguishable. (B) Generalized mechanism
for polyketide synthesis. Synthesis is initiated by loading of the Coenzyme A activated starter
unit onto the PKS, followed by loading of the elongation module. Elongation of the polyketide
chain happens via claisen condensation. When the elongation has been done reduction domains
may reduce the backbone if present in the PKS. After reduction, if needed another round of
elongation is done. The polyketide synthesis is terminated by unloading of the polyketide chain
which can also entail one or multiple ring formations of the polyketide chain.
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named intralinkers and these allows the different modules of the mPKS to interact
with each other and transport the growing polyketide chain through the mPKS
while keeping the individual modules in close vicinity. An exception to the general
rule of type I PKSs being a single polypeptide chain is found in mPKSs as these
are often not expressed in a single polypeptide chain, but often as one or several
of the modules in one chain. Then these chains of modules interact via what is
named interlinker domains. These are domains which serve the same function
as intralinkers, ie. to keep modules in close vicinity of one another, but does so
through protein-protein interactions instead of the covalent bonds of the amino
acid chain [15].
Reductions of the polyketide backbone while it is being synthesised are only
known in type I PKSs. The reducing domains can alter the formed β-keto carbon
chain into a partly or fully reduced chain. The initial reduction is carried out by
the keto reductase (KR) domain and reduces the β-keto group to an alcohol. A
second reduction can be carried out by the dehydratase (DH) domain and reduces
the alcohol to a double bond. The third and final possible reduction is carried
out by the enoyl reductase domain (ER), which eliminates the double bond and
produces a fully reduced carbon chain as is known in many fatty acids where these
three reducing domains are also present [5]. In type I mPKSs the level of reduction
is specific for each module in the PKS. It is important to note that the reduction is
carried out on the ketide unit fused to the chain by the upstream module to where
the reducing domains are present. Therefore, when predicting the product from
an mPKS, the modifications to the polyketide chain are dictated by the reducing
domains in the downstream module. One exception from the colinearity principle
in mPKSs are that sometimes domains are still present in a mPKS enzyme, e.g.
reducing domains, but is inactive. This can be due to gradual mutations yielding
some domains inactive, but evolution has not had enough time to completely delete
the reducing domain or that the inactive domain is essential for the overall protein
structure. When the final module has done the elongation of the polyketide chain
a thioesterase domain (TE) unloads the chain which often also includes cyclisation
of the chain to form macrolides [16].
The common product from type I mPKS are often polyketide backbones with
very complex reduction patterns and just as often they utilize alternative elonga-
tion units to the otherwise often used malonyl-CoA. The most intensively studied
mPKS is the 6-deoxyerythronolide synthase (DEBS), which produces a precursor
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Figure 2.2 The biosynthesis of 6-deoxyerythronolide by DEBS.
to erythromycin and serves as a good example of this. First of all the starter unit is
not an acetyl, but instead a propionyl is used as the initial unit of the final product
6-deoxyerythronolide. Subsequently six units of methylmalonyl-CoA are added to
the initial propionyl starter unit. Furthermore, the reduction of the backbone is
either to the fully reduced carbon backbone or to an alcohol. When the product
of DEBS is unloaded an ester is formed between the terminal carboxylic acid of
the polyketide chain and an alcohol, which was created by the second module via
reduction of the keto group on the initial propionyl. This yields the macrolide 6-
deoxyerythronolide, which is the first precursor of erythromycin (Figure 2.2) [15,
17].
2.1.2 Type I iterative PKSs
The type I iterative PKSs (iPKSs) are single a protein chain as is the case for
mPKSs, however they only contain one copy of each domain, that are used re-
peatedly during synthesis to produce the polyketide. The type I iPKSs resemble
the mechanism of type I FAS found in animals. Type I iPKSs are found almost
exclusively in fungi, but examples in bacteria have been found [7, 11].
Type I iPKSs are split into three distinct groups based on their level of reduc-
tion, which are non-reducing PKSs (NR-PKSs), partly-reducing PKSs (PR-PKSs)
and highly-reducing PKSs (HR-PKSs). As the names suggest the reducing ability
of the PKs and thus the resultant product from the PKS dictates the naming of
the PKS. The NR-PKSs produce backbones with only β-keto groups which can
then be folded in different ways to generate complex aromatic structures. The
folding carried out in NR-PKSs is directed by specific domains. The first ring
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Figure 2.3 Examples of the F- and S-mode first ring folding in natural products, with the
original polyketide backbone highlighted in black and the first ring formation highligted in red
in each compound. Carbon number 1 is part of the last ketide unit being fused to the polyketide
chain. F-mode examples: bikaverin [18], norosolonic acid [19], TAN-1612 [20]. S-mode examples:
granaticin [21] and pradimicin (Glc = sugar moiety) [22].
folding is directed by the product template domain (PT). The folding patterns
are determined by regarding the two carbons joined in the first ring closure and
determining the distance of these to the terminal carbon added to the polyketide
backbone, which usually is a carboxylic acid. Three possible folding patterns are
most often found to be catalyzed by the PT domains being the C2-C7, C4-C9 and
C6-C11 first ring folding patterns. It is important to note that this type of folding
with the lower number being even has been termed Fungal-mode (F-mode) folding
[23, 24] ,which is in contrast to Streptomyces-mode (S-mode) [25] folding (Figure
2.3), which will be explained in the following section of type II PKSs. The PT
domain directs the first and often also the second ring formation while further ring
formations may be directed by the TE domain, which in this case also acts as a cy-
clisation domain upon release. Up to four rings can be formed by the PKS itself as
is seen in the biosynthesis of bikaverin and TAN-1612 (Figure 2.3) [7, 20, 26]. Our
understanding of the NR-iPKSs domains has primarily been through the analysis
of PksA, which is involved in the biosynthesis of aflatoxin in Aspergillus flavus.
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Figure 2.4 The biosynthesis of norsolorinic acid anthrone by PksA.
In short, the PKS-part of the biosynthesis of aflatoxin is initiated by loading of
the starter unit hexanoyl-CoA, which is produced by the FAS enzymes HexA and
HexB. This is followed by seven rounds of malonyl-CoA elongation of the chain,
followed by PT catalyzed C4-C9 and C2-C11 ring formation and finally C1-C14
ring formation and unloading the norsolorinic acid anthrone product. The biosyn-
thesis of norsolorinic acid is summarized in figure 2.4 [19, 27]. An alternative to
the TE domain release is the reductive domain (R) release in which instead of a
terminal carboxylic acid group the terminal carbon is an aldehyde [28].
The PR- and HR-iPKSs have some or all of the reducing domains described
in the previous section on mPKSs present in the enzyme. The main difference
between the two reducing PKSs are, as the name suggests, the level of reduction
exerted on the polyketide backbone. PR-PKSs does not have all three reducing do-
mains in their structure and therefore they produce polyketide chains which have
double bonds or alcohol groups along with the ketone groups. 6-methyl salicylic
acid synthase (MSAS) from Penicillium patulum is one of the most intensively
studied PR-PKSs. The biosynthesis of 6-methyl salicylic acid (6-MSA) in P. pat-
ulum is initiated by loading of an acetyl-CoA starter unit followed by extensions
with three malonyl-CoA units of which only the C5 carbonyl is reduced to an
alcohol. The following C2-C7 ring closure catalyzed by the PT domain enables
unloading of the 6-MSA. The biosyntheis of 6-MSA is shown in figure 2.5 [7].
The hallmark of HR-PKSs are the presence of all reducing domains in the PKS.
This yields a polyketide backbone which cannot be folded by claisen condensation
as in NR- and PR-PKSs, but cyclisation of these compounds may instead carried
out via Diels-Alder cyclisation, as is seen in the biosynthesis of lovastatin [29].
The PKS LovB Aspergillus terreus producing the the precursor of lovastatin, di-
hydromonacholin L (Figure 2.6), is one of the most intensively studied HR-PKSs.
In short, the biosynthesis of dihydromonacholin L is intiated by loading acetyl
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as starter unit which is then elongated by eight malonyl-CoA units to yield a re-
duced nonaketide. The complex reduction machinery of LovB reduces several of
the integrated ketide untis to double bonds and alcohol groups. Several of the ke-
tides are fully reduced to single bonds by the trans acting ER LovC. Furthermore,
the C-methylation domain of the PKS selectively methylates the C12 position.
The characteristic double ring of lovastatin is formed via Diels-Alder ring forma-
tion and the product dihydromonacolin L, which is a precursor to lovastatin, is
released from the PKS [29, 30].
As in mPKSs the level of reduction is determined by the enzymatic structure,
but prediction of reduction is for now impossible for type I iPKSs. Predictions
of the product from type I iPKSs based on sequence, can only be proposed via
homology with other known iPKSs and the presence and absence of catalytic
domains. Currently, the best predictive power of the product from an unknown
iPKS is the folding pattern, which is catalyzed by the PT domain in NR-iPKSs
[23]
Some polyketide products have vastly different oxidation levels in different
parts of the backbone. Curvularin is an example of one such compound (Figure
2.7). In curvularin biosynthesis the first part of the synthesis is performed by a
HR-PKS named CURS1 and the product is a highly reduced tetraketide. This
tetraketide is then used as a starter unit for a NR-PKS CURS2 which carries
out an additional three elongations of the polyketide and forms the final product
curvularin. This polyketide is also one of the only known examples of a C3-C8 first
ring formation by a PT domain. This exception to the otherwise well described
F-mode folding was investigated by Xu et al. (2013). They found that two point
mutations switched the PT of CURS2 from the uncommon C3-C8 folding pattern
to the regular C2-C7 pattern [31]. Another example of variable oxidation levels are
found in polyenes like aurovertins and citreoviridins (Figure 2.7). The biosynthesis
Figure 2.5 The biosynthesis of 6-methyl salicylic acid by MSAS.
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Figure 2.6 The biosynthesis of dihydromonacholin L by LovB and LovC.
Figure 2.7 Compounds derived from type I iPKS systems.
of aurovertins and citreoviridins are carried out by one PKS (AurA and CtvA
respectively), which is in contrast to biosynthesis of curvularin. The middle part
of aurovertins and citreoviridins are polyenes and the terminal three elongations
of the polyketide chain is non-reduced β-ketones. This suggest that the access to
the DH reducing domain is dependent on the length of the polyketide chain [32,
33].
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Figure 2.8 The biosynthesis of 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid by the
actionorhodin PKS.
2.1.3 Type II PKSs
As described earlier the strong contrast between type I and type II PKSs is that
the catalytic domains of type II PKSs are located on individual enzymes instead
of being part of the same protein. Another interesting difference is that type II
PKSs are exclusively found in bacteria with actinobacteria having the vast ma-
jority of characterized type II PKSs [14, 34]. The malonyl-acetylation domain
(MAT) loads malonyl onto two KS domains named KSα and KSβ1, which forms a
heterodimer. The KS domains together with the ACP have long been named the
minimal PKS as these three are able to form polyketide products [35, 36]. With
this being said these minimal PKS products are often shunt products as more en-
zymes are needed for the formation of the native product. These enzymes act upon
the poly-β-keto chain to fold it in a certain shape and are named cyclases or aro-
matases. A subclass of these only act upon partly reduced ketide chains that have
a C-9 alcohol group instead of the ketone [11, 35]. The most widely studied and
best understood type II PKS system is from Streptomyces coelicolor and produces
actinorhodin. The function of the actinorhodin PKS to form the actinorhodin pre-
cursor 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (DMAC) is based
on elongation of the acetyl-CoA starter unit with seven malonyl-CoA units to cre-
ate the C16 backbone. The backbone is reduced at the C9 position and C-C bonds
are formed at C7-C12 and C5-C14 by trans acting KR and cyclase enzymes. Upon
release the last C2-C15 bond is formed spontaneously to yield DMAC (Figure 2.8)
[37, 38].
As mentioned earlier in NR-iPKSs there is a certain folding pattern observed
for type II PKSs. This folding pattern is named after the main source of type
II PKS namely Streptomycetes or S-mode folding. In contrast to F-mode folding
1KSβ is also often named chain length factor (CLF)
15
Chapter 2. Background
the lower number in the S-mode folding is odd and the most often found fist-ring
folding patterns for type II PKSs are C7-C12 and C9-C14 (Figure 2.3). When
the first cyclisation or cyclisations have been formed further ring cyclisations are
usually also directed by cyclases. This enables the type II PKSs to steer the
otherwise very reactive poly-β-keto chain into a certain structure [14, 25, 39].
Compared to the many different types of type I PKS enzymes and products,
type II PKSs and products are less diverse, as the diversity coming from the
PKSs themselves are determined by chain length and folding pattern. With that
being said, many interesting and important bioactive compounds originate from
type II PKSs and actinomycetes continue to be a rich source of novel bioactive
compounds, and many existing drugs are fully or partly derived from type II PKSs
in actinomycetes [5, 14, 40].
2.1.4 Type III PKSs
The type III PKSs were originally identified as enzymes catalyzing the formation
of chalcones and stilbenes in plants. These polyketide synthases utilize the large
starter unit p-coumaroyl-CoA and through three malonyl-CoA elongations they
form chalcones and stilbenes. The first and most intensively studied type III
PKS of this type is the chalcone synthase, which is widely distributed in plants.
Chalcone is the precursor of flavonoids which have several important roles such
as pigment, signalling and defence, and more than 6000 has been described in
nature. Naringenin chalcone biosynthesis starts as described by p-coumaroyl-CoA
being embedded in the active site of the chalcone synthase (CHS). Then three
elongations by malonyl-CoA followed by a enzyme specific C1-C6 ring formation
yields naringenin chalcone, which is a precursor of flavonoids. The biosynthesis of
naringenin chalcone by CHS is depicted in figure 2.9 [12, 41]. Other plant derived
type III PKSs also produce products utilizing acetyl-CoA as a starter unit and
malonyl-CoA as extender units results in the production of aromatic compounds
[42]. Aside from plants, type III PKSs have also been identified and characterized
in bacteria [43] and fungi [44].
Type III PKSs function as homodimers of two KS domains. Malonyl-CoA is
fed into the active site and the chain is elongated to form an unreduced polyketide
chain. During polyketide synthesis the growing chain is momentarily not linked
to the type III PKS, but to CoA instead [42]. The mechanism for formation of
the polyketide backbone makes type III PKSs leaky and along with the longest
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Figure 2.9 The biosynthesis of naringenin chalcone by CHS.
chain produced by the PKS, shorter chains are also formed, likely because the
active site allow water to enter, which leads to hydrolysis of premature polyketide
chains from the PKS. An example for that is the octaketide synthase OKS from
Aloe aborescens, which is thought to be responsible for the polyketide production
leading to barbaloin. When heterologously expressed the OKS forms hepta- and
hexaketide products in easily detectable amounts along with the octaketide [45].
The product from many type III PKSs are poly-β-keto chain, and the ability
to selectively fold these are sometimes nested in the PKS itself [41] while only
one example exists of a discrete cyclase folding a type III PKS product, being the
olivetolic acid cyclase (OAC) involved in biosyntheis of cannabinoids [46]. Many
of the investigated type III PKSs have unknown native products as they originate
from plants to which only few molecular tools exist. Heterologous expression
has therefore been used to investigate these PKSs, which often yields the shunt
products formed by the unfolded poly-β-keto chain formed by the type III PKS
[12, 45, 47].
2.2 Engineering of PKSs
While the different classes of PKSs and their basic functionality have been inves-
tigated for decades, the ability to pick apart a pathway by advances in molecular
genetic manipulation and chemical analysis has given us a much better under-
standing of the mechanisms at work. This has also lead to numerous examples
in literature of engineering attempts of these complex enzymes. The following
chapter will give examples of some of these attempts to engineer the enzymatic
machinery and the resultant products.
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2.2.1 Type I mPKS engineering
The principle of colinearity seen for type I mPKSs have lead to scientists to at-
tempt to engineer these large multidomain enzymes. By exchanging modules from
one mPKS to another the rationale has been that one should be able to design the
resultant polyketide [16]. Early studies of mPKS engineering were producing trun-
cated versions of the mPKSs to verify that shorter products could be obtained [48].
Later studies aimed at investigating the compatibility between different mPKSs.
One study did this by keeping the individual modules of the mPKS intact and then
swapping domains between two or more mPKSs. Such chimeric mPKSs were made
by combining modules by the use of interlinker domains enabling combination of
different modules by co-expression of different proteins, which would then interact
via these interlinker domains. It was found that the highest production was by do-
main combinations of different modules from the same mPKSs, ie. module 1 and 3
from DEBS. However, some chimeric mPKSs with modules from different mPKSs
produced novel compounds, showing that it to some degree was possible to design
compounds from chimeric mPKSs [49, 50]. An alternative approach was to create
a chimeric module by fusion of two different modules either from the same mPKS
or from two different mPKSs. This was achieved by utilizing homologous recom-
bination (HR) in Saccharomyces cerevisiae, which recognized homologous regions
between the two modules to form a chimeric module. These chimeric mPKS mod-
ules were largely inactive when combining two modules from different mPKSs and
active when combining modules from the same system. Therefore, the system can
be used to some degree to develop a new module, but the evolutionary distance
between the two modules cannot be too large [51].
Instead of combining parts from different mPKSs, another approach has been
to selectively mutate domains to be able to design compounds with an alterna-
tive oxidation pattern to native compound. This was achieved through selective
inactivation by mutation of reducing domains in the mPKS. In this method the
important interaction between modules, which had been fine tuned by evolution,
was intact by avoiding swapping whole modules [52].
These are some of the attempts to engineer the product of mPKSs and have
brought much more insight into the mPKS machinery, but for actual production
of polyketides alternative strategies are needed. This is because the engineering
attempts of mPKSs have been at the cost of production as the metabolite levels
of the engineered mPKSs are often at a tenth or less of the wildtype mPKS [16].
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2.2.2 Type I iPKS engineering
The understanding of type I iPKSs have increased substantially over the past
decade and with that several attempts have been made to understand and direct
product formation of these enzymes. In NR-iPKSs such understanding was gained
by creating a minimal type I iPKS, consisting of KS, AT and ACP domains,
capable of creating a poly-β-keto chain which then spontaneously folded into the
shunt products, which were already known from investigations of minimal type II
PKSs [53]. This understanding of the basic domains necessary for chain creation
enables the decoupling of chain elongation and folding of the polyketide backbone.
By combination of minimal PKSs from one system, and PT and TE domains from
other NR-iPKSs it was possible to create novel compounds [23, 54, 55]. Another
domain swap strategy has been to make chimera versions of a NR-iPKS in which
different proportions of the N-terminus was swapped between two NR-iPKSs. For
every domain that swapped the functionality was also changed. This made it
possible to change first the starter unit and then chain length by swapping the
SAT domain and the KS and AT domain respectively [56]. This ability to swap
domains in NR-iPKSs enables design of specific polyketides. An alternative to
domain swap has also been selective mutations in PT domain to alter folding
specificity [31].
Engineering attempts in PR- or HR-iPKSs are sparse and the catalytic func-
tionality of the domains is still not as well understood as that for NR-iPKSs [57].
One study did domain swapping between two homologous HR-iPKS-NRPS hy-
brids and found that the KR domain was pivotal in chain length determination
and that the C-methylation domains were independent of chain lengths in their
functionality [58].
2.2.3 Type II PKS engineering
The nature of type II PKSs allow combinatorial biosynthesis in a more simple
fashion than what is needed for type I PKSs. The fact that the system consist of
standalone enzymes allow swapping of a whole enzyme instead of having to swap a
specific domain. This is simpler as domain swaps require precise determination of
domain limitations. However, the substrate specificity and the required protein-
protein interactions between the individual enzymes in type II PKSs limits the
combinatorial spectrum. One method for development of novel compounds is the
combination of a given minimal PKS with a certain chain length co-expressed
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with non-native cyclases which has been show to allow control of chain length
and folding pattern [59, 60, 61, 62]. The very large number of type II PKSs
characterized allows for the utilization of parts from different systems to engineer
a compound of interest [34, 63]. This promiscuity of cyclases has also been used
in combination with type I [64] and type III PKSs [65, 66] to direct the folding of
a nascent poly-β-keto chain.
Another approach to engineer type II PKSs has been to utilize alternative
starter units. This has been through derivatising the native aromatic starter unit
[67, 68] or by incorporation of a nitrogen containing starter unit into new com-
pounds [69], thereby utilizing the promiscuity of the biosynthetic enzymes. In
these studies they also found that the incorporation of alternative starter units
were only partially successful as enzymes later in the pathways were sensitive to
what starter unit was used [34]. Aside from testing enzyme promiscuity, starter
unit specificity engineering to allow fatty acid substrates has also yielded novel
compounds by mutational changes in the biosynthetic enzymes [70].
2.2.4 Type III PKS engineering
The simplicity of type III PKSs and the availability of numerous high resolution
crystal structures [71, 72, 73, 74] has enabled point mutation engineering of type
III PKSs to alter the chain length produced especially by type III PKSs accepting
acetyl-CoA as the starter unit [47, 75]. This has enabled the octaketide synthase
from Aloe aborescens to produce dodecaketide (C24) products, which is the longest
product recorded from a type III PKS [76, 77]. As with other PKS systems starter
unit promiscuity has also been utilized for derivatization in type III PKS derived
products, with focus on different aromatic analogs as starter units for chalcone
synthase type III PKS [78] and other complex starter units in the PKS1 from
Huperzia serrata [79].
Another goal of type III PKS engineering has been on improving the output
of the enzymatic machinery. This has been achieved by protein engineering of the
2PS PKS from Gerbera hybrida to improve triacetic lactone (TAL) production by
2.5 fold of initial expression [80]. This is in strong contrast to other PKS systems as
protein engineering in general has led to reduced overall production of polyketide
[16, 34].
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2.3 Conclusion and outlook
The drive to discover novel natural products has led the field to also understand
the biosynthetic origin of natural products. As exemplified here this knowledge
has both been utilized to further understand the enzymatic machinery while it has
also enabled design of polyketides which are non-natural. The toolbox to produce
any polyketide of choice is still not available, but several techniques exist to begin
development of combinatorial enzymatic pipelines catalyzing biosynthesis of new
compounds.
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3.1 Abstract
The discovery and characterization of new polyketides has for a long time been
driven by the fact that many polyketides possess desirable bioactivities. Besides
the discovery of novel polyketides, much effort has also been put into understanding
the enzymes, named polyketide synthases (PKSs), that synthesize these complex
compounds. This has also brought about several attempts of altering the natural
products produced by the individual PKSs by protein engineering. Especially,
the PKSs that produce producing non-reduced polyketides have received atten-
tion as this subgroup of polyketides having cyclic and aromatic structures, which
often display relevant biological activities. In the current study we set out to pro-
vide proof-of-concept for a programmable microbial platform for the production of
cyclic and aromatic polyketides, which would allow control of the chain length and
folding pattern of the produced chain. This was achieved through co-expression of
different type III PKSs and type II polyketide cyclases catalyzing different folding
patterns, creating an artificial PKS systems. Expression of five plant derived type
III PKSs in S. cerevisiae resulted in the production of their previously described
products, varying in length from C6 to C16. Co-expression of the octaketide (C16)
producing type III PKS with two different polyketide cyclases from actinomycete
bacteria, allowed for directing different folding patterns. The cyclases were both
found to be able to direct the folding of the octaketide backbone, which was pro-
duced by the type III PKS. This proof-of-concept study lays the foundation for
29
Chapter 3. Steering polyketide production in yeast
further development of the platform, as it shows that it is possible to rationally
program this artificial PKS system.
Keywords: Yeast, Metabolic engineering, Polyketide synthases
3.2 Introduction
Many pharmacological compounds in clinical use are completely or partially de-
rived from natural sources. This has brought much interest into the discovery of
new compounds from natural sources as nature has shown to be an excellent source
of such compounds [1, 2]. Many of the pharmacologically active compounds are of
polyketide origin, and much effort has been put into understanding the biosythesis
of polyketides [3, 4, 5, 6]. Polyketides are biosynthesized by polyketide synthases
(PKSs) which are divided into three types (I, II and III) based on their tertiary
structure and mode of catalysis [7].
Much effort has been given to understanding the synthesis of the non-reduced
polyketides, as this subgroup is rich in bioactive compounds [7, 8]. Synthesis
mechanism of non-reduced polyketides can be split into two main steps. The
first being the synthesis of the non-reduced polyketide chain and the second being
folding of the chain in a given pattern to form a cyclic and aromatic structure
[7]. Folding of the polyketide chain can either be carried out by the same enzyme
producing the chain, which is observed in type I iterative PKSs [8], or by an trans
acting enzyme, which is observed in type II PKS systems [5]. The two given
examples are named F-mode and S-mode respectively referring to their fungal or
streptomycete origin (Figure 3.1). The known common F-mode folding patterns
referring to the first carbon-carbon bond being formed are C2-C7, C4-C9 or C6-
C11, while the known common S-mode folding patterns are C7-C12 or C9-C14 first
ring folding [9]. Even though type III PKSs often produce cyclic and aromatic
polyketides only a single cyclase has so far been described to fold a type III PKS
product in a natural system [10] and the general folding mechanisms for type III
PKS systems remain unknown.
The growing understanding of the biosynthesis of polyketides has over the
years lead to many attempts to engineer PKSs and thus alter the natural product
of many different PKSs. This has been achieved through domain engineering
[11], domain swapping [12, 13] and combinatorial libraries with components from
different natural pathways [14, 15] to name a few. The mentioned examples have
been engineering of PKSs within the same system while product engineering by
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Figure 3.1 The principle behind the F- and S-mode first ring folding in natural products.
combination of components from different PKS systems has also been made [16,
17]. Generally, applicable methods for rational reprogramming of PKS systems
to design a specific compound of interest has long been the goal of the research
field. It has, however, proven almost impossible to device general strategies as
the engineered PKSs typically loose the majority of their catalytic activity due
to incompatibilities between the different heterologous PKS elements that are
combined in the artificial systems.
In this study, we combine elements from two of the natural PKS types in an
attempt to bypass the protein-protein interaction challenges faced when combining
elements from different PKS belonging to the same PKS type. The aim of this
study was first to prove that a diverse set of plant derived type III PKSs with a
diversity of products could be functionally expressed in Saccharomyces cerevisiae.
Secondly, co-expression of a series of actinomycete derived cyclases from type II
PKS systems with the type III PKSs and test if they would be able to direct the
folding pattern of the produced polyketides. Type II cyclases and type III PKSs
have previously been shown to be able to produce folded products when expressed
in tobacco and Aspergillus nidulans [17, 18]. However, heterologous expression
in S. cerevisiae has not been tested, though it would provide a cleaner metabolic
background for metabolic engineering, and make the system more relevant for
industrial scale fermentation in connection with production of beverages [19] and
biopharmaceuticals [20].
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3.3 Materials and methods
3.3.1 Strains, vectors, media and synthetic genes
S. cerevisiae strains constructed in this study were derived from the CEN.PK102-
5B or CEN.PK111-61A [21]. An overview of all strains can be seen in table 3.1.
Episomal 2µ vector pBOSAL1-URA [22] as well as integrative vectors [23] were
used for expression of genes in S. cerevisiae. Yeast strains were maintained on
yeast extract peptone dextrose (YPD) medium (10 g/L Bacto yeast extract, 20
g/L Bacto Peptone, 20 g/L glucose), except for strains carrying a plasmid or
during transformation steps. For transformation or plasmid maintenance yeast
strains were grown on synthetic complete medium lacking leucine (SC-leu) or
uracil (SC-ura) [24] for selection of the 2µ plasmid carrying the LEU2 gene from
Kluyveromyces lactis or integrative transformation cassette carrying the URA3
gene from Kluyveromyces lactis. Escherichia coli strain DH5α was used for all vec-
tor assemblies and propagation [25]. E. coli strains were all grown in or on lysogeny
broth medium supplemented with 100 µg/L ampicillin (LB-Amp). The polymerase
PfuX7 [26] was used for all PCR reactions. All primers (Integrated DNA technolo-
gies, Belgium) used in this study are listed in appendix (Table S3.1). Synthetic
genes Gh2PS (P48391) [27], AaPCS (Q58VP7) [28], DluHKS (ABQ59603) [29],
AaPKS3 (C4MBZ5) [30], AaOKS (Q3L7F5) [31], Gra-orf4 (GU233672) [32] and
PdmD (EF151801) [33] were ordered from and codon optimized for S. cerevisiae
by Genscript (NJ, USA).
3.3.2 Vector and strain construction
Vectors were assembled by Uracil-Specific Excision Reagent (USER) fusion as de-
scribed in Jensen et al. (2014) [23]. An overview of all vectors can be found in table
3.1. The yeast promoters PTEF1 and PPGK1 were amplified from yeast genomic
DNA from CEN.PK117-7D [21]. All plasmids were verified by restriction analysis
and sequencing by Eurofins MGW Operon (Ebersberg, Germany). S. cerevisiae
transformations were performed via the LiAc/SS-DNA/PEG method [34]. Prior
to transformation of integrative vectors these were linearized by restriction as de-
scribed in Jensen et al. (2014) [23]. Transformation of integration of fragments
were verified by diagnostic colony PCR. Diploid strains were constructed from the
the haploid strains by mating on YPD for 6-8 hours, after which diploids were
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Table 3.1 List of vectors and S. cerevisiae strains used and constructed in this study.
Vector name Description Source
pBOSAL1 2µ Kl.LEU2 [22]
pBOSAL1-Gh2PS 2µ PPGK1-Gh2PS-TADH1-Kl.LEU2 This study
pBOSAL1-AaPCS 2µ PPGK1-AaPCS-TADH1-Kl.LEU2 This study
pBOSAL1-DluHKS 2µ PPGK1-DluHKS-TADH1-Kl.LEU2 This study
pBOSAL1-AaPKS3 2µ PPGK1-AaPKS3-TADH1-Kl.LEU2 This study
pBOSAL1-AaOKS 2µ PPGK1-AaOKS-TADH1-Kl.LEU2 This study
pCfB389 Int. XI-2 Kl.URA3 [23]
pCfB257 Int. X-3 Kl.LEU2 [23]
pCfB389-PdmD Int. XI-2 PTEF1-PdmD-TCYC1-Kl.URA3 This study
pCfB389-Gra-orf4 Int. XI-2 PTEF1-Gra-orf4-TCYC1-Kl.URA3 This study
Strain name Description Source
CEN.PK113-7D MATa MAL2-8c SUC2 P. Kötter
CEN.PK102-5B MATa MAL2-8c SUC2 ura3-52 his3∆1 leu2-3/112 P. Kötter
CEN.PK111-61A MATα MAL2-8c SUC2 ura3-52 his3∆1 leu2-3/112 P. Kötter
Ant-SC117 CEN.PK102-5B pBOSAL1-LEU2 This study
Ant-SC115 CEN.PK102-5B pBOSAL1-Gh2PS This study
Ant-SC136 CEN.PK102-5B pBOSAL1-AaPCS This study
Ant-SC125 CEN.PK102-5B pBOSAL1-DluHKS This study
Ant-SC126 CEN.PK102-5B pBOSAL1-AaPKS3 This study
Ant-SC116 CEN.PK102-5B pBOSAL1-AaOKS This study
Ant-SC090 CEN.PK111-61A XI-2::PTEF1-pdmD-TCYC1-Kl.URA3 This study
Ant-SC091 CEN.PK111-61A XI-2::PTEF1-gra-orf4-TCYC1-Kl.URA3 This study
Ant-SC110 CEN.PK111-61A XI-2::Kl.URA3 This study
Ant-SC111 CEN.PK102-5B X-3::Kl.LEU2 This study
Ant-SC127 Ant-SC116 x Ant-SC090 (diploid) This study
Ant-SC128 Ant-SC116 x Ant-SC091 (diploid) This study
Ant-SC132 Ant-SC116 x Ant-SC110 (diploid) This study
Ant-SC207 Ant-SC111 x Ant-SC090 (diploid) This study
Ant-SC209 Ant-SC111 x Ant-SC091 (diploid) This study
selected for on SC lacking uracil and leucine (Sc-ura/leu).
3.3.3 Cultivation, chemical extraction and chemical analysis
To prepare strains for chemical extraction these were grown for 5 days at 30◦C
in 500 mL Erlenmeyer flasks with baﬄes containing 50mL liquid SC-leu at 200
rpm. All flask were inoculated from an overnight culture to have OD600 = 0.1 to
initiate the cultivation. OD600 measurements were done on a Shimadzu UV-1800
spectrophotometer (Japan).
Chemical extractions were done by separating the biomass from the culture liq-
uid via centrifugation (8000 xg for 5 minutes) in a 50mL falcon tube (Subsequently
named tube A). The culture liquid was decanted into another 50mL falcon tube
(Subsequently named tube B). To lyse the yeast cells 25mL of extraction liquid
(ethylacetate with 1% v/v formic acid) was added to the pellet in tube A and sub-
jected to ultrasound for 1 hour. Afterwards, 25mL of the culture liquid from tube
B was decanted into the extraction liquid and yeast cell mixture. After vigorous
shaking the culture liquid was removed with a glass Pasteur pipette from tube
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A. Tube A was centrifuged (8000 xg for 5 minues) and the extraction liquid was
decanted into the remaining culture liquid tube B. After vigorous shaking with
the remaining culture liquid the culture liquid was removed with a glass Pasteur
pipette. The extraction liquid was evaporated to dryness under a gentle stream
of N2 at room temperature. The residue was redissolved in 300µL methanol and
exposed to ultrasound for 10 seconds and transferred to a 2 mL Eppendorph tube.
The Eppendorph tube was centrifuged (18000 xg for 5 minutes) and 150µL of
methanol was transferred to a HPLC-vial.
Chemical analysis was done by Ultra high performance-diode array detection-
time of flight mass spectrometry (UHPLC-DAD-TOFMS) on a Bruker maXis G3
QTOF mass spectrometer (Bruker Daltronics, Bremen, Germany) which used an
electrospray ionization source (ESI). Sample separation was done on a Dionex
Ultima 3000 UHPLC-DAD (Dionex, Sunnyvale, CA, USA) with a Kinetex C18
column (150 x 2.1 mm, 2.6 µm (Phenomenex Inc., Torrance, CA, USA)) which
was kept at 40◦C and a mobile phase of a gradient mixture of water (A) and
acetonitrile (B) both containing 20mM formic acid. The gradient profile started at
10% B and increased to a 100% B in 10 min, held there for 3 min and then returned
to 10% in 0.1 min and kept there for 1.5 min with a flowrate of 400µL/min. Mass
spectra were recorded for a mass range of m/z 75-1250 in negative MS mode and
UV spectra was collected from 200-700 nm.
3.3.4 Large scale cultivation, purification of compounds and
NMR structure elucidation
To produce sufficient biomass for purification of compounds for NMR based struc-
ture elucidation a larger scale cultivation was setup. The medium was synthetic
minimal (SM) [35] supplemented 125 mg/L histidine and 150 mg/L uracil [36].
The strain Ant-SC116 was chosen for purification of selected compounds. The
larger scale cultivation was carried out in 2L BioStat B bioreactor (B. Braun
Biotech International, Germany). The cultivation was initiated by inoculation to
a start OD600 = 0.01. Throughout the cultivation the pH was kept at 5 (adjusted
with 2M NaOH and 2M H2SO4), the temperature was 30◦C, the aeriation was
2L/min and agitation was at 600 rpm. Two reactors were run resulting in 4L of
total culture.
Culture liquid and yeast cells were separated by storing the culture liquid at
5◦C for 10 days. Yeast cells precipitated at the bottom and the supernatant was
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decanted. The supernatant was pH adjusted to 4 and extracted with two volumes
of ethylacetate. The precipitated yeast cells were redissolved in 30 mL methanol
and subjected to ultrasound for 1h. After a centrifugation step (8000 xg, 5 min),
the methanol fraction was added to the ethylacetate and evaporated to dryness in
a rotavapor. The raw extract (1.2 g) was adsorbed onto Diol material and dried
before packing onto a 25g SNAP column (Biotage, Uppsala, Sweden) with Diol
material. The extract was fractionated on an Isolera One flash purification system
(Biotage) via seven steps of heptane (Hep), dichloromethane (DCM), ethylacetate
(EtOAc) and methanol (MeOH), with each step having a volume of three column
volumes. The steps were as follows: 100% Hep, 50/50% Hep/DCM, 100% DCM,
50/50% DCM/EtOAc, 100% EtOAc, 50/50% EtOAc/MeOH and 100% MeOH.
The methanol fraction (212.4 mg) contained the compounds of interest and were
subjected to further fractionation on a semi-preparative HPLC on a Waters 600
Controller with a 996 photodiode array detector (Waters, MA, USA). The solid
phase was a Phenomenex Luna II C18 column (250x10 mm, 5µm (Phenomenex,
CA, USA)) and a mobile phase consisting of a mixture of water (A) and acetonitrile
(B) both containing 50ppm triflouroacetic acid. The gradient profile started at
25% B, increased to a 30% B in 10 min, increased to 100% in 1 min, held there
for 2 min and then returned to 25% in 1 min and kept there for 2 min with a
flowrate of 5 mL/min. The resultant pure compounds were 1 mg of SEK4, 0.5 mg
of SEK4b, 1 mg dSEK4 and 1.1 mg of dSEK4b.
The isolated compounds were analyzed by NMR on a Bruker AVANCE 800
MHz (Bruker Daltronics, MA, USA) with a 5mm prodigy cryoprobe using stan-
dard pulse sequences (1H-NMR, 13C-NMR, HSQC and HMBC). All spectra were
recorded in DMSO-d6. The signals of residual solvent protons and carbons were
used for reference (δH 2.50 and δC 39.5 ppm for DMSO-d6). All NMR data were
analyzed on Bruker topspin software (Bruker Daltronics, MA, USA). In general
NMR signals were not very strong and some NMR signals were missing in our
data when comparing to previous isolation of the compounds in literature. The
missing or altered signals are mentioned below for each compound. All recorded
spectra can be found in appendix (Figure S3.2 to S3.5).
SEK4 (1 mg): UV: λmax = 280 nm. ESI-MS: m/z 317.0667 [M-H]−. 1H-NMR
δH ppm: 1.56 (3H, s); 2.54 (1H, d, J = 15.9 Hz); 2.92 (1H, d, J = 15.9 Hz); 4.07
(1H, d, J = 15.9 Hz); 4.15 (1H, d, J = 15.9 Hz); 5.14 (1H, s); 5.61 (1H, s); 6.26
(1H, d, J = 2.4 Hz); 6.32 (1H, d, J = 2.4 Hz); 6.88 (1OH, s); 10.54 (1OH, s);
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11.06 (1H, s-broad). 13C-NMR δH ppm: 27.95; 38.05; 49.81; 88.55; 101.12; 103.36;
111.83; 113.48; 139.21; 162.40; 163.45; 164.42; 191.56. Apart from three missing
carbon signals (99.6; 165.4; 170.5) the recorded NMR spectra and assignments
were in agreement with published data [15].
SEK4b (0.5 mg): UV: λmax = 280 nm. ESI-MS: m/z 317.0668 [M-H]−. 1H-
NMR δH ppm: 2.46 (3H, s); 2.65 (1H, s); 2.91 (1H, d, J = 13.8); 2.98 (1H, d,
J = 16.6 Hz); 2.99 (1H, d, J = 13.8); 6.17 (1H, d J = 2.19 Hz); 6.26 (1H, d,
J = 1.79 Hz); 6.52 (1H, s); 7.1 (1OH, s); 10.37 (1OH, s); 11.91 (1OH, s-broad).
13C-NMR δH ppm: 22.97; 44.73; 47.96. The proton at 5.32 and carbons at 88.9,
100.2, 101.6, 104.6, 111.9, 112.7, 142.5, 160.4, 161.4, 162.8, 164.0, 172.2, and 192.3
were not detected in our dataset. Also, the proton at 2.65 was a singlet in our
data, but was supposed to create correlate to the proton at 2.98 which is a double
with a J = 16.6 Hz, as they are attached to the same carbon 47.96, which is also
revealed in the HSQC spectrum. The absence of this doublet was likely due to
the low signal intensity and thus unclear peak assignment. Remaining detected
signals were in agreement with previously published data [37].
dSEK4 (1 mg): UV: λmax = 293 nm. ESI-MS: m/z 299.0560 [M-H]−. 1H-
NMR δH ppm: 2.30 (3H, s); 4.36 (2H, s); 5.11 (1H, s); 5.54 (1H; s); 6.02 (1H,
s); 6.73 (1H, d, J = 2.04 Hz), 6.77 (1H, d, J = 2.04 Hz); 10.86 (1OH, s); 11.67
(1OH, s). 13C-NMR δH ppm: 19.83; 37.74; 88.41; 100.70; 102.53; 111.11; 114.16;
118.05;.138.35; 159.72; 161.72; 164.46; 164.83; 165.8; 178.15. Protons at 5.11 and
5.54 were singlets in our dataset and the carbon at 170.4 ppm was not detected.
These protons should be doublets due to aromatic interactions which was not
detected in our dataset. Remaining NMR signals were in agreement with published
data [38].
dSEK4b (1.1 mg): UV: λmax = 292 nm. ESI-MS: m/z 299.0564 [M-H]−.
1H-NMR δH ppm: 2.65 (3H, s); 3.85 (2H, s); 5.18 (1H, s); 6.09 (2H, s); 6.61 (1H,
d, J = 2.16); 6.64 (1H, d, J = 2.13); 10.67 (1OH, s); 11.98 (1OH, s-broad). 13C-
NMR δH ppm: 22.83; 37.51; 89.15; 101.03; 103.33; 112.59; 114.83; 117.29; 142.19;
159.62; 161.56; 161.70; 164.15; 178.51. The carbons at 160.8 and 172.2 were not
detected in our data but all other signals and assignments were in agreement with
published data [38].
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Figure 3.2 Compounds produced by type III PKSs used in this study. The highlighted bonds
represent C2 ketide units added in polyketide synthesis.
Table 3.2 Expressed type III PKSs, their origin and their reported products. Structures of
products can be found in figure 3.2.
Name Organism Expected primary product(s) Ref.
Gh2PS G. hybrida triacetic acid lactone (1) [27]
AaPCS A. aborescens 5,7-dihydroxy-2-methylchromone (2) [28]
DluHKS D. lusitanicum 6-(2’,4’-dihydroxy-6’-methylphenyl)-4-hydroxy-2-pyrone (3) [29]
AaPKS3 A. aborescens TW93a (4) and aloesone (5) [30]
AaOKS A. aborescens SEK4 (6), SEK4b (7), dSEK4 (8) and dSEK4b (9) [31]
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3.4 Results and discussion
3.4.1 Expression of type III PKSs in S. cerevisiae
The initial steps toward building the envisioned platform was to test if the cho-
sen type III PKSs would be functionally expressed in S. cerevisiae. To make the
product spectrum as wide as possible the type III PKSs were selected on the basis
of producing polyketides of different lengths (C6 to C16) along with using either
malonyl-CoA or acetyl-CoA as starter units. The selected type III PKSs were
the 2-pyrone synthase from Gerbera hybrida (Gh2PS) which produces triacetic
acid lactone (1) [27] and has previously been functionally expressed in S. cere-
visiae [39], the hexaketide synthase from Drosophyllum lusitanicum (DluHKS)
which produces the hexaketide 6-(2’,4’-dihydroxy-6’-methylphenyl)-4-hydroxy-2-
pyrone (3) [29] and the pentaketide synthase (AaPCS), PKS3 (AaPKS3) and
octaketide synthase (AaOKS) all from Aloe aborescens producing 5,7-dihydroxy-
2-methylchromone (2) [28]; TW93a (4) and aloesone (5) [30]; and SEK4 (6),
SEK4b (7), dSEK4b (8), and dSEK4 (9) [18, 31] respectively as their primary
products. An overview of the expressed type III PKSs and their reported primary
products can be found in table 3.2 and structures of the reported compounds can
be found in figure 3.2.
LC-MS based identification of compounds
To putatively identify the compounds expected to be produced by the heterolo-
gously expressed PKSs we used the exact masses of the expected compounds to
create EICs. Furthermore, UV spectra and relative retention time of the produced
compounds were compared to other polyketides from previous studies when avail-
able. UV-spectra were recorded in a raw extracts instead of pure compound and
other co-eluting compounds could therefore interfere with the spectra, which led
to some discrepancies in λmax observations when comparing to previous literature
Figure 3.3 On opposite page: Extracted ion chromatograms (ESI–) of S. cerevisiae strains
expressing type III PKSs. Relevant peaks representing compounds of interest are highlighted. (A)
m/z = 125.0233 ± 0.01, highlighted compound is triacetic acid lactone (1); (B) m/z = 191.0350
± 0.01, highlighted compound is 5,7-dihydroxy-2-methylchromone (2); (C) m/z = 233.0455 ±
0.01, highlighted compound is 6-(2’,4’-dihydroxy-6’-methylphenyl)-4-hydroxy-2-pyrone (3); (D)
m/z = 275.0550 ± 0.01, highlighted compound is TW93a (4); (E) m/z = 231.0652 ± 0.01,
highlighted compound is aloesone (5); (F) m/z = 317.0667 ± 0.01, highlighted compounds are
SEK4 (6) and SEK4b (7) ; (G) m/z = 299.0561 ± 0.01, highlighted compounds are dSEK4b
(8) and dSEK4 (9).
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reporting the UV spectrum of the pure compound. An overview EICs with exact
masses of each of the expected compounds can be found in figure 3.3 and UV
and MS spectra of the tentatively identified compounds can be found in appendix
(Figure S3.1).
Triacetic lactone (compound 1) was expected to be produced by the Gh2PS
PKS. The reported UV characteristic of a λmax = 284nm [40] was also observed
in our analysis along with an m/z = 125.0256 [M-H]−. Also, a low RT of 1.4 min
compared to other polyketides further supported the identification of compound
1.
The expected pentaketide chromone (compound 2) from AaPCS had an ex-
pected UV spectrum with λmax = 228, 248, 256, 293 and 310nm [41]. The exact
mass of m/z = 191.0348 [M-H]− (Calculated m/z = 191.0350) offered good sup-
port and the observed λmax = 222, 248, 254sh, 294 also strongly supported the
identification of the pentaketide chromone. The longer retention time of com-
pound 3 (RT = 4.1 min) compared to the octaketides SEK4 (6, RT = 3.2 min)
and SEK4b (7, RT = 3.3 min) was also in agreement with relative retention in
reverse phase HPLC observed in a previous study by Abe et al. (2005) [28].
The hexaketide pyrone (compound 3) had a λmax = 302nm which was in good
agreement with a previous study by Abe et al. (2005) [31]. Also, the detected
exact mass of m/z = 233.0457 [M-H]− (Calculated m/z = 233.0455) supported
the identification.
The strain expressing octaketide producing AaOKS produced higher levels of
the heptaketide TW93a (compound 4), than the strain expressing the heptaketide
producing AaPKS3. TW93a has also been reported to be produced by AaOKS
in easily detectable amounts in the study by Mizuuchi et al. (2009) [30]. TW93a
had a reported λmax = 216, 238 and 282 [42], which was in agreement with the
observed λmax = 216 and 278. Exact mass was determined to m/z = 275.0558
[M-H]− (calculated m/z = 275.0550) which supported the identification. An al-
ternative compound identification of compound 4 could be the heptaketide 6-(2-
(2,4- dihydroxy-6-methylphenyl)-2-oxoethyl)-4-hydroxy-2-pyrone (10), which has
the same molecular formula. The heptaketide pyrone (10) almost co-elutes with
TW93a (4) in the HPLC system where it is isolated, but in much lower concentra-
tion [30]. Therefore, it is most likely that the detected compound in our analysis
is 4 as our UV-spectrum was more similar to the reported of 4 than what was re-
ported for the heptaketide pyrone (10). Another heptaketide, aloesone (5), which
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was reported to be produced by AaPKS3 had a reported λmax = 243, 259 and 291
nm [43], and our observed UV-spectrum was in agreement with λmax = 268 and
294 nm. The observed exact mass of m/z = 231.0660 [M-H]− (calculated m/z =
231.0652) also supported the identification of aloesone (5).
LC-MS and NMR based identification of compounds
The octaketides SEK4 and SEK4b both had a reported λmax = 280 [28], which
was also observed. The observed exact mass of m/z = 317.0663 (6) and m/z =
317.0668 (7) [M-H]− (calculated m/z = 317.0667 for both) supported the iden-
tification. The sequence of elution in the used reverse phase HPLC system for
hexaketide, heptaketide and octaketide derived compounds are in agreement with
the study by Mizuuchi et al. (2009) [30]. The dehydrated octaketides dSEK4b
and dSEK4 (8 and 9 respectively) were also detected in our chemical analysis,
based on their exact mass and elution sequence when comparing with previous
studies [18]. The observed exact mass of m/z = 299.0559 (8) and m/z = 299.0563
(9) (Calculated m/z = 299.0561 for both) supported their identification. No UV
characteristics has been published for 8 and 9, but there is a slight shift of λmax =
280 nm for the non dehydrated octaketides SEK4 (6) and SEK4b (7) to a λmax =
292 nm for the dehydrated octaketides dSEK4b (8) and dSEK4 (9). This can be
explained with the higher number of conjugated double bonds in the dehydrated
octaketides. An overview of the metabolites tentatively identified by HPLC-UV-
MS and their characteristics in our chemical analysis system can be found in table
3.3. The octaketides 6, 7, 8 and 9 were purified by preparative chromatography
and NMR analyses were done to verify the putative identifications of the octake-
tides based on HPLC-UV-MS. The observed NMR data was in agreement with
previous studies [15, 37, 38]. NMR, MS and UV spectra from our analyses of the
octaketides can be found in appendix (Figure S3.2 to S3.5).
A clear tendency in our efforts to express type III PKSs in S. cerevisiae was
that the PKSs along with the longest possible polyketide chain also produced the
shorter chains though in much lower titers than the longest polyketide chain. The
titers were also much lower in comparison with PKS producing the polyketide as
its longest polyketide chain. This effect has also been reported in previous studies
of type III PKSs characterized under in vitro conditions [30]. An exception to this
rule was DluHKS which was not found to produce the pentaketide 3, but still was
found to produce the triketide 1. Also, the highest production of the heptaketide
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Table 3.3 Above: The observed characteristics of detected metabolites. Below: Detection
metabolites in strains.
Met
#
RT Molform Calculated
m/z [M-H]−
Observed
m/z [M-H]−
Reported
λmax [nm]
Observed
λmax [nm]
1 1.4 C6H6O3 125.0233 125.0256 284 288
3 4.1 C10H8O4 191.0350 191.0353 228, 248, 256,
293, 310
222, 248,
254sh, 294
2 2.9 C12H10O5 233.0455 233.0457 304 302
4 3.0 C14H12O6 275.0550 275.0558 216, 238, 282 216, 278
5 3.7 C13H12O4 231.0652 231.0666 243, 259, 291 268, 294
6 3.2 C16H14O7 317.0667 317.0663 280 280
7 3.3 C16H14O7 317.0667 317.0668 280 282
8 3.7 C16H12O6 299.0561 299.0559 - 292
9 3.8 C16H12O6 299.0561 299.0563 - 292
Gh2PS AaPCS DluHKS AaPKS3 AaOKS
1 + + + + +
3 nd + nd + +
2 nd nd + + +
4 nd nd nd + +
5 nd nd nd + +
6 nd nd nd nd +
7 nd nd nd nd +
8 nd nd nd nd +
9 nd nd nd nd +
4 was obtained by the octaketide producing AaOKS. This could be due to the
aloesone producing AaPKS3 had a preference to produce the heptaketide aloesone
5, instead of the heptaketide pyrone 4. This is also in agreement with observations
in the study by Mizuuchi et al. (2009) [30].
3.4.2 Co-expression of type III PKSs and type II cyclases
To test if it was possible to direct the folding of the produced polyketide back-
bone formed by the type III PKSs two bacterial polyketide cyclases were ex-
pressed by chromosomal integration in combination with the AaOKS type III
PKS. The strain expressing the cyclases were of mating type α to enable crossing
with strains expressing the octaketide synthase AaOKS as this were of mating type
a. The chosen bacterial cyclases were PdmD from Actinomadura hibisca involved
in pradimicin (Figure 2.3) biosynthesis [33] expected to promote the C9-C14 first
ring folding pattern[44] and gra-orf4 from Streptomyces vietnamensis involved in
granaticin (Figure 2.3) [32] expected to promote the C7-C12 first ring folding pat-
tern. Only the octaketide producing type III PKS was chosen for co-expression
with the cyclases as we assumed that this was the only PKS to produce a polyke-
tide of a length, which would be foldable by both gra-orf4 and PdmD. The diploid
strains expressing AaOKS and cyclases were created along with diploid control
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Figure 3.4 Compounds expected to be produced by co-expression of AaOKS and cyclases. The
colored curved arrows indicate the first C-C bond formation which is induced spontaneously or
by the cyclases gra-orf4 or PdmD.
strains expressing only the cyclases. These strains were found not to have altered
metabolism compared to the parent strain (CEN.PK111-61A) not expressing the
cyclases (data not shown).
The co-expression of AaOKS and Gra-orf4 was expected to increase the pro-
duction of SEK4 (6) and dSEK4 (9) when comparing to the production of SEK4b
(7) and dSEK4b (8). This was due to SEK4 (6) and dSEK4 (9) having the C7-C12
folding pattern promoted by the cyclase Gra-orf4, while SEK4b (7) and dSEK4b
(8) has the C10-C15 spontaneous folding pattern. For the co-expression of the
AaOKS and PdmD the expected compound to be promoted was the previously
characterized UWM1 (compound 11), which was observed when co-expressing the
octaketide producing actinorhodin minimal PKS in combination with the tetra-
cenomycin cyclase TcmN, which promotes the C9-C14 folding pattern [45]. An
overview of the expected compounds, which would be produced by co-expression
of the AaOKS and the cyclases, can be found in figure 3.4.
To evaluate the effects of the cyclases the area under peak for the different
octaketides was measured for each strain grown in triplicate. The C7-C12 folded
products were SEK4 and dSEK4 (compounds 6 and 9), the C10-C15 folded prod-
ucts were SEK4b and dSEK4b (compound 7 and 8), and the C9-C14 folded prod-
uct was UWM1 (compound 11). The percentage of the total production of oc-
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Table 3.4 Production of octaketides by diploid strains grown in triplicate. The values are
average percentages of the total area under peak for each of the folding patterns. The C7-C12%
are representing SEK4 and dSEK4, C9-C14% are UVM1 and C10-C15 are representing SEK4b
and dSEK4b. Standard deviations for triplicates are given in parentheses.
Enzymes OD600 C7-C12 % C9-C14 % C10-C15 %
AaOKS 9.87 (0.06) 47.77 (2.39) 1.09 (0.23) 51.14 (2.17)
AaOKS + Gra-orf4 8.49 (0.5) 54.02 (0.77) 0.19 (0.06) 45.8 (0.8)
AaOKS + PdmD 10.4 (0.96) 35.75 (0.36) 22.54 (2.71) 41.71 (2.35)
taketide for each of these folding patterns was calculated and these are shown in
table 3.4. The identification of UWM1 (11) was only tentative as no previous
studies have specified a UV spectrum for UWM1 (11). A strong support for the
identification is the sequence of elution of SEK4, UWM1, and SEK4b, which is
identical to the previous study by Seow et al. (1997) in which they also use reverse
phase chromatography [14]. Also, an exact mass of m/z = 299.0568 (Calculated
m/z = 299.0561) supported the tentative identification of the octaketide UWM1
(11). The elution sequence of the octaketides can be found in figure 3.5. The
recorded MS and UV spectra for UWM1 (11) can be found in appendix (Figure
S3.1).
The measured area under peak of octaketides (6, 7, 8 and 9) for each culti-
vation of the diploid strains expressing AaOKS with and without cyclases can be
found in appendix (Table S3.2). It was found that the gra-orf4 cyclase was not
able to fold all of the produced polyketide. Only about half of the produced oc-
taketide was detected as the C7-C12 folded 6 and 9. Nevertheless, the percentage
of the total produced octaketide, which was folded in the C7-C12 folding pat-
tern was significantly higher (p = 0.049) when co-expressing the C7-C12 cyclase.
Therefore, this data shows that the cyclase gra-orf4 was able to direct the folding
of the polyketide backbone. The co-expression of AaOKS and PdmD resulted in
significantly higher levels of UWM1 (11) compared to the expression of AaOKS
Figure 3.5 Detection of compounds to be quantified to evaluate folding patterns. Extracted
ion chromatograms at m/z = 317.0656 ± 0.01 (black) and m/z = 299.0550 ± 0.01 (blue).
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alone (p = 0.006). The change in the percentage was also much more prominent
for the C9-C14 PdmD cyclase compared to the C7-C12 Gra-orf4 foldase. This
shows that the nature of the foldases matters in terms of how efficient they are
at accepting and converting the AaOKS octaketide into the final specific aromatic
polyketide product.
When evaluating the efficiencies of the cyclases the natural substrate needs to
be taken into account. In the natural pathway gra-orf4 folds an octaketide chain
C16 [46], and issues with chain length of the AaOKS polyketide should not be
present. The low efficiency originates from other factors such as non-functional or
low expression, or high degradation rate of the gra-orf4 enzyme in S. cerevisiae.
PdmD folds a dodecaketide (C24) chain in the biosynthesis of pradicmicin [33],
and it is therefore surprising that the PdmD cyclase is that efficient at folding the
octaketide from AaOKS. The formation of the C6-C15 second ring is hypothesized
to be spontaneous as this ring is not present in pradimicin, and thus not likely to
be formed by PdmD.
3.5 Conclusion and perspectives
In this report we have shown that it is possible to express functional type III
PKSs in S. cerevisiae that can produce an array of different polyketide backbones.
Also, we have shown that it is possible to direct the first ring folding pattern of
the polyketide backbone by co-expression of a type II cyclase with the polyketide
directing the folding towards either the C7-C12 or C9-C14 folding pattern. Further
direction of the folding pattern of the polyketide backbone by having second and/or
third ring folding cyclases in the platform, would enable production of a vast array
of compounds. This has been successfully done in Aspergillus nidulans previously
for the production of the industrial colorant carmine [18]. The work presented here
functions as a proof-of-concept setting the scene for using a wider range of type III
PKSs producing longer polyketide products. In this way, the range of polyketides
the platform would be able to produce would grow fast as longer chains can be
folded in more complex ways. Also, it would be interesting to test cyclases from
other type II PKS systems, as it may be possible to find cyclases which would
be more efficient in producing the C7-C12 or C9-C14 folding pattern, or enzymes
that catalyze other cyclisation patterns.
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4.1 Abstract
Carmine is an industrial colorant which has long been recognized for its indus-
trial importance as it has many favorable traits for industrial use. The current
production of carmine is vulnerable to uncontrollable factors and thus an artificial
biosynthetic pathway for production of the carminic acid precursor flavokermesic
acid has been successfully expressed in Nicotiana benthamiana and Aspergillus
nidulans. However, the production of shunt products in these organisms was found
to be high and an alternative method is therefore needed. We aimed firstly to ex-
press the pathway in Saccharomyces cerevisiae to investigate the performance of
the pathway in S. cerevisiae and secondly to investigate if translational fusion of
the biosynthetic enzymes would improve output of the pathway and reduce shunt
products. We found that S. cerevisiae was able to produce 52 mg flavokermesic
acid per liter culture while the fusion of the biosynthetic enzymes was found to
have a detrimental effect on the performance of the artificial biosynthetic pathway.
Proteomics analysis of the cultivated strains revealed that fused enzymes were in
much lower relative abundance compared to non fused enzymes. This lead us to
hypothesize that fusion of the biosynthetic enzymes interfered with their ability to
form dimers. The creation of a S. cerevisiae cell factory producing flavokermesic
acid serves as an important step towards creating a stable fermentation based
production of carminic acid.
Keywords: Yeast, Metabolic engineering, Polyketide synthases
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4.2 Introduction
The industrially important natural colorant carmine is derived from carminic acid
which is extracted from the scale insect Dactylopius coccus along with related com-
pounds such as flavokermesic acid (FK) and kermesic acid (KA) [1]. Carmine has
reached this importance because of its solubility, coloring potential and stability,
and humans have a long history of using the compound as dye for textiles, paints,
food and cosmetics [2]. The current production method for carmine is vulnerable
to a series of uncontrollable factors that typically plague agricultural products,
such as the weather and prevalence of plant or insect pathogens, which result in
large yearly fluctuations in the available carmine levels, leading to a very unstable
market and pricing. An increasing demand for natural colors from consumers has
further increased pricing of carmine. To circumvent this, a fermentable cell factory
would stabilize the supply and increase the production levels to meet demands.
However, the natural biosynthetic pathway and the involved enzymes in D. coccus
is currently unknown [3], and it has been necessary to build an artificial biosyn-
thetic pathway [4, 5]. The three initial steps of the artificial biosynthetic pathway
in question are shown in figure 4.1 and has been shown to lead to the production of
Figure 4.1 The artificial biosynthetic pathway for the production of flavokermesic acid, including
possible spontaneous reactions and products. The carbons in the structures are numbered based
on their position in the octaketide chain.
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flavokermesic acid in Nicotiana benthamiana[4] and when expressed in Aspergillus
nidulans also kermesic acid [5].
The artificial biosynthetic pathway for production of flavokermesic acid was
created by combining enzymes from a plant type III PKS and a bacterial type II
PKS systems. The pathway is initiated by the Aloe arborescens octaketide syn-
thase (OKS), which produces an non-reduced polyketide consisting of 16 carbons
[6]. This unstable octaketide can spontaneously fold to form flavokermesic acid,
but with very low yields due to multiple competing spontaneous reactions creating
shunt products. The desired reactions can, however, be promoted by enzymes cat-
alyzed formation of the C7-C12 bond in the molecule, using the cyclase ZhuI, and
formation of the second C5-C14 bond can likewise be promoted using the cyclase
ZhuJ1. The two cyclases originate from Streptomyces sp. R1128, where they par-
ticipate in biosynthesis of anthraquinones from a octaketide chain [7]. Formation
of the third C2-C15 bond that forms flavokermesic anthrone, and the subsequent
oxidation of the central ring to form the quinone of flavokermesic acid, are both
hypothesized to be spontaneous reactions in N. benthamiana and A. nidulans [4,
5].
The production levels and product spectra reported in the two proof-of-concept
studies for the pathway [4, 5], however, showed that the pathway in its current form
is inefficient. This is primarily due to a high level of shunt reactions leading to the
formation of e.g. SEK4 and SEK4B instead of the desired flavokermesic acid and
kermesic acid. A situation that makes it futile to attempt to optimize production
to industrially relevant levels simply by increasing the precursor supply in the
cell or the enzyme levels as this would not mend the problem of shunt product
formation.
In the current study we test different strategies to optimize the specificity of the
artificial biosynthetic pathway by first expressing it in Saccharomyces cerevisiae,
which is widely recognized and utilized in academia and industry for the devel-
opment and production of small molecules and proteins. S. cerevisiae features a
less complex metabolism and reactome compared to the previously tested hosts,
which reduces the chances of shunt product formation via competing endogenous
pathways. Secondly, we investigated if fusion of the biosynthetic enzymes could
increase the efficiency and specificity of the pathway and allow for elevated levels
1The polyketide fold catalyzing enzymes ZhuI and ZhuJ have vastly different domain struc-
ture and the names cyclase and aromatase are used for the respectively, but for ease of reading
they are both called cyclase in this manuscript.
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of flavokermesic acid.
4.3 Materials and methods
4.3.1 Synthetic genes, vectors and strains, and media
Biosynthetic genesOKS (Q3L7F5, [6]), ZhuI (AAG30197, [7]), and ZhuJ (AAG30196,
[7] were codon optimized for S. cerevisiae and de novo synthesized by Genscript
(http://www.genscript.com). The three enzymes were translationally fused in dif-
ferent configurations via two different amino acid linkers, here called L1 (Sequence:
MGSGGGGS), designed by Albertsen et al. (2011) [8], and amino acid linker L2
(Sequence: MGGSGSAG) which was designed for this study based on the design
rules for designing L1, by utilizing small polar amino acids, such as serine and
glycine, which ensures that the linker is flexible and water soluble [8]. The yeast
integrative expression vectors used in this study were derived from the system
described by Mikkelsen et al. (2012) [9], and a complete list of the used and con-
structed vectors can be found in appendix (Table S4.2). Escherichia coli strain
DH5α was used to assemble and propagate all plasmids. An overview of all used
and created S. cerevisiae strains from this study can be found in appendix (Table
S4.3). Lysogeny broth (LB) medium supplemented with 100 µg/L ampicillin was
used for all E. coli vector propagations. Synthetic complete (SC) medium lacking
uracil [10] was used for selecting yeast transformants based on acquisition of the
URA3 marker in the introduced expression cassette. Subsequent propagation of
transformants was performed on yeast peptone dextrose (YPD) medium consisting
of 10 g/L Bacto yeast extract (BD Bionutrients, NJ, USA), 20 g/L Bacto Peptone
(BD Bionutrients, NJ, USA) and 20 g/L glucose. To allow for consecutive trans-
formation steps in the yeast strains, the introduced URA3 marker was removed
via direct repeat recombination and counter selection for the URA3 marker by
growing transformants on SC supplemented with 740 mg/L 5-fluoroorotic acid
(USBiological, MA, USA).
4.3.2 Vector and strain construction
The coding sequence of the three genes were PCR amplified from the plasmids
delivered from GenScript using the combinations of primers listed in appendix
(Table S4.1). As up to three enzymes would need to be fused with the linkers in
between, three positions (beginning (B), middle (M) and end (E)) was designated.
Directional assembly was possible as universal primer overhangs containing in the
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linkers (L1 or L2) were designed. The yeast promoters PTEF1 and PPGK1 were
PCR amplified from pSP2 [11] using primers also with universal overhangs. These
universal overhangs allowed for directional seamless DNA assembly. The yeast ex-
pression vectors were assembled via the Uracil-Specific Excision Reagent (USER)
fusion cloning method as described in Mikkelsen et al. (2012) [9]. The result-
ing plasmids were verified by restriction analysis and sanger sequencing (GATC
biotech, Konstanz, Germany). The individual expression cassettes were excised
from the vectors via restriction enzyme digestion and gel-purified prior to intro-
duction into yeast, as described in Mikkelsen et al. (2012) [9]. Transformation of
S. cerevisiae was performed using the LiAc/SS-DNA/PEG method [12]. Trans-
formants with the desired genotype were verified via diagnostic colony PCR using
primers specific for the integrated genes and the backbone (Colony PCR/Sequenc-
ing primers in table S4.1).
4.3.3 Cultivation and chemical extraction
S. cerevisiae strains were cultured in triplicates for 5 days at 30◦C in 500 mL Er-
lenmeyer flasks with bafles containing 50mL YPD at 200 rpm. All cultures were
innoculated with an overnight YPD preculture to an OD600 of 0.1. OD600 mea-
surements were performed using a Shimadzu UV-1800 spectrophotometer (Japan).
Following completion of the cultivation the end-point OD600 was measured and
1 mL of the culture was removed for proteomics analysis, and the remaining was
used for the metabolite analysis. The cells in the proteomics sample were col-
lected by centrifugation at 8000 xg and washed once with milliQ water and stored
at -18◦C until all samples were ready for proteomics analysis.
Chemical extractions were done by separating the biomass from the culture
liquid via centrifugation (8000 xg for 5 minutes) in a 50mL falcon tube (Subse-
quently named tube A). The culture liquid was decanted into another 50mL falcon
tube (Subsequently named tube B). To lyse the yeast cells 25mL of extraction liq-
uid (ethylacetate with 1% v/v formic acid) was added to the pellet in tube A
and subjected to ultrasound for 1 hour. Afterwards, 25mL of the culture liquid
from tube B was decanted into the extraction liquid and yeast cell mixture. Af-
ter vigorous shaking the culture liquid was removed with a glass Pasteur pipette
from tube A. Tube A was centrifuged (8000 xg for 5 minutes) and the extrac-
tion liquid was decanted into the remaining culture liquid tube B. After vigorous
shaking with the remaining culture liquid the culture liquid was removed with a
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glass Pasteur pipette. The extraction liquid was evaporated to dryness under a
gentle stream of N2. The residue was redissolved in 300µL HPLC grade methanol
and exposed to ultrasound for 10 seconds to dissolve residuals and transferred to
a 2 mL eppendorph tube. The eppendorph tube was centrifuged (18000 xg for 5
minutes) to remove undissolved residuals and 150µL of the liquid was transferred
to a HPLC-vial.
4.3.4 HPLC-MS quantification
Samples were separated on an Agilent Infinity 1290 UHPLC (Agilent Technologies,
CA, USA) fitted with a Kinetex Biphenyl (100 x 2.1 mm, 2.6 µm) column kept at
40◦C. The gradient elution was performed with a solvent A consisting of H2O with
50mM formic acid and a solvent B consisting of acetonitrile with 50mM formic
acid. The gradient profile was as follows: 15% B and kept there for 0.5 min, 15%
B to 25% B in 1.5 min, 25% B to 25.56% B in 3.5 min, 25.56% B to 100% B in 0.5
min kept at 100% for 1.5 min and returned to 15% B in 0.1 min and equilibrated
for 1.9 min with a flow of 0.4 mL/min. The sample injection volume was 1µL.
The MS quantification was performed on an Agilent 6490 Triple Quadropole MS
fitted with an electrospray ionisation (ESI) ion source. The source settings were
as follows: gas temp 200◦C, gas flow 16 l/min, nebulizer 25 psi, sheath gas temp
300◦C sheath gas flow 12 l/min, capillary voltage 4000V and nozzle voltage 500V.
iFunnel parameters were at High pressure RF of 150V and low pressure RF of 60V.
To quantify the compounds of interest the parent masses were the [M-H]− for the
individual compounds, with collision energies of 10, 20 and 40V, and the quantified
product ions as follows: SEK4 (m/z 233, RT = 2.05 min), SEK4b (m/z 191, RT
= 2.17 min), dSEK4 (m/z 213, RT = 2.78 min), dSEK4b (m/z 83, RT = 2.62
min) and flavokermesic acid (m/z 269, RT = 3.90 min). Standards of each of the
quantified compounds were used for a calibration curve (0.1-100 µg/L) with only
the linear part being used for quantification. Cultivation samples were diluted (5,
10 or 20 times with methanol) if needed. HPLC-MS data analysis was performed
in Agilent QQQ Quantitative analysis (Agilent Technologies, CA, USA).
4.3.5 Proteomics analysis
Lysate preparation and digestion was done according to Kulak et al. (2014) [13].
Briefly, cells were lysed using 50µl of lysis buffer (consisting of 6 M Guanidinium
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Hydrochloride, 10 mM TCEP, 40 mM CAA, 100 mM Tris pH8.5). Samples were
boiled at 95◦C for 5 minutes, after which they were sonicated on high for 3 times
10 seconds in a Bioruptor sonication water bath (Diagenode) at 4◦C. After de-
termining protein concentration with Bradford (Sigma), 10ug was taken forward
for digestion. Samples were diluted 1:3 with 10% acetonitrile, 25 mM Tris pH
8.5, LysC (MS grade, Wako) was added in a 1:50 (enzyme to protein) ratio, and
samples were incubated at 37◦ for 4 hours. Samples were further diluted to 1:10
with 10% acetonitrile, 25 mM Tris pH 8.5, trypsin (MS grade, Promega) was
added in a 1:100 (enzyme to protein) ratio and samples were incubated overnight
at 37◦. Enzyme activity was quenched by adding 2% trifluoroacetic acid (TFA)
to a final concentration of 1%. Prior to TMT labeling, the peptides were desalted
on in-house packed C18 Stagetips [14]. For each sample, 2 discs of C18 material
(3M Empore) were packed in a 200µl tip, and the C18 material activated with
40µl of 100% methanol (HPLC grade, Sigma), then 40µl of 80% acetonitrile, 0.1%
formic acid. The tips were subsequently equilibrated 2x with 40µl of 1%TFA,
3% acetonitrile, after which 10ug of sample was loaded using centrifugation at
4,000x rpm. After washing the tips twice with 100µl of 0.1% formic acid, the pep-
tides were eluted into clean 500µl Eppendorf tubes using 40% acetonitrile, 0.1%
formic acid. The eluted peptides were concentrated in an Eppendorf Speedvac,
and re-constituted in 50mM HEPES (pH8.5) for TMT labeling. Labeling was
done according to manufacturer’s instructions, and subsequently, labeled peptides
were mixed 1:1:1:1:1:1:1:1:1:1:1 (11-plex), acidified to 1% TFA and acetonitrile
concentration brought down to <5% using 2% TFA. Prior to mass spectrometry
analysis, the peptides were fractionated using Strong Cation Exchange (SCX) in
StageTip format. For each sample, 3 discs of SCX material (3M Empore) were
packed in a 200µl tip, and the SCX material activated with 80µl of 100% acetoni-
trile (HPLC grade, Sigma). The tips were equilibrated with 80µl of 0.2% TFA,
after which the samples were loaded using centrifugation at 4,000x rpm. After
washing the tips twice with 100µl of 0.2% TFA, 2 initial fractions were eluted
into clean 500µl Eppendorf tubes using 75 and 200mM ammonium acetate in 20%
acetonitrile, 0.5% formic acid respectively. The final fraction was eluted using 5%
ammonium hydroxide, 80% acetonitrile. The eluted fractions were frozen on dry
ice and concentrated in an Eppendorf Speedvac, and re-constituted in 1% TFA,
2% acetonitrile containing iRT peptides for Mass Spectrometry (MS) analysis.
For each sample, peptides were loaded onto a 2 cm C18 trap column (Ther-
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moFisher 164705), connected in-line to a 50 cm C18 reverse-phase analytical col-
umn (Thermo EasySpray ES803) using 100% Buffer A (0.1% Formic acid in water)
at 750 bar, using the Thermo EasyLC 1000 HPLC system, and the column oven
operating at 45◦C. Peptides were eluted over a 140 minute gradient ranging from
6 to 60% of 80% acetonitrile, 0.1% formic acid at 250 nl/min, and the Q-Exactive
instrument (Thermo Fisher Scientific) was run in a DD-MS2 top10 method. Full
MS spectra were collected at a resolution of 70000, with an AGC target of 3 x
106 or maximum injection time of 20 ms and a scan range of 300–1750 m/z. The
MS2 spectra were obtained at a resolution of 35000 and an AGC target value of
1 x 106 or maximum injection time of 120 ms, a normalised collision energy of 28
and an intensity threshold of 8.3 x 103. Dynamic exclusion was set to 60 s, and
ions with a charge state < 2 or unknown were excluded. MS performance was
verified for consistency by running complex cell lysate quality control standards,
and chromatography was monitored to check for reproducibility.
The raw files were analysed using Proteome Discoverer 2.2. TMT reporter
ion quantitation was enabled in the processing and consensus steps, and spectra
were matched against the CEN.PK113-7D (proteome ID UP000013192) database
obtained from Uniprot, with sequences of the heterologously expressed enzymes
added (See appendix page 132 for the added sequences). Dynamic modifications
were set as Oxidation (M), Deamidation (N,Q) and Acetyl on protein N-termini.
Cysteine carbamidomethyl was set as a static modification. All results were filtered
to a 1% FDR, and protein quantitation done using the built-in Minora Feature
Detector, combined with the built-in ANOVA feature for statistical significance
testing.
4.3.6 Analysis of protein structures
To investigate the protein structures the crystal structure for OKS and ZhuI was
downloaded and visualized in PyMOL [15]. As no crystal structure for ZhuJ had
been published, a homology model was build by utilizing HHPRED followed by ho-
mology modelling with the best sequence homologs. The homolog search and mod-
elling was done with the Bioinformatics toolkit (Available at https://toolkit.tue-
bingen.mpg.de) [16].
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4.4 Results and discussion
4.4.1 Expression of artificial flavokermesic acid producing
biosynthetic pathway in S. cerevisiae
To investigate the functionality of the artificial flavokermesic acid biosynthetic
pathway in S. cerevisiae, we first constructed a series of yeast strains contain-
ing the three individual genes encoding the biosynthetic enzymes in all possible
combinations. These were OKS, OKS + ZhuI, OKS + ZhuJ and OKS + ZhuI
+ ZhuJ, along with control strains only expressing the cyclases ZhuI and ZhuJ.
The expression of the artificial pathway producing flavokermesic acid was found to
produce flavokermesic acid along with the shunt products SEK4, SEK4b, dSEK4
and dSEK4b (Figure 4.2). The control strains which were not expressing OKS did
not produce any detectable amounts of the metabolites quantified in the strains
expressing OKS. Mutactin was detected in A. nidulans when expressing the arti-
ficial pathway [5], but mutactin was not detected when expressing the pathway in
S. cerevisiae.
The production of flavokermesic acid was found to be highest by the strain
expressing all three biosynthetic enzymes with a production of 52.26 mg flavoker-
mesic acid per liter culture (Table 4.1). While this was a high yield it was also
positive to conclude that as good as 100% of the detected metabolites was flavok-
ermesic acid meaning that the system was very efficient at producing flavokermesic
Figure 4.2 Total ion chromatogram (TIC) traces of strains expressing the artificial biosynthetic
pathway. (A) An overview of the TIC chromatogram highlighting production of flavokermesic
acid. (B) Same chromatogram as A but scaled differently to view production of shunt products
SEK4, SEK4b, dSEK4b, dSEK4.
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Table 4.1 Metabolic performance of the strains expressing the artificial pathway producing
flavokermesic acid. Total is the summed amount of metabolites SEK4, SEK4b, dSEK4b, dSEK4,
and FK in mg per litre culture. FK is the specific production of flavokermesic acid in mg per
litre culture. C7-C12 % is the percentage of the total metabolites, which had the C7-C12 folding
pattern. FK% is the percentage of total metabolites being FK.
Enzymes Total FK C7-C12 % FK %
OKS 0,44 (0,27) 0,24 (0,06) 36,45 (10,6) 28,57 (13,08)
OKS + ZhuI 1,21 (0,3) 0,57 (0,13) 72,82 (2,8) 47,42 (5,99)
OKS + ZhuJ 12,36 (1,82) 12,09 (1,67) 97,96 (0,85) 97,84 (0,9)
OKS + ZhuI + ZhuJ 52,26 (4,16) 52,23 (4,17) 99,95 (0,04) 99,95 (0,04)
acid with very few shunt products. Previous studies did not report quantification
of metabolites, which made direct comparison of cell factories troublesome, but
with very limited production of shunt products compared to flavokermesic acid
the artificial biosynthetic pathway appeared to be performing substantially better
in S. cerevisiae than in N. benthamiana and A. nidulans [4, 5]. In previous studies
the level of flavokermesic acid was comparable or lower than the shunt products [4,
5], whereas we found that the level of flavokermesic acid was more than 2000-fold
that of shunt products in the strain expressing OKS, ZhuI and ZhuJ.
With this positive first expression in S. cerevisiae of the artificial pathway for
production of flavokermesic acid we explored methods for optimizing the pathway
in S. cerevisiae to obtain even higher production of flavokermesic acid. Fusion
of biosynthetic pathway enzymes has previously been shown to improve pathway
turnover and specificity because the intermediates released from one enzyme are
more likely to diffuse to the next enzyme in the pathway if these are fused and thus
in close proximity [17]. We chose to utilize flexible, water soluble and relatively
long linkers (8 amino acids) [8]. As we did not know how the enzymes would
react to having the linkers and other enzymes attached, we wanted to allow the
individual enzymes to move freely in reference to each other. Furthermore, as
we did not know what combination or sequence of the enzymes would be best
for production of flavokermesic acid when fused, we would have to investigate all
possible combinations of fusions of two and three enzymes.
4.4.2 Effect of different translation fusion of OKS, ZhuI and
ZhuJ on flavokermesic acid production
The construction of translational fusion required that the OKS would be fused to
the other enzymes, which might impact its performance. We therefore tested the
effects of appending the L1 and L2 linkers to the OKSs N- and C-terminal ends, to
learn the if linkers would effect the function of the OKS. Not only would this show if
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Figure 4.3 Production of Flavokermesic acid by strains expressing the OKS only.
the linkers could interfere with the active site, but as the OKS functions as a dimer
it would also give an indication if the linker interfered with the dimeric space. The
level of flavokermesic acid was comparable for all strains except for the construct
expressing the L1 linker linked to OKS N-terminal (L1-OKS), as this configuration
produced significant lower levels of flavokermesic acid than all other constructs in
this sample set (Figure 4.3). The low production of flavokermesic acid could not
be explained by higher production of the spontaneous shunt products, octaketides
SEK4 and SEK4b, as the total production of metabolites was also significantly
lower (Table 4.2). The negative effect of the L1 linker was only observed if it
was linked N-terminally onto the OKS. Surprisingly, N-terminal linking of L2 did
not have a negative impact on the OKS, though the two linkers were similar.
A possible bias in this analysis was that the performance of the different OKS
versions was assayed at cell level, normalized to biomass content, rather than the
OKS protein levels. Meaning that it was impossible to rule out that the lower
level of flavokermesic acid from the strain expressing L1-OKS was due to a lower
protein level of L1-OKS as compared to the other strains.
To rule out this possibility we next analyzed the OKS protein levels in the
different OKS expressing strains (Table 4.3). This analysis showed that the L1-
OKS strain had the highest OKS protein levels of the analyzed strains, with a OKS
relative abundance of 113 compared to the average OKS relative abundance of 96
for all strains in this sampleset (FusP-SC01 to FusP-SC06). Proteomics results
showed that N-terminal fusion of L1 to the OKS did not reduce the translation
rate nor had a negative effect on the half-life of the OKS. Based on this we could
therefore concluded that the lower output of flavokermesic acid could be attributed
to inefficiency of the L1-OKS enzyme. This could impair OKS when fused with
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Table 4.2 Production of flavokermesic acid by strains expressing the OKS enzyme. Numbers in
parentheses are standard deviations. Total and flavokermesic acid (FK) concentrations are given
in average mg compound per L culture. C7-C12% are the percentage of compound having the
C7-C12 fold (SEK4, dSEK4 and flavokeremsic acid). FK% is the percentage of total compound
being flavokermesic acid.
Production of metabolites Percentage of metabolites
Sc# Enzyme Total FK C7-C12 % FK %
Strains expressing OKS only
Sc01 OKS 0.97 (0.20) 0.24 (0.06) 36.45 (10.6) 28.57 (13.08)
Sc02 OKS-L1 0.64 (0.2) 0.24 (0.04) 44.2 (10.56) 38.89 (11.75)
Sc03 L1-OKS 0.12 (0) 0.08 (0.01) 66.26 (6.37) 66.26 (6.37)
Sc04 OKS-L2 1.17 (0.58) 0.24 (0.07) 33.89 (6.8) 22.47 (8.86)
Sc05 L2-OKS 0.57 (0.04) 0.28 (0.06) 52.71 (6.3) 48.72 (7.75)
Sc06 OKS + XI-2(empty) 1.03 (0.29) 0.22 (0.04) 31.91 (1.2) 21.58 (2.91)
Strains expressing OKS and one cyclase
Sc07 OKS + ZhuI 1.21 (0.3) 0.57 (0.13) 72.82 (2.8) 47.42 (5.99)
Sc08 OKS + L1-ZhuI 3.89 (0.1) 0.49 (0.07) 53.33 (0.8) 12.7 (1.4)
Sc09 OKS + ZhuI-L1 4.69 (0.12) 0.55 (0.06) 55.47 (4.36) 11.65 (1.24)
Sc10 OKS + L2-ZhuI 3.94 (0.03) 0.63 (0.05) 56.09 (1.76) 16.02 (1.44)
Sc11 OKS + L1-ZhuI-L2 3.86 (0.27) 0.63 (0.13) 57.57 (2.38) 16.25 (2.4)
Sc12 OKS-L1-ZhuI 0.44 (0.16) 0.3 (0.01) 78.11 (17.02) 74.24 (22.94)
Sc13 ZhuI-L1-OKS 1.37 (0.89) 0.39 (0.05) 55.29 (15.67) 37.57 (23)
Sc14 OKS-L2-ZhuI 0.88 (0.73) 0.24 (0.03) 52.08 (15.58) 38.5 (19.53)
Sc15 ZhuI-L2-OKS 0.93 (0.2) 0.32 (0.04) 50.2 (7.14) 35.96 (11.72)
Sc16 OKS + ZhuJ 12.36 (1.82) 12.09 (1.67) 97.96 (0.85) 97.84 (0.9)
Sc17 OKS + L1-ZhuJ 10.41 (0.83) 7.34 (0.97) 80.96 (1.27) 70.35 (3.91)
Sc18 OKS + ZhuJ-L1 23.63 (0.78) 21.15 (0.82) 92.07 (0.79) 89.5 (0.67)
Sc19 OKS + L2-ZhuJ 10.71 (3.36) 8.26 (3.35) 83.47 (2.98) 75.19 (9.34)
Sc20 OKS + L1-ZhuJ-L2 12.41 (1.47) 9.65 (1.5) 85.73 (2.38) 77.57 (3.07)
Sc21 OKS-L1-ZhuJ 0.53 (0.13) 0.53 (0.13) 99.66 (0.59) 99.66 (0.59)
Sc22 ZhuJ-L1-OKS 0.39 (0.1) 0.39 (0.1) 100 (0) 100 (0)
Sc23 OKS-L2-ZhuJ 0.67 (0.2) 0.67 (0.2) 99.13 (1.33) 99.13 (1.33)
Sc24 ZhuJ-L2-OKS 0.37 (0.03) 0.37 (0.03) 100 (0) 100 (0)
Strains expressing OKS and two cyclases
Sc25 OKS + ZhuI + ZhuJ 52.26 (4.16) 52.23 (4.17) 99.95 (0.04) 99.95 (0.04)
Sc26 OKS + ZhuI-L1-ZhuJ 34.58 (16.19) 34.37 (16.07) 99.49 (0.48) 99.43 (0.54)
Sc27 OKS + ZhuI-L2-ZhuJ 24.75 (1.57) 24.51 (1.33) 99.12 (0.86) 99.04 (0.97)
Sc28 OKS + ZhuJ-L1-ZhuI 3.55 (0.58) 3.3 (0.39) 94.46 (4.64) 93.49 (5.74)
Sc29 OKS + ZhuJ-L2-ZhuI 5.28 (0.31) 5.04 (0.12) 96.41 (3.29) 95.72 (4.1)
Sc30 OKS-L1-ZhuI + ZhuJ 38.51 (3.89) 38.44 (3.84) 99.85 (0.13) 99.84 (0.15)
Sc32 OKS-L2-ZhuI + ZhuJ 40.57 (4.01) 40.57 (4.01) 100 (0) 100 (0)
Sc34 OKS-L1-ZhuJ + ZhuI 3.27 (0.82) 3.27 (0.82) 100 (0) 100 (0)
Sc35 ZhuJ-L1-OKS + ZhuI 2.94 (0.84) 2.94 (0.84) 100 (0) 100 (0)
Sc36 OKS-L2-ZhuJ + ZhuI 2.64 (0.32) 2.64 (0.32) 100 (0) 100 (0)
Sc37 ZhuJ-L2-OKS + ZhuI 1.48 (0.77) 1.48 (0.77) 100 (0) 100 (0)
Sc38 OKS-L1-ZhuI-L2-ZhuJ 7.25 (0.36) 7.25 (0.36) 100 (0) 100 (0)
Sc40 ZhuI-L1-OKS-L2-ZhuJ 0.85 (0.21) 0.85 (0.21) 100 (0) 100 (0)
Sc41 ZhuJ-L1-OKS-L2-ZhuI 0.37 (0.13) 0.37 (0.13) 100 (0) 100 (0)
Sc42 ZhuI-L1-ZhuJ-L2-OKS 16.61 (1.42) 14.97 (1.4) 92.11 (0.75) 90.1 (0.78)
Sc43 ZhuJ-L1-ZhuI-L2-OKS 0.69 (0.11) 0.07 (0.05) 31.61 (5.53) 9.88 (6.95)
the L1 linker in the N-terminus to other biosynthetic enzymes.
Fusion of OKS with one cyclase
Next, we wanted to investigate what effect translational fusion of the OKS with one
of the cyclases ZhuI or ZhuJ would have on the production of flavokermesic acid
and specificity of the pathway. This was investigated by co-expressing the OKS
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Figure 4.4 Production of Flavokermesic acid by strains expressing the OKS and one of the
cyclases ZhuI or ZhuJ. Low producers of flavokermesic acid (<1mg/L culture) are in the left
panel while the high producers of flavokermesic acid (>5mg/L culture) are in the right panel.
in combination one of the cyclases as fusion enzymes in all possible configurations
(8 strains, FusP-SC12-15 and FusP-SC21-24) and also we wanted to investigate
the effect of appending linkers to the cyclases (8 strains, FusP-SC08-11 and FusP-
SC17-20); L1 or L2 linker in the N-terminus, the L1 linker in the C-terminus
or the L1 linker in the N-terminus and the L2 linker in the C-terminus. This
should cover all of the possible configurations in which the cyclases could have
a linker. The production of flavokermesic acid in these strains was compared
to the flavokermesic acid production in the initial expressions of the OKS and
the cyclases individually. The strains were then cultured and the production of
flavokermesic acid determined by HPLC-MS (Figure 4.4). Analysis of the results
revealed that the 18 strains divided into two groups that differed in the levels
of flavokermesic acid produced. A low producing group with flavokermesic levels
below 1 mg/L culture consisting of constructs co-expressing OKS and ZhuI and
constructs expressing OKS and ZhuJ as a fused enzymes (Figure 4.4, left panel).
The second group of strains that all produced flavokermesic acid at levels higher
than 5 mg per L culture, consisted of strains co-expressing OKS and ZhuJ as
standalone enzymes (Figure 4.4, right panel).
ZhuI is in the pathway responsible for catalyzing formation of the first aromatic
ring via a C7-C12 bond (Figure 4.1), direct the metabolic flux toward formation
of SEK4 and flavokermesic acid. A fair evaluation of the functionality of ZhuI
should therefore not only focus on flavokermesic acid, but instead compare the
percentage of metabolites having the C7-C12 fold (C7-C12%) of strains express-
ing the ZhuI combinations with OKS to that of strains only expressing the OKS
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(Figure 4.5). Analysis of the strains showed all strains expressing the OKS and
ZhuI as standalone enzymes (FusP-SC07 to FusP-SC11) had a significantly higher
C7-C12% than strains only expressing OKS (FusP-SC01), 53-73% compared to
36%. The data here confirms the findings by Andersen-Ranberg et al. (2017) [4]
and Frandsen et al. (2018) [5], in which ZhuI was found to direct synthesis in the
desired direction. Evaluation of the effect of the used linkers on the performance
of the ZhuI revealed that both linkers had a detrimental effect on the efficiency
of ZhuI, when comparing to coexpression of OKS + ZhuI without linkers. The
level of flavokermesic acid was found to be significantly higher for all strains co-
expressing OKS and ZhuI as standalone enzymes, compared to strains with only
the OKS, indicating that when the first ring was formed correctly by ZhuI the
spontaneous formation of flavokermesic acid was still possible. When ZhuI and
OKS were linked together the C7-C12% was comparable to the standalone expres-
sion. Even though ZhuI was still able to fold the nascent octaketide chain when
fused to OKS the production of flavokermesic acid was not significantly higher
indicating that the OKS was not as efficient when fused to ZhuI. An interesting
observation was that the strains expressing fusions of OKS an ZhuI with ZhuI in
the N-terminus had a slightly higher average flavokermesic acid level, though not
significant, than the strains with ZhuI in the C-terminus (Figure 4.4, left panel).
Figure 4.5 Percentage of quantified metabolites having the C7-C12 folding pattern. The effect
of linkers on the efficiency of the cyclases as well as effect of fusion is highlighted.
The co-expression of the cyclase ZhuJ and OKS as standalone enzymes led
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to a strong increase in the level of flavokermesic acid as previously mentioned.
Compared to the strain only expressing the OKS the strains co-expressing the ZhuJ
cyclase as a standalone enzyme, including expression of ZhuJ with linkers, led to a
30 to 89 fold increase in flavokermesic acid production. Surprisingly, the strain co-
expressing OKS and the ZhuJ-L1 had a significantly (p < 0.05) higher production
of flavokermesic acid than the other strains expressing the OKS and ZhuJ as
standalone enzymes (Appendix Figure S4.2). This indicated that L1 had a positive
effect on ZhuJ activity when linked to the C-terminus of the enzyme. Possible
explanations for this could be increased substrate uptake or enzymatic turnover
rate for the ZhuJ enzyme. An alternative explanation could be faster translation or
slower degradation of the enzyme as the protein level of ZhuJ-L1 was considerably
higher than the other strains expressing the OKS and ZhuJ as standalone enzymes
(FusP-SC16 to FusP-SC20, table 4.3). The constructs expressing the fused versions
of OKS and ZhuJ all had significantly higher flavokermesic acid levels compared to
the strain expressing OKS except the strain expressing ZhuJ-L1-OKS. With that
being said the level of flavokermesic acid was significantly lower than the strains co-
expressing OKS and ZhuJ as standalone enzymes. Therefore, it can be concluded
that ZhuJ was functional when fused to OKS, but as concluded for OKS and ZhuI
fusions OKS was not as productive when fused to ZhuJ. Interestingly both the
fused and non-fused ZhuJ and OKS co-expressions had a very low levels of the
shunt products SEK4, SEK4b, dSEK4 and dSEK4b with all having above 70% of
quantified products (FK%) being flavokermesic acid. The fusion enzymes had a
FK% which was close to 100% (Figure 4.5), indicating that when fused to OKS,
ZhuJ was very successful in converting the nascent octaketide to flavokermesic acid
instead of letting it fold to the shunt products. This could indicate that ZhuJ does
not need the C7-C12 ring to form before it can make the C5-C14 ring formation
and it may even catalyze the formation of C7-C12 at the same time of making the
C5-C14 ring. Inversely to what was found for ZhuI the strains expressing ZhuJ in
the C-terminus had a slightly higher average level of flavokermesic acid than the
strains expressing ZhuJ in the N-terminus.
To conclude on the productivity of the OKS in combination with one of the cy-
clases, the co-expression of ZhuI and OKS had a significant effect on the C7-C12%,
but not a significant effect on the level of flavokermesic acid for the non-fused ver-
sions of the co-expression. Co-expression of ZhuJ and OKS led to elevated levels
of flavokermesic acid. This effect was only observed for non-fused versions. Thus,
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for both the ZhuI and ZhuJ the fusion with OKS did not have a positive effect on
the flux towards flavokermesic acid compared to the non-fused versions. The high-
est production of flavokermesic acid was with co-expression of OKS and ZhuJ-L1
which had a 89-fold increase in the flavokermesic acid production compared to the
strain expressing only OKS.
Fusion of the OKS with both cyclases
The final sample set consisted of strains co-expressing OKS, ZhuI and ZhuJ and
fusions of these in different sequences. The expectations were that we would reach
the highest levels of flavokermesic acid as this was found in previous studies [5].
Similarly to the strains expressing two enzymes these strains could be split into
two different groups based on their production of flavokermesic acid. A low pro-
ducing group produced up to 5 mg flavokermesic acid per L culture (Figure 4.6,
left panel) while the high producing group reached level in the range from 7 to
52 mg flavokermesic acid per L culture (Figure 4.6, right panel). Unfortunately,
three of the constructed strains, namely ZhuI-L1-OKS + ZhuJ, ZhuI-L2-OKS +
ZhuJ and OKS-L1-ZhuJ-L2-ZhuI, did produce detectable levels of the metabolites
quantified here. For the strains expressing ZhuI-L1-OKS + ZhuJ and ZhuI-L2-
OKS + ZhuJ this was very surprising as both parent strains (ZhuI-L1-OKS and
ZhuI-L2-OKS) produced metabolites before the introduction of the ZhuJ encoding
gene. The protein levels were also detected lower for these strains indicating issues
with protein expression (Table 4.3). This situation points towards the introduc-
tion of critical mutation(s) in the OKS encoding gene during or after the second
transformation step.
The strain expressing ZhuI, ZhuJ and OKS as standalone enzymes (FusP-
SC25) had an average level of 52 mg flavokermesic acid per L culture, as previously
mentioned, and this was also the highest level detected for all created strains. As
good as all of the quantified metabolites were detected as flavokermesic acid (FK%
= 99,95, table 4.2) and the flavokermesic acid level was 1.3 fold higher than second
highest producer expressing OKS-L2-ZhuI + ZhuJ. This shows that not only was
the cell factory very efficient at producing flavokermesic acid, but at the same time
generated very few shunt products were formed.
The strains co-expressing OKS as a standalone enzyme with ZhuI and ZhuJ
fused together showed that a N-terminal localization of ZhuI resulted in 22 to 25
mg flavokermesic acid per L culture compared to only 4 to 5 mg flavokermesic
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Figure 4.6 Production of Flavokermesic acid by strains expressing the OKS and both of the
cyclases ZhuI and ZhuJ.
acid per L culture for strains having the opposite sequence of ZhuI and ZhuJ. This
finding was in agreement with the finding from expressing fusion enzymes of the
OKS and ZhuI or ZhuJ, which also found that the level of flavokermesic acid was
highest with ZhuI in the N-terminus and ZhuJ in the C-terminus.
The strains expressing fusion enzymes of OKS and ZhuI or ZhuJ likewise
showed different levels of flavokermesic acid when supplemented with the missing
cyclase as a standalone enzyme. All strains except the strain expressing ZhuJ-L2-
OKS + ZhuI had significantly higher levels of flavokermesic acid than the strains
only expressing the fused version without the standalone supplementary cyclase.
This shows that the addition of the standalone cyclase drives the overall pro-
duction of flavokermesic acid. The strains expressing OKS-L1-ZhuI + ZhuJ and
OKS-L2-ZhuI + ZhuJ reached very high levels of flavokermesic acid of 38 to 41
mg flavokermesic acid per L culture. It was very unfortunate that the strains
expressing ZhuI-L1-OKS + ZhuJ and ZhuI-L2-OKS + ZhuJ did not produce any
detectable metabolites as these had a higher level of flavokermesic acid in the pre-
vious dataset with only OKS and one cyclase. Therefore, it was expected that
these strains would have a higher production level of flavokermesic acid, which
could even be as high or higher than the level reached by the standalone expres-
sion of the three biosynthetic enzymes. The strains expressing the fusion of OKS
and the ZhuJ cyclase with standalone expression of ZhuI all had comparable levels
of flavokermesic acid between 1 and 3 mg flavokermesic acid per L culture. This
level was significantly higher than the strains expressing the OKS and ZhuJ fu-
sions without the standalone expression of ZhuI except for ZhuJ-L2-OKS + ZhuI
as mentioned earlier, but the level of flavokermesic acid produced was still low
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compared to other constructs expressing all three biosynthetic enzymes.
Finally, for strains expressing the OKS and the two cyclases as one fusion
enzyme, the highest average levels of flavokermesic acid was obtained by strains
expressing OKS-L1-ZhuI-L2-ZhuJ and ZhuI-L1-ZhuJ-L2-OKS producing 7 and 15
mg flavokermesic acid per L culture respectively. These strains each partly follow
the tendency of having ZhuI in the N-terminus and ZhuJ in the C-terminus for
having high production of flavokermesic acid. Interestingly the two strains express-
ing OKS in the C-terminus of the fusion enzymes with either of the cyclases had
very different performances, where the ZhuI-L1-ZhuJ-L2-OKS expressing strain
produced 15 mg flavokermesic acid per L culture with a C7-C12% of 92 while the
ZhuJ-L1-ZhuI-L2-OKS expressing strain produced 0.1 mg flavokermesic acid per L
culture with a C7-C12% of 32. This significant difference reveals that the neither
ZhuJ nor ZhuI was very efficient in the latter construct. The remaining strains
expressed ZhuI-L1-OKS-L2-ZhuJ and ZhuJ-L1-OKS-L2-ZhuI and both were not
very successful in producing flavokermesic acid with levels of 0.8 and 0.4 mg fla-
vokermesic acid per L culture respectively. This indicated that having the OKS
as the middle enzyme was very unfavorable.
To conclude on expression of OKS and both of the cyclases it was found that
the standalone expression of all enzymes reached the highest production level of
flavokermesic acid. The tendency found in fusion of the OKS with one of the
cyclases showed that ZhuI performs best in the N-terminus and ZhuJ in the C-
terminus was confirmed in this dataset as constructs abiding by this rule reached
significantly higher production levels of flavokermesic acid. The strains expressing
fusions of all three enzymes were not as successful in producing flavokermesic acid
as other constructs expressing the enzymes as fusions of two of the enzymes or as
standalone enzymes.
4.4.3 Protein quantification
The proteomics dataset has been used to explain performance of individual strains
in the metabolomics dataset. In this section focus will be put on finding general
trends of how the protein levels did or did not vary between different groups of
constructs. A number of calculations were done to compare different constructs
and an overview of these along with the detected protein abundances for individual
strains can be found in table S4.6 (Whole proteomics dataset and calculated values
are available in appendix table 4.3).
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Table 4.3 Overview of the proteomics dataset collected in this study. Protein levels are relative
to the levels recorded in the normalization sample. Full dataset is available in appendix table
S4.6
Strain # Enzymes OKS ZhuI ZhuJ
FusP-SC01 OKS 87.1 - -
FusP-SC02 OKS-L1 75.4 - -
FusP-SC03 L1-OKS 113.3 - -
FusP-SC04 OKS-L2 90.8 - -
FusP-SC05 L2-OKS 105.2 - -
FusP-SC06 OKS + XI-2(empty) 101.6 - -
FusP-SC07 OKS + ZhuI 88.9 202.9 -
FusP-SC08 OKS + L1-ZhuI 92.3 174.1 -
FusP-SC09 OKS + ZhuI-L1 79.1 360.1 -
FusP-SC10 OKS + L2-ZhuI 88.6 152.5 -
FusP-SC11 OKS + L1-ZhuI-L2 75.4 164.7 -
FusP-SC12 OKS-L1-ZhuI 92.8 78.3 -
FusP-SC13 ZhuI-L1-OKS 127 118.8 -
FusP-SC14 OKS-L2-ZhuI 78.7 115.5 -
FusP-SC15 ZhuI-L2-OKS 103.4 96 -
FusP-SC16 OKS + ZhuJ 95.9 - 312
FusP-SC17 OKS + L1-ZhuJ 95.8 - 108.5
FusP-SC18 OKS + ZhuJ-L1 98.2 - 370.4
FusP-SC19 OKS + L2-ZhuJ 89.3 - 158.8
FusP-SC20 OKS + L1-ZhuJ-L2 90.8 - 168.7
FusP-SC21 OKS-L1-ZhuJ 37.2 - 137.4
FusP-SC22 ZhuJ-L1-OKS 48.5 - 82.4
FusP-SC23 OKS-L2-ZhuJ 47.4 - 106
FusP-SC24 ZhuJ-L2-OKS 38.2 - 85.6
FusP-SC25 OKS + ZhuI + ZhuJ 100.6 207.5 175
FusP-SC26 OKS + ZhuI-L1-ZhuJ 91.4 55.4 214.8
FusP-SC27 OKS + ZhuI-L2-ZhuJ 83.9 64.6 220.1
FusP-SC28 OKS + ZhuJ-L1-ZhuI 81.7 31 89.8
FusP-SC29 OKS + ZhuJ-L2-ZhuI 93.5 54.8 132.5
FusP-SC30 OKS-L1-ZhuI + ZhuJ 61.8 83.1 476.4
FusP-SC32 OKS-L2-ZhuI + ZhuJ 84.1 91.4 386.7
FusP-SC34 OKS-L1-ZhuJ + ZhuI 51.8 224.9 122.5
FusP-SC35 ZhuJ-L1-OKS + ZhuI 32.9 277.3 84.9
FusP-SC36 OKS-L2-ZhuJ + ZhuI 47.5 166.3 141.3
FusP-SC37 ZhuJ-L2-OKS + ZhuI 40.4 214.6 130.4
FusP-SC38 OKS-L1-ZhuI-L2-ZhuJ 44.9 35.8 121.8
FusP-SC40 ZhuI-L1-OKS-L2-ZhuJ 36.1 60.2 95.8
FusP-SC41 ZhuJ-L1-OKS-L2-ZhuI 43.1 46.3 134.7
FusP-SC42 ZhuI-L1-ZhuJ-L2-OKS 46.5 66.4 172.6
FusP-SC43 ZhuJ-L1-ZhuI-L2-OKS 43.5 28.4 88.3
Initially, we wanted to investigate how fusions affected the enzyme levels of the
individual biosynthetic enzymes. To allow for this comparison we calculated the
average enzyme levels for each of the enzymes OKS, ZhuI and ZhuJ, in strains
expressing these as standalone enzymes or as fusion enzymes with one or two
of the other enzymes. This calculation revealed that the levels of enzymes were
significantly higher for enzymes expressed as standalone enzymes compared to the
same enzymes expressed in fusions (Table 4.4). The levels of enzymes, comparing
fused enzymes, were higher when two enzymes were fused than when three were
fused though this was not significant. Therefore, we concluded that fusion of
the enzymes had a detrimental effect on the overall level of enzyme available for
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biosynthesis and thereby also the possible output of the artificial biosynthetic
pathway. This lower level of enzyme when expressed as fusion enzymes could be
due to issues with translation of the larger enzymes or incomplete folding as a
consequence of the fusion and therefore higher degradation rates. Alternatively,
issues could be linked to secondary structures in the mRNA, which are only present
in fusion of two or three of the enzymes. These secondary structures could impair
translation and thus result in a lower level of protein.
As mentioned earlier in the metabolomics section, strains expressing fused
version of enzymes had a tendency for higher flavokermesic acid production if
ZhuI was placed in the N-terminus and ZhuJ in the C-terminus. This lead to the
question of whether the higher productivity was due to higher levels of enzyme
in these strains or if it was truly due to the two enzymes being more effective in
this sequence. To settle this we analyzed the data for the strains expressing fusion
enzymes consisting of the OKS and one of the two cyclases. The enzyme levels of
these fusion enzymes were not significantly different from one another (Appendix
table S4.6) and therefore, it can be concluded that the higher output of enzymes
having ZhuI in the N-terminus and/or ZhuJ in the C-terminus can be coupled to
the fusion enzymes catalytic properties rather than the enzyme levels in the cell.
Next, we wanted to investigate if and how high levels of flavokermesic acid
were correlated to the level of the individual enzymes. For this we compared the
enzyme levels in a group of high and low performing strains that expressed all
three biosynthetic enzymes, either as fusions or standalone enzymes. The high
performers consisted of 5 strains that all produced more than 10 mg flavokermesic
acid per L culture, while the 5 strains of low performers produced less than 3 mg
flavokermesic acid per L culture. The comparison (Table 4.5) showed that enzyme
levels for OKS and ZhuJ along with the summed level of OKS, ZhuI and ZhuJ pro-
teins were all significantly higher for strains producing high levels of flavokermesic
acid, and that the enzyme level for ZhuI was lower, though insignificant, for the
strains producing high levels of flavokermesic acid. The same tendency was found
Table 4.4 The level of enzymes when expressed as standalone enzymes or dual or triple fusion
enzymes. Significance (T-test) between the different groups were calculated. (Sin - single, Dua
- Dual fusion, Tri - Triple fusion)
Enzymatic levels Significance
Enz Sin Dua Tri Sin vs Dua Sin vs Tri Dua vs Tri
OKS 91.4 (9.5) 61.3 (27.7) 43.9 (4.4) 4.52 E-05 7.49 E-12 0.15
ZhuI 214.5 (63.0) 71.9 (30.5) 49.2 (15.0) 1.41 E-07 1.11 E-06 0.11
ZhuJ 281.6 (124.5) 129.0 (46.7) 121.2 (30.3) 2.72 E-05 8.08 E-04 0.72
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Table 4.5 Comparison of a strains expressing all three biosynthetic enzymes divided into a high
producing group of strains and a low producing group of strains with regards to the level of
flavokermesic acid.
Enz. High producers Low producers T-test HP vs LP
OKS 78.1 (20.1) 40.6 (5.3) 0.001
ZhuI 94.7 (56.8) 132.2 (102.3) 0.451
ZhuJ 274.3 (126.6) 112.6 (25.6) 0.012
Summed 447.1 (130.0) 285.3 (104.9) 0.039
for strains expressing the OKS and one of the cyclases (Table 4.3). Therefore, it
appears that high levels of flavokermesic acid can be reached independently from
the concentration of ZhuI. This could mean that ZhuI was extremely efficient at
folding the nascent octaketide produced by OKS. This hypothesis was however not
supported by the data for the strains that co-expressed OKS and ZhuI as stan-
dalone or as fusion enzymes without ZhuJ as all had a C7-C12% between 50 and
80, compared to the co-expression of OKS and ZhuJ having a C7-C12% between
80 to 100. With that being said the co-expression of all three enzymes yielded
the best C7-C12% between 92 to 100 with the exception of ZhuJ-L1-ZhuI-L2-OKS
having a C7-C12% of 32 (Table 4.2).
Therefore, it can be concluded that ZhuI had a positive effect when co-expressed
with OKS and ZhuJ while the effect of ZhuI was not as clear when only co-
expressed with OKS. The pattern we found was different to findings in Frandsen
et al. (2018) where the co-expression of OKS and ZhuI in A. nidulans lead to a
2.1-fold increase in flavokermesic acid level and co-expression of OKS, ZhuI and
ZhuJ lead to a 4.1 fold increase in flavokermesic acid level. When making the
same comparison in our dataset we saw a comparable 2.4-fold increase in flavok-
ermesic acid level when co-expressing OKS and ZhuI compared to expression of
OKS alone, while we saw a 220-fold increase when co-expressing ZhuI and ZhuJ
with OKS compared to expressing OKS alone. This effect can be attributed to the
effect of ZhuJ in S. cerevisiae as we saw a 51-fold increase in flavokermesic acid
level for co-expression of OKS and ZhuJ compared to expression of OKS, whereas
only a 2.7-fold increase was observed by Frandsen et al. (2018) [5].
In an attempt to identify the best enzyme configuration for production of fla-
vokermesic acid, we analyzed how enzyme level was correlated to flavokermesic
acid level, by normalizing the flavokermesic acid levels to the level of the three
enzymes for each construct. This was calculated as flavokermesic acid production
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divided by the enzyme levels of OKS, ZhuI, ZhuJ or the summed amount of OKS,
ZhuI and ZhuJ enzymes in each sample (Table 4.6). This analysis revealed that
strains that produced the highest levels of flavokermesic acid also had the highest
ratios of flavokermesic acid per enzyme, showing that high flavokermesic acid lev-
els were not only due to a higher concentration of the enzymes, but also a function
of the nature of the constructs. This support the claim that the enzyme config-
urations impact the efficiency of the pathway towards flavokermesic acid. The
highest flavokermesic acid per OKS ratio was observed in the strain expressing
OKS-L1-ZhuI + ZhuJ, closely followed by the highest flavokermesic acid producer
expressing OKS + ZhuI + ZhuJ. The highest enzyme specific activity (mg fla-
vokermesic acid per summed enzyme level) was obtained by the strain expressing
OKS + ZhuI + ZhuJ.
From the proteomics dataset it can be concluded that the higher levels of
flavokermesic acid observed for the cell factory was not only depending on actual
enzyme levels, but that different constructs also featured different performance
levels with regards to their ability to produce flavokermesic acid.
4.4.4 Potential issues with fusion of biosynthetic enzymes
The second aim of this study was to investigate if fusing the enzymes in the artifi-
cial pathway producing flavokermesic acid, could improve the overall productivity
and specificity of the cell factory. The hope was that the physical linkage of the
enzymes would increase the local substrate levels for the individual enzymes and
thereby reducing the time the highly reactive intermediates would spend in the
free form before encountering the next enzyme in the pathway. This rational has in
several systems been proven correct, e.g. production of terpenes or small aromatic
compounds [8, 18]. However, this was unfortunately not true for the pathway
in question as translational fusion of the enzymes had detrimental effects on the
performance of the pathway. A possible explanation for this may be that the three
enzymes in this study do not act as monomers in solution in their natural systems,
but form homodimers or -multimers to achieve functionality. Fusion with the other
biosynthetic enzymes could therefore hinder the formation of these dimers.
The structure of OKS was elucidated by Morita et al. (2007) [19]. The struc-
ture has not been made public but was found to be very homologous to that of the
pentaketide chromone synthase for which the structure is public. OKS is a dimer
which could lead to structural clashes and problem when attempting to make fu-
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Figure 4.7 Protein structures of the Biosynthetic enzymes. (A) Structure of PCS (PDB code:
2D52) with N- and C-termini of the dimer highlighted. (B) Structure of ZhuI (PDB code: 3TFZ)
with N- and C-termini, and the active site entrance of the dimer highlighted. (C) Modelled
structure of ZhuJ superimposed on the Isatin hydrolase (PDB: 4M8D) which was used as the
template. ZhuJ is shown in magenta and the Isatin hydrolase dimer is shown in cyan and green.
N- and C-termini of the dimer highlighted.
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Table 4.6 Calculated values comparing the level of flavokermesic acid and the enzymatic levels
of OKS, ZhuI and ZhuJ individually and also the summed amount of OKS, ZhuI and ZhuJ
enzymes for each strain. The list is sorted by the level of flavokermesic acid produced by the
individual strains (Conc. FK).
Strain Conc. FK FK/OKS FK/ZhuI FK/ZhuJ FK/summed
OKS + ZhuI + ZhuJ 52.26 0.519 0.252 0.299 108.171
OKS-L2-ZhuI + ZhuJ 40.57 0.482 0.444 0.105 72.165
OKS-L1-ZhuI + ZhuJ 38.51 0.623 0.463 0.081 61.982
OKS + ZhuI-L1-ZhuJ 34.58 0.378 0.624 0.161 95.631
OKS + ZhuI-L2-ZhuJ 24.75 0.295 0.383 0.112 67.151
OKS + ZhuJ-L1 23.63 0.241 - 0.064 45.228
ZhuI-L1-ZhuJ-L2-OKS 16.61 0.357 0.250 0.096 58.177
OKS + L1-ZhuJ-L2 12.41 0.137 - 0.074 41.180
OKS + ZhuJ 12.36 0.129 - 0.040 27.109
OKS + L2-ZhuJ 10.71 0.120 - 0.067 34.716
OKS + L1-ZhuJ 10.41 0.109 - 0.096 45.068
OKS-L1-ZhuI-L2-ZhuJ 7.25 0.161 0.202 0.060 35.790
OKS + ZhuJ-L2-ZhuI 5.28 0.056 0.096 0.040 18.797
OKS + ZhuI-L1 4.69 0.059 0.013 - 9.247
OKS + L2-ZhuI 3.94 0.044 0.026 - 10.698
OKS + L1-ZhuI 3.89 0.042 0.022 - 10.539
OKS + L1-ZhuI-L2 3.86 0.051 0.023 - 10.907
OKS + ZhuJ-L1-ZhuI 3.55 0.043 0.115 0.040 17.546
OKS-L1-ZhuJ + ZhuI 3.27 0.063 0.015 0.027 8.182
ZhuJ-L1-OKS + ZhuI 2.94 0.089 0.011 0.035 7.441
OKS-L2-ZhuJ + ZhuI 2.64 0.056 0.016 0.019 7.427
ZhuJ-L2-OKS + ZhuI 1.48 0.037 0.007 0.011 3.849
ZhuI-L1-OKS 1.37 0.011 0.012 - 3.644
OKS + ZhuI 1.21 0.014 0.006 - 3.283
OKS-L2 1.17 0.013 - - 3.699
OKS + XI-2(empty) 1.03 0.010 - - 3.273
ZhuI-L2-OKS 0.93 0.009 0.010 - 2.766
OKS-L2-ZhuI 0.88 0.011 0.008 - 3.177
ZhuI-L1-OKS-L2-ZhuJ 0.85 0.023 0.014 0.009 4.410
ZhuJ-L1-ZhuI-L2-OKS 0.69 0.016 0.024 0.008 4.292
OKS-L2-ZhuJ 0.67 0.014 - 0.006 2.975
OKS-L1 0.64 0.008 - - 2.954
L2-OKS 0.57 0.005 - - 2.767
OKS-L1-ZhuJ 0.53 0.014 - 0.004 2.155
OKS 0.44 0.005 - - 1.797
OKS-L1-ZhuI 0.44 0.005 0.006 - 1.790
ZhuJ-L1-OKS 0.39 0.008 - 0.005 2.481
ZhuJ-L2-OKS 0.37 0.010 - 0.004 2.091
ZhuJ-L1-OKS-L2-ZhuI 0.37 0.008 0.008 0.003 1.634
L1-OKS 0.12 0.001 - - 0.374
sions with other enzymes as the OKS is only active when the dimer is formed due
to the opposite dimer participating in forming the catalytic cavity [20]. Also, the
N- and C-termini of the OKS are in close vicinity on the surface, which could lead
to issues when attaching linkers and enzymes on both of the termini if the linkers
are not sufficiently long to prevent strain on the protein structures due to steric
clashes of the enzymes (Figure 4.7).
The structure of ZhuI was elucidated by Ames et al. (2011). It is dimeric and
features a helix-grip fold [21], which has also been observed for other polyketide
cyclases [22, 23]. The N- and C-termini of ZhuI are in opposite ends of the protein
which should lead to less issues when attaching enzymes to both ends of the
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amino acid chain. That being said, the trend for ZhuI to maximize conversion to
flavokermesic acid was that ZhuI should be in the N-terminal end of the fusion
protein. This could be because the N-terminal end of ZhuI was susceptible to
strain from the other enzymes in the fused enzyme rendering ZhuI unfunctional or
that the attached enzyme could cover the active site entrance of ZhuI (Figure 4.7).
The latter is unlikely as the entrance to the active site, though in the N-terminal
end of the enzyme, is opposite the central alpha helix (named αC in Ames et al.
(2011)) and at a distance of 22Å (measured in PyMOL).
The structure of ZhuJ is unknown and no structures exists for closely related
cyclases that has been shown to catalyze a similar polyketide folding pattern.
The closest amino acid sequence homolog (43% similarity) is the isatin hydrolase
Labrenzia aggregata (PDB entry 4M8D), which is a dimer and has a swiveling
α/β/α domain with two essential domains to stabilize the dimer, named domain
swaps, as these domains "hug" the other monomer [24]. Based on the sequence
of ZhuJ one of these domain swaps is likely present in ZhuJ (Figure 4.7). Other
sequence homologous proteins for which a structure is known are kyrnurenine for-
mamidase from Pseudomonas aeruginosa, metal-dependent hydrolase from Bacil-
lus stearothermophilus, the novel cyclase from an uncultured organism, and protein
of unknown function from Methanocaldococcus jannaschii (PDB entries 4COB,
1R61, 5IBZ, and 2B0A respectively). These sequence homologs are also dimers
and feature the domain swap 2 described in the isatin hydrolase structure. There-
fore, we find that it is safe to assume that ZhuJ is also a dimer in solution.
To conclude all of the expressed enzymes are expected to be dimers in solution.
The formation of dimers may be troublesome when the enzymes are expressed
as fusions either due to direct sterical clashes between the proteins or due to
the individual enzymes being unable to form its homodimer. As an example, in
the fusion of all three biosynthetic enzymes. The enzymes are assumed to be
expressed correctly, but when one of them forms the homodimer the strain on
the other enzymes renders the other enzymes in the fusion inactive. Also, if the
enzymes are required to be dimeric to be stable, they could therefore denature as
a consequence of being monomeric, and therefore be tagged for degradation by the
cell. This could offer an explanation to why the enzyme fusions attempted here
were not successful in improving the production of flavokermesic acid compared to
unfused enzymes. This explanation is also supported by the lower level of enzyme
detected when the enzymes were expressed as fusions of two or three enzymes
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compared to the expression of the standalone enzymes.
4.5 Conclusion and perspectives
The initial goal of this study was to establish the pathway producing flavokermesic
acid in S. cerevisiae, which had previously been established in N. benthamiana
and A. nidulans. This was successfully done and the expected metabolites SEK4,
SEK4b, dSEK4, dSEK4b and flavokermesic acid were all detected when expressing
the artificial pathway in S. cerevisiae. Another aim of this study was to investi-
gate if fusion of the three biosynthetic enzymes would yield higher titers of the
desired flavokermesic acid and less of the shunt products SEK4, SEK4b, dSEK4
and dSEK4b. The production of shunt products was found to be strongly corre-
lated to which, and how many, of the biosynthetic enzymes were expressed, instead
of the option of having the enzymes expressed as fusion or as standalone enzymes.
The highest level of 52 mg flavokermesic acid per L of culture was obtained by
the strain expressing the three biosynthetic enzymes as standalone enzymes and
this level of flavokermesic acid provides a good starting point for creating a cell
factory for production of flavokermesic acid and later carminic acid.
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5.1 Abstract
Species of the fungal genus Fusarium have long been in the interest of researches,
and because of the toxin production found in several fusaria the metabolic po-
tential has received much attention. This has led to understanding of many of
the secondary metabolic pathways for important toxins and pigments in Fusarium
spp. Here we wanted to investigated the pgl1 biosynthetic gene cluster across the
whole genus of Fusarium as well as propose a common biosynthetic pathway for
pigments thought to be produced by enzymes from the pgl1 gene cluster. We have
named this the metabiosynthetic pathway. We compared the pgl1 gene cluster
in 22 Fusarium species and a synteny plot revealed high conservation of clus-
ter topology throughout the genus of Fusairum. The proposed metabiosynthetic
pathway showed many common biosynthetic steps, but also highlighted that many
biosynthetic steps could not be explained with the current biosynthetic cluster.
Therefore, on the basis of a different gene cluster topology and apparent higher
metabolite diversity, we investigated buxicola, decemcellulare and solani species
complexes in order to unveil missing enzymatic capabilities. We found that sev-
eral genes in the said species complexes could contain enzymatic activities needed
to explain the chemodiversity observed in the metabiosynthetic pathway.
Keywords: Fusarium, Polyketide synthase, metabiosynthetic pathway, gene cluster, evolu-
tion, PGL1, fsr1
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5.2 Introduction
The ascomycete genus Fusarium includes both species with a saprophytic and
plant pathogenic life style. The pathogenic members are responsible for significant
agricultural losses for many important crops, via wilts and rot diseases and due
to their production of mycotoxins that accumulates in the harvested crops [1, 2].
Their importance has fostered a whelm of studies into the individual species mode
of infection, production of small molecules and the toxicology of these molecules.
The investigated secondary metabolism within fusaria includes prominent myco-
toxins includes fumonisins, zearalenone and trichothecenes [3], as well as many
different pigments such as aurofusarin, bikaverin and fusarubins [4, 5, 6]. In the
last decade focus has been on elucidating the genetic basis and understanding of the
biosynthetic pathways responsible for production of these secondary metabolites,
fuelled by the ever increasing availability of whole genome sequences for fusaria
species. Comparative genomics studies focused on the distribution of polyketide
synthase (PKSs) has revealed a huge diversity within the genus, and showed that
only a three of the 67 different PKSs are conserved among all members of the genus
[7]. The unusually conserved PKS gene, pks3/pgl1/fsr1, has via several studies
been found to be responsible for formation of the dark perithecial pigmentation
of many Fusarium spp. (all members of the former Giberella genus) [8] and for
mycelium pigmentation in other species[4]. The chemical nature of the experimen-
tally proven PGL1-produced pigments includes the fusarubin [4] and bostrycoidin
compound families [9].
Several biosynthetic models for the formation of fusarubins, bostrycoins and
structurally related compounds in Fusarium spp. have previously been proposed.
The first model, proposed by Gatenbeck and Bentley (1965), suggest that ja-
vanicins and fusarubins are formed from an aromatic acid, which is converted into
fusarubinoic acid and javanicin [10]. The second biosynthetic model was conceived
by Arsenault (1968) and goes into a description of the biosynthesis of solaniol and
bostrycoidin as well as fusarubin and javanicin [11]. The third proposed biosyn-
thesis was formulated by Kurobane et al. (1980), in which a common intermedi-
ate of fusarubinalcohol leads to the formation of dihydrofusarubin, which is then
converted to bostrycoidin, fusarubin, norjavanicin, and anhydrofusarubin [12]. Re-
cently, two models have been made on the basis of genetic studies of F. fujkuroi and
F. graminearum. Studt et al. (2012) investigated biosynthesis of fusarubins and
related compounds in F. fujikuroi and found 6-O-demethylfusarubinaldehyde as
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Figure 5.1 Chemical diversity originating from the PGL1 gene cluster.
the first stable intermediate and likely the product of the PKS PGL1, named FSR1
in F. fujikuroi [4]. Frandsen et al. (2016) investigated biosynthesis of perithecial
pigmentation of F. graminearum and found 6-O-demethyl-5-deoxybostrycoidin an-
throne to be the first stable intermediate [9]. The naphthoquinone structure makes
many of the Fusarium naphthoquinones antibacterial, but some metabolites have
also been found to be phytotoxic and fungicidal [13, 14].
The fusarubin and bostrycoidin metabolite families share carbon core struc-
tures with that of solaniols, nectriafurones, marticinins and javanicins, which have
been isolated from several other members of the Fusarium genus. Some of the
chemical diversity of the PGL1 gene cluster is shown in figure 5.1. All members of
these compound families include a naphthoquinone scaffold, but at the same time
features distinctly different molecular features in their structure. The pattern of
decoration of the core structures across the different metabolite families is in ad-
dition surprisingly similar [13]. With these structure similarities we hypothesized
that all of these compounds have the same biosynthetic origin, but are the results
of different evolutionary trajectories in the different subgroups of the genus.
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Therefore, we wanted to investigate whether the chemical and underlying
biosynthetic diversity within the Fusarium genus was reflected in the structure
and enzymatic potential encoded by the pgl1 gene cluster across the genus. Sec-
ondly, we set out to formulate a common biosynthetic model (metabiosynthetic
pathway) for the pgl1 cluster derived compounds with the aim of describing the
theoretical minimum number enzymatic reactions that can explain the chemical
diversity found across the whole genus of Fusarium.
5.3 Materials and methods
5.3.1 Bioinformatic analysis of pgl1 gene cluster
The 343 analyzed Fusarium genome sequences (see appendix for full list) included
all the Fusarium genomes, publicly available via NCBI, JGI, Broad/MIPS, along
with recently sequenced isolates. Sequencing was done by following methods de-
scribed in Brown and Proctor (2016) [7]. In breif, DNA extraction was done by
using ZR Fungal/Bacterial DNA MiniPrepTM Kit (Zymo Research, Irvine, Cal-
ifornia) and a NExtera XT DNA Library Preparation Kit (Illumina, San Diego,
California) to prepare the DNA libraries for the Iillumina MiSeq. The Genomic
data was trimmed and the genomes were de novo assembled using CLC Genomics
Workbench (CLC bio, Qiagen, Aarhus, Denmark). Whole genome gene predictions
were performed using AUGUSTUS (http://augustus.gobics.de/).
The genomes were first analyzed by antiSMASH with the aim of identifying
the pgl1 gene cluster in the individual species [15]. Functional annotation for the
encoded enzymes in the different pgl1 gene clusters were made using Blast2GO
[16]. A list of all analyzed strains, their source and antiSMASH analysis output can
be found in appendix (Table S5.1). A subset of 22 isolate (Appendix Table S5.2
for strain table) were selected for further investigation, based on representing the
whole genus of Fusarium and difference in gene cluster topologies. The existing
automatically generated gene calls (AUGUSTUS) were manually inspected via
multiple sequence alignments, using CLC Genomics Workbench (CLC bio, Qiagen,
Aarhus, Denmark), of the nucleotide sequences with that of gene models for the
same gene in the whole subset. This was done to ensure the same start and stop
codon was used for all genes. When discrepancies in gene calls were found the
gene call having highest consensus in the subset was also made for the sequences
with deviating gene calls. Next, a nucleotide sequence synteny analysis of the pgl1
gene cluster was made for the selected subset using Easyfig [17], with BLAST
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parameters set to a bit size of minimum 50 bp and a minimum identity of 50%.
To search for enzymatic activities, functional annotation of the encoded enzymes,
which were not part of the pgl1 clusters, was made using Pfam domain search [18]
in CLC Genomics Workbench (CLC bio, Qiagen, Aarhus, Denmark).
5.4 Results and discussion
The pigmentation of fusaria has been investigated thoroughly and three polyketide
compound groups have been found to be used as mycelial pigmentation for different
subclades of the Fusarium genus. Members of the Nectria clade produces yellow
and red mycelial pigmentation which have a naphthoquinone structure and is
produced by the pgl1 gene cluster [19]. Species in the fujikuroi and oxysporum
species complexes produce the red bikaverin as the main mycelial pigmentat via
the bik1 gene cluster [5], and the members of the sambucinum and tricinctum
species complexes owe their red mycelial color to aurofusarin produced by the
gene cluster of pks12 [6]. All species in the Gibberella clade have dark perithecia
and get this pigmentation via the action of the pgl1 gene cluster [8]. The produced
pigment of perithecia has been proposed to be the dark purple purpurfusarin [9].
While the chemical composition of perithecial pigmentation for the Nectria clade
is still unknown, deletion of the gene pksN produces colorless perithecia [20]. A
thorough overview of naphthoquinones produced by fusaria and other fungi can
be found in the review by Medentsev and Akimenko (1998) [13].
5.4.1 The pgl1 gene cluster
In previous genetic studies of the genus Fusarium the pgl1 backbone gene has
been found for all investigated species [7, 21, 22]. For the investigated sequences
in this study a different pattern was observed. To search for the pgl1 gene cluster
in the available genome sequences they were analyzed using antiSMASH. Based
on the species complexes, as defined by O’Donnell et al. (2013) [21] four of the
20 species complexes were found not to have the pgl1 backbone gene, namely
staphyleae, albidum, ventricosum and dimerum, while all other species complexes
did (See appendix Figure S5.1 for phylogeny of all isolates). The most parsimony
explanation for this distribution is that the gene cluster was gained as the solani
species complex evolved and then subsequently lost when the staphyleae species
complex branched off from the rest. Previous studies have investigated the pgl1
gene cluster and delimited it to consist of six genes pgl1 to pgl6. Transcriptional
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analysis in F. graminearum showed that six genes were co-regulated by the PGL6
transcription factor, named PglR in Fusarium graminearum [9], and transcrip-
tional analysis of F. fujikuroi, grown under pgl1 cluster inducing conditions also
showed co-transcription of the same six genes [4]. An overview of the genes in the
cluster can be found in table 5.1.
A subset (22 isolates) of the genomes investigated in the initial dataset were se-
lected for further analysis of the pgl1 gene cluster across the Fusarium genus. The
subset of genomes was selected firstly based on the availability of genomic scaf-
folds that included the whole pgl1 gene cluster. Secondly, to reflect the variability
in cluster topology and finally, to include representatives for the different species
complexes within the Fusarium genus (See appendix table S5.1 for antiSMASH
output). Pairwise nucleotide sequence similarity analysis of the plg1 cluster genes
were done (Figure 5.2 (plg1 ) and appendix (pgl2 to pgl6 )). The highest similar-
ity within genes was found between species of the same or closely related species
complexes as defined by O’Donnell et al. (2013) [21].
Pairwise analysis of the nucleotide sequence identity for all genes in the var-
ious pgl1 gene cluster (Appendix figure S5.2 to S5.6). Revealed the existence of
four distinct groups, which followed the species complexes defined by O’Donnell
et al. (2013) [21]. The first group included clusters from members of the sam-
bucinum and chlamydosporum species complexes, while tricinctum and heterospo-
rum formed a second group group. Then fujikuroi, niskadoi and oxysporum species
complexes the third, and finally buxicola, decemcellulare and solani species com-
plexes formed a fourth group. The pgl1 gene of the fourth group was very different
from three the other groups. This is in agreement with the fourth group being of
the Nectria clade in the Fusarium genus and first, second and third group belong-
ing to the Gibberella clade. To further investigate the pgl1 gene cluster, a synteny
Table 5.1 The genes in the pgl1 cluster in the investigated Fusarium species. Length bp is the
maximum and minimum length in the subset of the investigated species. The enzymatic domains
for the biosynthetic genes in F. fujikuroi IMI58289 is given [4].
Gene
name
Length of
gene (bp)
Conserved comains in the resulting
enzyme (F. fujikuroi)
Predicted function
of enzyme
pgl1 7046-7211 SAT, KS, AT, PT, ACP, ACP, R PKS
pgl2 1206-1256 SAM-dependant methyl transferase O-methyl transferase
pgl3 1640-1722 FAD-dependent oxidoreductase Monooxygenase
pgl4 1196-1243 NAD(P)H dependent enoyl-reductase like Oxidoreductase
pgl5 795-807 Short-chain dehydrogenase Oxidoreductase
pgl6 990-1188 Zn(II)2Cys6 transcription factor Transcription factor
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Figure 5.2 Identity plot showing the nucleotide identity of the pgl1 genes from different species
within the Fusarium genus. The lower triangle shows the number of identities while the upper
triangle show the identity percentage. The species complexes as well as species complex groups
are highlighted.
plot of the cluster was made for the subset of genome sequences (Figure 5.3).
The synteny analysis of genes in the pgl1 gene cluster showed that seven genes
were highly conserved across the Fusarium genus, which was supported by the
identity plots of the biosynthetic genes (see figure 5.2 and appendix). The se-
quence and direction of the genes from pgl1 to pgl6 was identical for all analyzed
sequences except for two sequences. In F. longipes pgl3 had translocated down-
stream of pgl1 and in Fusarium sp. 62941 two parts of the cluster, pgl1 to pgl3 and
pgl4 to pgl6 was inverted compared to other sequences. Within the sambucinum
species complex the sequence synteny plot showed a very high degree of sequence
conservation of the whole gene cluster including both coding and non-coding re-
gions. Atypically, this level of conservation was also observed to transcend the
species complex boundaries for between fujikuroi, nisikadoi and oxysporum species
complexes. The topology of the cluster in members of the solani and decemcellu-
lare species complexes differed significantly from that of the other isolates, as the
cluster was split in two and the two parts were separated by 12-17 genes between
pgl3 and pgl4. This was also previously noted by Frandsen et al. (2016) for F.
virguliforme and F. solani [9]. The genes separating the two halves of the cluster
85
Chapter 5. The pgl1 metabiosynthetic pathway in Fusarium
Figure 5.3 Synteny plot of the pgl gene cluster across the Fusarium genus. The color coding
alongside the species names refer to the species complexes in figure 5.2. Genes which are not
part of the pgl1 biosynthetic cluster are grey.
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only shows limited synteny between the species. For Fusarium sp. 62941 the gene
synteny with F. solani was quite high for the pgl1 cluster and the genes between
pgl3 and pgl4, but the two parts of the cluster was inverted compared to F. solani.
The same pattern of clustering of the biosynthetic genes in all species com-
plexes except the solani species complex was in good agreement with the findings
in Frandsen et al. (2016) [9]. Also, we found that decemcellulare and to some
extent buxicola species complexes also had genes inserted between the two parts
of the cluster. As the buxicola species complex is closer related to oxysporum
and fujikuroi species complexes not having the aforementioned insert, it could be
hypothesized that F. buxicola represents an intermediate stage of the pgl1 clus-
ter development towards becoming clustered. The gene downstream of pgl6 in F.
graminearum, which was named pglE in Frandsen et al. (2016) and named Gene
of interest A here, was found not to be co-regulated with the other genes in the
cluster in F. graminearum [9] nor in F. fujikuroi [4]. However, the conservation of
the gene in all the investigated clusters suggests that the encoded enzyme could be
important for the function of the cluster as other genes around the cluster genes
change throughout the Fusarium genus. The presence of an esterase domain in
pglE could indicate that the gene has a function in the biosynthetic pathway, but
that it is regulated independently of the other genes in the cluster. The majority
of compounds that have been shown to or hypothesized to be products of the pgl1
cluster have been isolated from Fusarium species belonging to the solani species
complex. Interestingly members of the solani, buxicola and decemcellulare species
complex share one addition conserved gene, named Gene of interest B, located
downstream of pgl3 in these species. This gene encodes an enzyme with an alco-
hol dehydrogenase domain, an activity which is often observed in the tailoring of
aromatic polyketides. The conservation of the gene and the relevant enzymatic
potential makes the gene a good candidate for being involved in the biosynthesis
of PGL1 derived compounds in these species, and possibly explaining part of their
unique chemical diversity.
5.4.2 The metabiosynthetic pathway of PGL1-derived
compounds
Many of the metabolites associated with the pgl1 gene cluster has been observed
as extracellular [4, 24] or perithecial pigments [8, 9], while others have also been
found to be toxins coupled to pathogenicity in plants on which fusaria are often
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Figure 5.4 Proposed metabolic pathway leading to chemodiversity of fusarubins and anhydro-
fusarubins in Fusarium spp. All compounds are described in Medentsev and Akimentko (1998),
Studt et al. (2012) and Parisot et al. (1991) [4, 13, 23] A. Proposed biosynthesis of fusarubins.
Compounds with asterics (*) have also been isolated as anhydrofusarubins. Emphasized bonds
are the group on which the previous enzymatic reaction has happened. Boxed and coloured
reactions are common for all described biosynthetic schemes in figures 5.4 to 5.9. B. Conversion
between fusarubins and anhydrofusarubins by C3 reduction.
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found [25, 26]. To create a more detailed biosynthetic model and to identify gen-
eral biosynthetic conversions, we searched the available literature, and identified
bostrycoidin- and fusarubin-like compounds produced by Fusarium spp. Based
on their shared substructural features, we formulated a metabiosynthetic model
including 47 known compounds and a number of theoretical intermediates. In the
following proposed biosynthetic pathways the carbon numbering system follows
the system shown in Studt et al. (2012) [4].
The initial product from the PKS PGL1 has been found to be 6-O-demethyl-
fusarubinaldehyde (compound 1), based on heterologously expression of the F.
solani pgl1 inAspergillus oryzae [19]. Furthermore, deletion of the flavin-dependant
monooxygenase (FMO) encoding gene pgl3 in F. fujikuroi resulted in the accumu-
lation of only fusarubinaldehyde (compound 2) [4], which showed that the oxida-
tion on C5 and C10 is required for biosynthesis of fusarubins and anhydrofusaru-
bins (Figure 5.4). While oxidation seems to be the required for production of later
stage compounds, deleting the O-methyltransferase (O-MT) pgl2 in F. fujikuroi
yielded the C5 oxidized 6-O-demethyl-10-deoxyfusarubin (compound 3) and 6-O-
demethylfusarubinaldehyde (compound 2) [4]. Here it can be concluded that the
fusarubin ring formation can happen without the C6 O-methylation. The oppo-
site biosynthetic sequence of reactions was observed for formation of bostrycoidins
in F. graminearum, where the 6-O-demethyl-5-deoxybostrycoidin anthrone (com-
pound 16) was observed when overexpressing the PKS pgl1 [9]. This compound
has the bostrycoidin ring confirmation while it does not have C6 methylation nor
C5 or C10 oxidation. An overview of our proposed biosynthesis in the Fusarium
genus can be found in figure 5.4 for fusarubins and anhydrofusarubins, and in
figure 5.5 for bostrycoidins.
For formation of the pyran ring in fusarubins the C1 carbon needs to be re-
duced to an alcohol, to allow formation of the pyran ring via acetal formation.
This C1 reduction is hypothesized to be carried out by the FMO pgl3 by Studt
et al. (2012) [4]. However, we would find it surprising and unlikely that the
same FMO would do both oxidations and reductions on the same molecule and
on vastly different parts of the molecule. Hence, we expect that one or more
enzymes are responsible for the C1 reductions, but the identity of the responsi-
ble enzyme or enzymes remains unknown. We hypothesize that the conversion
between fusarubins and anhydrofusarubins to be driven by an enzyme to create
the C3/C4 double bond in anhydrofusarubins. An alternative explanation of this
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Figure 5.5 Proposed biosynthesis of bostrycoidins produced by Fusarium spp. All compounds
are described in Frandsen et al. (2016) and Medentsev and Akimentko (1998) [9, 13]. Emphasized
bonds are the group on which the previous enzymatic reaction has happened. Boxed and coloured
reactions are common for all described biosynthetic schemes in figures 5.4 to 5.9.
double bond could be formed by high acid concentrations during purifications as
culture filtrate fractions often were acidified prior to extraction [27, 28, 29]. A step
in the biosynthesis of bostrycoidins are also missing further investigation. Parisot
et al. (1989) observed that incorporation of nitrogen in bostrycoidins can happen
spontaneously by co-incubation of ammonia and fusarubin lactol (compound 37),
even though free ammonia is unlikely to be present inside the cell [30]. A simi-
lar formation of a pyridine ring is observed in monascus pigments by Chen et al.
(2017) [31], where incorporation of nitrogen can also happen via incubation of a
precursor containing a pyran moiety with ammonia. For monascus pigments the
nitrogen does not have to originate from ammonia, but can also come from free
amino acids [31]. An alternative bostryocoidin biosynthetic route was proposed
by Wagoner et al. (2008) [32], which is also shown in our proposed biosynthesis of
bostrycoidins (Figure 5.5). In this route the conversion is initiated with enzymatic
transamination of the C1 aldehyde to an imine, which then via nucleophilic attack
on the C3 carbonyl group followed by water loss forms the pyridine ring.
Dihydrofusarubins (compounds 11, 14 and 15) which have the reduced C13/C14
bond, have only been isolated from F. solani [14, 28]. Dihydrofusarubin has been
hypothesized to be a precursor of fusarubin by Kurobane et al. (1980) as it sponta-
neously was converted to fusarubin when exposed to oxygen under basic conditions
[12]. An alternative hypothesis could be that dihydrofusarubin is formed by re-
90
5.4. Results and discussion
Figure 5.6 Javanicins and solaniols produced by Fusarium spp. All compounds are described in
medentsev and Akimentko (1998) and Parisot et al. (1990) [13, 33]. Emphasized bonds are the
group on which the previous enzymatic reaction has happened. Boxed and coloured reactions
are common for all described biosynthetic schemes in figures 5.4 to 5.9.
duction of the C13/C14 bond after formation of fusarubin. As dihydrofusarubin
only has been isolated from F. solani the gene responsible for the C13/C14 reduc-
tion may be unique to F. solani. The existence of C3 methylation and ethylation
of fusarubin (compounds 12 and 13) and dihydrofusarubin (compounds 14 and
15) has been hypothesized to be artifacts, which would occur during chemical pu-
rification. Nonetheless, Kurobane et al. (1986) obtained these compounds while
purification was done without the presence of methanol and ethanol which could
lead to formation of methyl- and ethyl ethers [14]. The absence of a characterized
ethyl transferase in nature leaves some speculation on the biosynthesis of the C3
ethyl compounds. The formation of the ethyl may happen via first O-methylation
and then addition of another carbon by a different C-methyl transferase.
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Another group of metabolites derived from the pgl1 gene cluster are the solan-
iols and javanicins. For production of solaniols and javanicins the C1 aldehyde
would have to be reduced to an alcohol or to an methyl group (Figure 5.6). The
sequence of reduction of C1 and the C5 and C10 oxidation and C6 O-methylation
appears to be in favor of the latter being the initial one as most solaniols and ja-
vanicins have been isolated as having both of the C5 and C10 oxidations and the C6
O-methylation. An exception to this observation is 10-deoxyjavanicin (compound
24). Interestingly this metabolite along with 5- or 10-deoxyfusarubin (compound
6 or 7) and 5- or 10-deoxyanhydrofusarubin (compound 6* or 7*) have been
isolated from yellow mutants of F. solani [23, 34]. The accumulation of the 5-
and 10-deoxy compounds in these yellow mutants could offer a quick avenue, via
genome sequencing, to identify other genes which may modulate the activity of the
FMO pgl3. Therefore, it could be interesting to investigate the genome of these
yellow mutants and search for the mutations leading to the accumulation of the
5- and 10-deoxy compounds.
The biosynthesis of solaniols and javanicins requires the C1 aldehyde to be
reduced to a methyl, and furthermore, the C3 carbonyl to be reduced to an alco-
hol. Also, the 6-deoxynaphthoquinones (compounds 26 and 27) is dependent on
another enzymatic activity, which is able to reduce the C6 alcohol. The anhydroja-
vanicins (compounds 34, 35 and 36) have only been isolated from F. solani or the
closely related F. decemcellulare [13, 27]. As with dihydrofusarubins, this could
mean that specific genes are needed for the alternative ring formation seen in anhy-
drojavanicin. These may have been lost or gained as the cluster evolved throughout
the Fusarium genus to become more clustered as seen in the Gibberella clade. For-
mation of dihydroanhydrojavanicin and 1-hydroxydihydroanhydrojavanicin (com-
pounds 34 and 35) both depends on reduction of the C3 position and it would
therefore make more sense to name these as anhydrosolaniols instead of anhydro-
javanicins.
The next group of metabolites which will be put into the biosynthetic context
of the pgl1 gene cluster here, are produced by ringformation of the C1 aldehyde
with the C3 ketone to form fusarubin lactol (compound 37) or by oxidation of
C1 aldehyde to form fusarubinoic acid (compound 39), which can then undergo
ring formation with the C3 ketone to make fusarubin lactone (compound 40).
Through decarboxylation, fusarubinoic acid can also yield norjavanicin (compound
41), which can finally be transformed to 13-hydroxynorjavanicins (compound 42,
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Figure 5.7 Fusarubin lactone, fusarubin lactol and norjavanicins produced by Fusarium spp.
Compounds are described in Medentsev and Akimenko (1998) and Studt et al. (2012) [4, 13].
Emphasized bonds are the group on which the previous enzymatic reaction has happened. Boxed
and coloured reactions are common for all described biosynthetic schemes in figures 5.4 to 5.9.
Figure 5.8 Proposed biosynthesis of novarubin by Fusarium spp. if derived from the PGL1
pathway. Novarubin is described in Medentsev and Akimenko (1998) [13]. Emphasized bonds
are the group on which the previous enzymatic reaction has happened. Boxed and coloured
reactions are common for all described biosynthetic schemes in figures 5.4 to 5.9.
also named 6-hydronorjavanicins in literature) by C13 oxidation. The reductive
release from PGL1 followed by C1 oxidation as seen for synthesis of fusarubinoic
acid and later derivatized compounds is uncommon in biosynthesis of natural
products. Nonetheless, fusarubinoic acid and the later derivatized compounds, ie.
fusarubin lactone and norjavanicins which have been isolated in several different
studies isolating naphtoquinone pigments from Fusarium spp. [13, 27, 35, 36].
A compound isolated from Fusarium spp., which share chemical features with
the naphthoquinones described here, is novarubin. Previous reports of novarubin
isolation has been from species in the solani and decemcullulare species complexes
[13, 37]. Recently, novarubin has been detected, based on MS charateristics, in
cultivations of wildtype F. graminearum [38], which has not been previously shown
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Figure 5.9 Proposed biosynthesis of nectrifurones and marticin produced by Fusarium spp.
Compounds are described in Medentsev and Akimenko (1998), Studt et al. (2012) and Parisot
et al. (1991) [4, 13, 23]. Emphasized bonds are the group on which the previous enzymatic
reaction has happened. Boxed and coloured reactions are common for all described biosynthetic
schemes in figures 5.4 to 5.9.
to produce fusarubins, javanicins or solaniols. This could lead one to speculate
that the biosynthetic origin of novarubin is not from the pgl1 cluster even though
the basic structure is very similar to that of norjavanicin. If novarubin is derived
from the pathway it is most likely via C4 methylation of norjavanicin (compound
41) followed by oxidation of the same carbon (Figure 5.8).
The final group of metabolites for which a biosynthetic route will be proposed
are nectriafurones and marticin (Figure 5.9). The biosynthesis of nectriafurones
has been proposed by Studt et al. (2012) to be derived from an intermediate with
the C1 in form of an alcohol, which then forms the furan ring in equilibrium [4].
It appears to be more likely that the precursor of nectriafurone is the C1 aldehyde
as this would give the correct oxidation state prior to the furan ring formation
as depicted in our biosynthesis, though a good mechanism for this formation is
absent. The biosynthesis of marticin have been proposed to be addition of malic
acid [39] and this is also depicted in our proposed biosynthesis.
In general compounds having the C8 or C9 O-methylations have rarely been
isolated from F. solani, but instead they have been isolated from species in the
fujikuroi and oxysporum species complexes. This pattern is observed for 8-O-
methylnectriafurone (compound 46), 8- and 9-O-methylfusarubin (compounds 9
and 10), 8-O-methylanhydrofusarubin (compound 10*), 8- and 9-O-methyl-6-
hydroxynorjavanicin (compounds 43 and 44), 8-O-methylsolaniol (compound 31),
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8-O-methylbostrycoidin (compound 22), and 8-O-methylanhydrofusarubinlactol
(compound 38) [4, 9, 13]. The only compound for which this is not observed are for
8-O-metyljavanicin (compound 30) which has been isolated from F. solani [40] as
well as F. fujikuroi and F. oxysporum [13]. This exception to the C8 O-methylation
brings one to speculate that the identification of F. solani by Kimura et al. (1981)
could be wrong and the isolate from which they isolated 8-O-metyljavanicin (com-
pound 30) could have been a F. fujikuroi or F. oxysporum. If true and the C8
and C9 O-methylations are indeed unique to F. oxysporum and F. fujkuroi, then
the O-methyltransferase pgl2 could be more promiscuous in F. oxysporum and F.
fujkuroi as proposed by Studt et al. (2012) or a completely different enzyme or
enzymes are responsible for the C8 and C9 O-methylations, which is only present
in these species.
5.4.3 Comparison of the metabiosynthetic pathway and the
pgl1 biosynthetic gene cluster
When observing the biosynthetic pathways proposed in figure 5.4 to 5.9 a common
biosynthetic pattern is observed. The C6 O-methylation and the C5 and C10 ox-
idations are found for the vast majority of the isolated compounds, as well as the
C8 O-methylation as has also been highlighted in the figures. Therefore, the main
differences between compounds are observed for the C1 reductions or oxidations as
well as the different possible ring formations. In figure 5.10 we attempt to present
the otherwise large and complicated metabiosynthetic pathway in as few chemical
conversions as possible, by dividing the conversions into an A-side reactions for
C1 to C4 and C15, and a B-side reactions for C5 to C14. Here focus has been put
on the enzymatic conversions instead of the individual compounds. To link the
chemodiversity presented the previous section with the genetic diversity investi-
gated in section 5.4.1, we made an overview of the enzymatic conversions needed
for the presented chemodiversity (Table 5.2).
Not all reactions listed in table 5.2 are necessarily enzyme catalyzed. An
example is cyclisation reactions as some of these are likely to be spontaneous,
but eight different cyclisation reactions are found in figure 5.10 and therefore
some of them are likely to be enzyme directed. As an example, the formation of
the nectriafurone furan ring are likely to be enzyme catalyzed as the furan ring
formation puts more strain on the ring. Furthermore, the biosynthesis of marticin
is likely to be enzyme catalysed, but an enzyme with such an activity is currently
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Figure 5.10 Simplified metabiosynthetic pathway representing the possible conversions of the
A- and B-side of the PGL1 derived compounds. Emphasized bonds are the group on which the
previous enzymatic reaction has happened. Boxed and coloured reactions are common for all
described biosynthetic schemes in figures 5.4 to 5.9.96
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Table 5.2 Overview of enzymatic activities needed for putative metabiosynthetic pathway pre-
sented in figures 5.4 to 5.9.
Carbon # Reaction Putative/Known enzyme
1 Red CHO to CH2OH Reductase
1 Red CH2OH to CH3 Reductase
1 Oxi CHO to COOH Oxidase
1 Decarboxylation Decarboxylase
1 Transamination Transaminase
1 Addition of malate Unknown
1-3 Cyc C1-O-C3 or C1-N-C3 Unknown
1-4 Cyc C1-O-C4 Unknown
3 O-methylation or ethylation O-MT
3 Red CO to CHOH Reductase
3-10 Cyc C3-O-C10 Unknown
5 Oxi CH2 to CHOH pgl3 (FMO)
6 O-methylation pgl2 (O-MT)
6 Red CHOH to CH3 Reductase
8 O-methylation pgl2
9 O-methylation pgl2 or similar O-MT
10 Oxi CH2 to CHOH pgl3 (FMO)
13 Oxi CH to COH FMO
13-14 Red C=C to C-C Reductase
unknown.
The number of presented biochemical conversions, which have been connected
to a specific enzyme, is rather limited and leads one to speculate about how the
observed chemical diversity is created. Therefore, the identity of at least five
different enzymes for biochemical conversions of C1 is currently unknown being
reduction, oxidation, decarboxylation, transamination and addition of malate. At
least two biochemical conversions of C3 is currently not assigned to a specific
enzyme being reduction and methylation or ethylation. Studt et al. also proposes
that the O-methylase pgl2 is responsible for O-methylations on C6 and C8 [4].
While O-methylation of C9 is not often observed this could also be catalysed by
pgl2 though we find this unlikely and therefore another O-methylase is needed for
this conversion. Finally, two more enzymes are currently unknown. Namely the
enzymes responsible for the C13 oxidation for biosynthesis of 6-hydronorjavanicins,
which most like is catalyzed by an FMO and a reductase to reduce the C13-C14
double bond for dihydrodusarubin biosynthesis. This brings the total number of
unknown enzymes to ten.
These unknown enzymatic activities could to some degree be explained by
the biosynthetic enzymes being promiscuous and having low substrate and reac-
tion specificity. This promiscuity can be used by an organism to diversify the
metabolites and develop novel pathways [41]. An example of the promiscuity of
the biosynthetic enzymes can be found for the C5 and C10 oxidation by pgl3 and
C6 and C8 O-methylation by pgl2. These are both, to a certain degree, inde-
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pendent of what state other parts of the substrate is in. This can be concluded
when regarding lack of sequence of C6 O-methylation and C5 and C10 oxidations
observed for fusarubins (Figure 5.4) and bostrycoidins (Figure 5.5) and the oxida-
tion and O-methylation appear to occur completely independently of one another.
The only limitation appears to be in fusarubins where at least one of the C5 or
C10 oxidations have to occur before C6 O-methylation. This difference can either
be attributed to the difference of bostrycoidins and fusarubins or to difference in
enzyme specificity in F. fujikuroi and F. graminearum.
An alternative explanation of unknown enzymatic activities could simply be
that these genes have not been identified yet. The large distance between pgl1
to pgl3 and pgl4 to pgl6 in species complexes buxicola, decemcellulare, and solani
could be due to more biosynthetic enzymes being part of the biosynthetic cluster
in these species. To investigate this we did Pfam domain search in these coding
sequences and the results for these can be found in appendix (Table S5.3). This
search found several enzymes to have FMO or cytochrome P450 domains as well
as several dehydrogenases and reductases. Several transcription factors were also
identified, which could be controlling other parts of the biosynthetic genes for
synthesis of PGL1 derived compounds, than what is controlled by Pgl6. Some
methyltransferases were also identified. Finally, in F. decemcellulare an enzyme
could be speculated to be linked to transamination, as the enzyme was found to
be binding pyroxidal phosphate (PLP), which is known from transaminases [42].
However, this enzyme cannot be found in any of the other sequences investigated in
this study, and a central role for biosynthesis of bostrycoidins is therefore unlikely.
Further studies are needed on the metabolism of the pgl1 gene cluster in fusaria
in order to fully understand the chemodiversity of the metabiosynthetic pathway
presented here.
5.5 Conclusion and perspectives
This study set out to investigate the genetic diversity of the pgl1 gene cluster and
secondly to propose a metabiosynthetic pathway for compounds assumed to orig-
inate from the PGL1 biosynthetic pathway. We found that the pgl1 biosynthetic
cluster was highly conserved across the Fusarium genus with genes and topology
being highly homologous for all species, except for species complexes buxicola, de-
cemcellulare and solani. The metabiosynthetic put 47 previously isolated Fusarium
spp. metabolites into one biosynthetic context and found common biosynthetic
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steps in many parts of the pathway. The metabiosynthetic pathway also high-
lighted that the currently identified pgl1 biosynthetic cluster would not suffice
to explain the chemodiversity in the present pathway. Therefore, we searched in
sequences from buxicola, decemcellulare and solani species complexes for genes
possessing domains with relevant secondary metabolism activity and several genes
were found to possess interesting biocatalysis domains. Transcriptome analysis of
the pgl1 gene cluster and neighbouring genes in the said species complexes could
unveil enzymes with biosynthetic relevance for PGL1 derived compounds.
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6 Overall discussion, conclusion and
perspectives
The overall goal for this PhD project was to develop a platform for design and pro-
duction of cyclic and aromatic polyketides. This goal was addressed in chapter 3
and 4 with two manuscripts describing a proof-of-concept for the general platform
for designing polyketides with a given chain length and folding pattern, and the
application of the platform to produce a compound of interest, respectively. Fi-
nally, chapter 5 gave an example of how nature generates a large chemical diversity
starting from one common polyketide scaffold.
Chapter 3 - Manuscript I found that it was possible to produce an array
of polyketides (C6 to C16) produced by heterologous expression of type III PKSs
in Saccharomyces cerevisiae. Furthermore, we showed that control of the folding
of the polyketide backbone was possible by co-expression of type II PKS cyclases,
which directed either the C7-C12 or C9-C14 folding patterns. The results pre-
sented in the manuscript offers a proof-of-concept for the platform and lays the
foundation for further work to develop the potential of the platform. As described
in chapter 2 the longest chain produced by a type III PKS was by the engineered
AaOKS, which with two point mutations in the internal catalytic chamber allowed
the OKS to produce a dodecaketide (C24) chain [1]. The formation of longer chains
from type III PKSs may be possible to achieve through further protein engineering
of the OKS or other type III PKSs, as well as investigation of natural sources for
new type III PKSs. If the platform was able to create longer polyketide chains than
the current C16 length, the product range would enter into some very interesting
compounds of pharmaceutical importance. e.g. tetracyclines [2].
Another strong improvement of the platform would be to investigate other cy-
clases. The current C7-C12 cyclase gra-orf4 was not very efficient and much of the
produced polyketide ended up as the shunt products SEK4b and dSEK4b. This
issue could be alleviated by testing other C7-C12 promoting cyclases. An initial
test would be ZhuI, which was implemented in the flavokermesic acid producing
strain in manuscript II, as ZhuI improved the C7-C12 percentage from ∼30% to
∼70% compared to the ∼48% to ∼54% improvement by gra-orf4 in manuscript
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I. This highlights that the performance of cyclase enzymes varies substantially.
Therefore, the next step to develop the platform would be to test other cyclases
promoting the C7-C12 or C9-C14 folding pattern, and benchmark these against
the already tested cyclases. With the first ring folding being well established, fur-
ther ring formations could also be cyclase catalyzed by implementation of more
cyclases, as exemplified in manuscript II. The number of possible folding patterns
rise substantially when directing more ring formations and the number of possible
compounds would likewise increase. Finally, it would be important to test sub-
strate specificity and limitation of the individual cyclases as different cyclases may
not be able to catalyze folding of the same polyketide chain length.
When comparing the performance of OKS expressed alone in manuscript I and
manuscript II, the level of produced metabolites and the percentages of the differ-
ent folding patterns differ, with manuscript I and II having a C7-C12% of ∼48%
and ∼35% respectively. Furthermore, standalone expression of OKS in manuscript
II produced flavokermesic acid, while this was not found in detectable amounts in
manuscript I. To offer an explanation for this it is important to take the differ-
ence in expression strategies of the two studies into consideration. In manuscript
I the OKS was expressed on a 2µ high copy plasmid, which ensured a high level of
expression, while expression in manuscript II was by integration into the genome
of S. cerevisiae, which has lower expression levels [3]. Furthermore, the cultiva-
tion medium in manuscript I was the minimal medium synthetic complete, while
the cultivation medium in manuscript II was the complex medium YPD, which
changes the metabolic state of yeast [4]. The discrepancies in OKS performance
can therefore be attributed to different levels of OKS enzyme being formed and
the metabolic state of the yeast cells in the different media. The 2µ plasmid is a
good tool for discovery as it offers high gene expression while it is not applicable
for an industrial cell factory. For cell factory design integration into the genome
is more applicable and other methods such as integration of multiple copies of the
heterologous gene or genes can be used for increasing gene expression [5].
Chapter 4 - Manuscript II applied the principle of the platform to produce
a polyketide product of interest, flavokermesic acid which is a precursor to the
industrial pigment carminic acid. The artificial biosynthetic pathway for flavoker-
mesic acid production had previously been expressed in Nicotiana benthamiana [6]
and Aspergillus nidulans [7]. Furthermore, the three involved enzymes were fused
in all possible configurations in an attempt to improve production of the pathway.
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However, it was found that the highest production of flavokermesic acid was from
the strain expressing the three enzymes as non-fused proteins yielding 52 mg fla-
vokermesic acid per liter of culture. This showed that the fusion method applied
here was not appropriate for the given pathway. This finding was attributed to
the fact that the biosynthetic enzymes are likely homodimers. Alternative design
of linkers with them being longer and/or less flexible to create distance between
the biosynthetic enzymes could be tested [8, 9], while An alternative method to
bring biosynthetic enzymes in close vicinity could be enzyme scaffolding [10, 11].
The utilization of scaffolds and peptide ligands instead of translational enzyme
fusion to bring biosynthetic pathway enzymes in close vicinity could alleviate the
issues with enzymes being unable to form dimers and allow dimers to form. This
method of scaffolding could also give a better understanding of the correct ratio
between enzymes needed for optimal production of a desired product [10].
Another factor to optimize for increased flavokermesic acid production would
be expression of biosynthetic enzymes in a yeast strain that has been optimized
for production of polyketides. Many steps can be taken towards improving a
S. cerevisiae strain for production of polyketides. This could be increasing the
cytosolic pool of malonyl-CoA to improve substrate availability for polyketide
production [12, 13, 14], considering compartmentalisation [15, 16] or amplification
of the pathway [5], and fine tuning of enzymatic levels to maximize output of the
biosynthetic pathway [3, 17, 18].
Two more biosynthetic steps are needed to convert flavokermesic acid to carminic
acid. One being the specific oxidation and another being glycosylation. The latter
of the two reactions has been found to be catalyzed by UGT2 from Dactylopius
coccus, while a P450 monooxygenase able to catalyze the oxidation is currently
unknown. Kermesic acid and carminic acid both having the needed oxidation was
detected in A. nidulans when OKS, ZhuI, ZhuJ and UGT2 were co-expressed, indi-
cating that the oxidation was carried out by an A. nidulans endogenous monooxy-
ganse [7]. If a suitable monooxygenase was found and co-expressed with the biosyn-
thetic enzymes it may be possible to produce carminic acid in S. cerevisiae.
Chapter 5 - Manuscript III investigated the biosynthetic gene cluster pgl1,
which is widely distributed in the fungal genus Fusarium. Furthermore, previ-
ously isolated and described compounds assumed to originate from the common
pgl1 biosynthetic gene cluster, were put into one biosynthetic context named a
metabiosynthetic pathway. The biosynthetic gene cluster was present in all but
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four species complexes of the Fusarium genus, which is in contrast to previous
studies, which found it in all investigated species [19, 20]. The species contain-
ing the cluster all had the previously identified genes present with high homology
between the genes while the topology of the cluster was less conserved across the
genus.
To fully understand the biosynthesis of pgl1 biosynthetic gene cluster derived
metabolites further studies are needed, as some of the proposed biosynthetic steps
could not be linked to the current pgl1 biosynthetic gene cluster. The next steps
to gain insight on this would be to investigate species from the solani species
complex as these have been a rich source for isolation of the pgl1 biosynthetic
cluster derived compounds [21].
If the chemical diversity from the pgl1 biosynthetic gene cluster is produced
mostly from the current recognized genes, the pgl1 metabiosynthetic pathway
serves as an example of how few enzymes can bring about very high levels of
chemodiversity. This is hypothesized to occur because the enzymes are promiscu-
ous in their substrate and reaction specificity. The concept of having one pathway
producing many different compounds can be an advantage over producing one or
few compounds, as chemodiversity also lead to diversity in bioactivity, and thus
likely a competitive advantage for the producing organism [22].
The chemodiversity originating from few biosynthetic enzymes as described
in manuscript III can also be used in the context of the platform in manuscript
I. The chemodiversity from relatively few enzymes can be utilized to create a
broad array of compounds. If the platform was to be used for drug development
it would be desirable to be able to produce a wide array of compounds in the
sense of development of novel bioactivities. Here the promiscuity of the enzymes
would be a positive trait [23]. On the other hand, this would be undesirable if the
platform was to be utilized to create cell factories. For creation of a cell factory to
produce one or very few products the involved enzymes have to be very specific and
efficient [24]. The specificity of enzymes can be increased by enzyme engineering
or directed evolution strategies [25]. With that being said it may be more giving
to search for enzymes with higher specificity than utilizing the genes found in the
pgl1 biosynthetic gene cluster for creation of a cell factory.
Overall, the results presented in this thesis presents an approach to produce
polyketides in a programmable fashion. The potential of the platform needs further
work to be fully developed with longer polyketide chains being produced and
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further direction of the folding of the polyketide backbone. Furthermore, the
incorporation of tailoring enzymes to carry out specific reductions, oxidations,
methylations, glycosylations et al. would vastly expand the chemodiversity, which
the platform would be able to produce.
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7 Appendices
7.1 Appendix – Manuscript I
Table S3.1 List of Primers used in this study.
Name Sequence Purpose
Sc_Gh_2-PS-F ATCAACGGGUAAAAATGGG
TTCCTACTCTTCTGATGAT
GTTG
Amplification of Gh2PS for
USER cloning
Sc_Gh_2-PS-R CGTGCGAUTTAGTTACCAT
TAGCAACAGCAGCAGTAAC
TC
Sc_Aa_PCS-F ATCAACGGGUAAAAATGTC
CTCCTTGTCTAATTCCTTG
C
Amplification of AaPCS for
USER cloning
Sc_Aa_PCS-R CGTGCGAUTTACATCAAAG
GCAAAGAATGCA
Sc_DluHKS-F ATCAACGGGUAAAAATGGC
TTTCGTTGAAGGTATGGGT
Amplification of DluHKS for
USER cloning
Sc_DluHKS-R CGTGCGAUTTAGTTGTTGA
TTGGGAAGGATCTCAAGA
Sc_AaPKS3-F ATCAACGGGUAAAAATGGG
TTCCTTGTCTGATTCTACT
CCA
Amplification of AaPKS3 for
USER cloning
Sc_AaPKS3-R CGTGCGAUTTAGACTGGTG
GCAAAGAATGCAACA
Sc_ZhuI-F AGCGATACGUAAAAATGAG
ACACGTTGAACACACAGTT
ACCG
Amplification of ZhuI for
USER cloning
Sc_ZhuI-R CACGCGAUTTATTATGCAG
TTACGGTACCAACACCAC
Sc_pdmD-F AGCGATACGUAAAAATGAC
TCAATGGAGAACCGATTCC
Amplification of pdmD for
USER cloning
Sc_pdmD-R CACGCGAUTTATCTAGCAC
CTCTAGCAGCTCTTTCAA
Sc_gra-orf4-F AGCGATACGUAAAAATGGC
TAGAACTGCTGCTTTGC
Amplification of gra-orf4 for
USER cloning
Sc_gra-orf4-R CACGCGAUTTAACCTGCTT
CAGCAGCTTCAGC
L1-pBOSAL1 FW AGACTTCGUCCTCGTGATA
CGCCTATTTTTATAG
Amplification of pBOSAL1
vector for USER cloning
L2-pBOSAL1 RV AGTAGACTUCCCGGGAATT
GCCATGAAG
L2-pKl.LEU2 FW AAGTCTACUAGCTCGCTGT
GAAGATCC
Amplification of KlLEU2 for
USER cloning
L1-tKl.LEU2 RV ACGAAGTCUGATCCGCAGG
CTAACCGG
pBOSAL1-LEU2 SQ FW GCTTGAGAAGGTTTTGGGA
C
Sequencing of pBOSAL1-
LEU2 vector
pBOSAL1-LEU2 SQ RV TTGGATTAGTCTCATCCTT
CAATG
AaOKS FW ATCAACGGGUAAAAATGAG
TAGTTTATCAAATGCCAGT
CAC
Amplification of AaOKS for
USER cloning
AaOKS RV CGTGCGAUTTACATCAATG
GCAAGGAATGCAATAAG
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pTEF1 F CACGCGAUCCACACACCAT
AGCTTCAAAATG
Amplification of PTEF1 for
USER cloning
pTEF1 R ACCCGTTGAUTTGTAATTA
AAACTTAGATTAGATTGCT
ATGC
pPGK1 F CACGCGAUAAGTACCTTCA
AAGAATGGG
Amplification of PPGK1 for
USER cloning
pPGK1 R ACCCGTTGAUTGTTTTATA
TTTGTTGTAAAAAGTAGAT
AATTAC
PGK1-R ATCATCAAGGAAGTAATTA
TCT
Colony PCR / sequencing
ADH1-F CATAAATCATAAGAAATTC
GCT
TEF1_F ACTTTTTTTACTTCTTGCT
CAT
CYC1-R2 GGACCTAGACTTCAGGTT
XI-2-up-out-sq CAATATCAGTGTGGT GAAC Colony PCR
C1_ADH1_F CTTGAGTAACTCTTTCCTG
TAGGTC
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Figure S3.1 MS and UV spectra of tentatively identified compounds from heterologous expres-
sion of type III PKSs.
MS (ESI−) and UV spectra of triacetic acid lactone (1).
MS (ESI−) and UV spectra of 5,7-dihydroxy-2-methylchromone (3).
MS (ESI−) and UV spectra of 6-(2’,4’-dihydroxy-6’-methylphenyl)-4-hydroxy-2-pyrone (2).
MS (ESI−) and UV spectrum of TW93a (4).
MS (ESI−) and UV spectra of aloesone (5).
MS (ESI−) and UV spectra of UWM1 (11).
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Figure S3.2 UV and MS spectra of SEK4 (6).
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Figure S3.3 UV and MS spectra of SEK4b (7).
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Figure S3.4 UV and MS spectra of dSEK4b (8).
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Figure S3.5 UV and MS spectra of dSEK4 (9).
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Table S3.2 The measured final OD 600 and area under peak for each of the cultivations of
diploid strains.
Enzymes OD SEK4 SEK4b dSEK4b dSEK4 UWM1
AaOKS 1 9,92 4,77E+06 5,13E+06 2,75E+06 2,75E+06 1,47E+05
AaOKS 2 9,8 3,72E+06 3,89E+06 1,63E+06 1,86E+06 1,08E+05
AaOKS 3 9,88 5,02E+06 5,90E+06 3,19E+06 2,66E+06 2,32E+05
AaOKS + Gra-orf4 1 8,72 2,47E+06 1,96E+06 1,18E+06 1,37E+06 1,67E+04
AaOKS + Gra-orf4 2 7,92 2,58E+06 2,18E+06 1,13E+06 1,23E+06 1,44E+04
AaOKS + Gra-orf4 3 8,84 2,95E+06 2,42E+06 1,53E+06 1,66E+06 1,04E+04
AaOKS + PdmD 1 9,56 2,59E+06 3,11E+06 1,42E+06 1,51E+06 2,97E+06
AaOKS + PdmD 2 11,44 4,18E+06 5,26E+06 2,75E+06 2,57E+06 4,08E+06
AaOKS + PdmD 3 10,2 4,15E+06 5,34E+06 2,81E+06 2,60E+06 3,82E+06
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7.2 Appendix – Manuscript II
Table S4.1 List of Primers used and constructed in this study.
Name Sequence Purpose
TEF1-F CGTGCGAUGCACACACCATAGCTTCAAAATGTT Amplification of PTEF1
and PPGK1 for USER
cloning
TEF1-R ATGACAGAUGTGAGTCGTATTACGGATCCTTG
PGK1-R AGTGCAGGUAAAAATGTCCGGTAG
OKS-B-F ATCTGTCAUAAAAATGAGTAGTTTATCAAATGCC
AGTC
Amplification of OKS in
first position for USER
cloningOKS-B-R ACCACCUGAACCCATCAATGGCAAGGAATGC
OKS-M-F AGGTGGUGGTGGTTCTATGAGTAGTTTATCAAAT
GCCAGTC
Amplification of OKS in
second position for USER
cloningOKS-M-R AGAACCUGAACCACCCATCAATGGCAAGGAATGC
OKS-E-F AGGTTCUGCTGGTATGAGTAGTTTATCAAATGCC
AGTC
Amplification of OKS in
third position for USER
cloningOKS-E-R CACGCGAUTCACATCAATGGCAAGGAATGC
L1-OKS-F ATCTGTCAUAAAAATGGGTTCAGGTGGTGGTGGT
TCTATGAGTAGTTTATCAAATGCCAGTC
Amplification of OKS with
L1 linker for USER cloning
OKS-L1-R CACGCGAUTCAAGAACCACCACCACCTGAACCCA
TCAATGGCAAGGAATGC
L2-OKS-F ATCTGTCAUAAAAATGGGTGGTTCAGGTTCTGCT
GGTATGAGTAGTTTATCAAATGCCAGTC
Amplification of OKS with
L2 linker for USER cloning
OKS-L2-R CACGCGAUTCAACCAGCAGAACCTGAACCACCCA
TCAATGGCAAGGAATGC
ZhuI-B-F ATCTGTCAUAAAAATGAGACACGTTGAACACACA
GTTA
Amplification of ZhuI in
first position for USER
cloningZhuI-B-R ACCACCUGAACCTGCAGTTACGGTACCAACACCA
ZhuI-M-F AGGTGGUGGTGGTTCTATGAGACACGTTGAACAC
ACAGTTA
Amplification of ZhuI in
second position for USER
cloningZhuI-M-R AGAACCUGAACCACCTGCAGTTACGGTACCAACA
CCA
ZhuJ-M-F AGGTGGUGGTGGTTCTATGTCCGGTAGAAAGACC
TTTTTAG
Amplification of ZhuI in
third position for USER
cloningZhuI-E-R CACGCGAUTCATGCAGTTACGGTACCAACACCA
ZhuJ-B-F ATCTGTCAUAAAAATGTCCGGTAGAAAGACCTTT
TTAG
Amplification of ZhuJ in
first position for USER
cloningZhuJ-B-R ACCACCUGAACCATCTTCTTCTTCTTGTTCGAAA
ACAGC
ZhuJ-M-F AGGTGGUGGTGGTTCTATGTCCGGTAGAAAGACC
TTTTTAG
Amplification of ZhuJ in
second position for USER
cloningZhuJ-M-R AGAACCUGAACCACCATCTTCTTCTTCTTGTTCG
AAAACAGC
ZhuJ-E-F AGGTTCUGCTGGTATGTCCGGTAGAAAGACCTTT
TTAG
Amplification of ZhuJ in
third position for USER
cloningZhuJ-E-R CACGCGAUTCAATCTTCTTCTTCTTGTTCGAAAA
CAGC
ZhuJ-PGK-F AGTGCAGGUAAAAATGTCCGGTAG Amplification of ZhuJ with
the PKG1 promoter
position for USER cloning
ZhuJ-PGK-R CGTGCGAUTCATGCAGTTACGGTACCAACACCA
Val-OKS-Fw CTTGCGGTGTCGATATGCCT
Colony PCR / sequencing
Val-OKS-Rv AGGCATATCGACACCGCAAG
Val-ZhuI-Fw TAGGTCATATGTCTGGTGAATGGAG
Val-ZhuI-Rv CTCCATTCACCAGACATATGACCTA
Val-ZhuJ-Fw GTTACGGTCCTGGTGTTAGATTG
Val-ZhuJ-Rv CAATCTAACACCAGGACCGTAAC
ADH1-sq-F CATAAATCATAAGAAATTCGCT
CYC1-sq-R GGACCTAGACTTCAGGTT
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Table S4.2 List of vectors and S. cerevisiae strains used and constructed in this study. All
vectors carry the Kl.URA3 selectable marker, and all strains except the starting CEN.PK 113-
5B strain are uracil prototroph.
Name Description Source
pX-3 X-3 [1]
pXI-2 XI-2 [1]
pFusP01 X-3::PTEF1-OKS This study
pFusP02 X-3::PTEF1-OKS-L1 This study
pFusP03 X-3::PTEF1-L1-OKS This study
pFusP04 X-3::PTEF1-OKS-L2 This study
pFusP05 X-3::PTEF1-L2-OKS This study
pFusP06 XI-2::PTEF1-ZhuI This study
pFusP07 XI-2::PTEF1-ZhuJ This study
pFusP08 XI-2::PPGK1ZhuJ;PTEF1-ZhuI This study
pFusP09 X-3::PTEF1-OKS-L1-ZhuI This study
pFusP10 X-3::PTEF1-ZhuI-L1-OKS This study
pFusP11 X-3::PTEF1-OKS-L2-ZhuI This study
pFusP12 X-3::PTEF1-ZhuI-L2-OKS This study
pFusP13 X-3::PTEF1-OKS-L1-ZhuJ This study
pFusP14 X-3::PTEF1-ZhuJ-L1-OKS This study
pFusP15 X-3::PTEF1-OKS-L2-ZhuJ This study
pFusP16 X-3::PTEF1-ZhuJ-L2-OKS This study
pFusP17 XI-2::PTEF1-ZhuI-L1-ZhuJ This study
pFusP18 XI-2::PTEF1-ZhuI-L2-ZhuJ This study
pFusP19 XI-2::PTEF1-ZhuJ-L1-ZhuI This study
pFusP20 XI-2::PTEF1-ZhuJ-L2-ZhuI This study
pFusP21 X-3::PTEF1-OKS-L1-ZhuI-L2-ZhuJ This study
pFusP22 X-3::PTEF1-OKS-L1-ZhuJ-L2-ZhuI This study
pFusP23 X-3::PTEF1-ZhuI-L1-OKS-L2-ZhuJ This study
pFusP24 X-3::PTEF1-ZhuJ-L1-OKS-L2-ZhuI This study
pFusP25 X-3::PTEF1-ZhuI-L1-ZhuJ-L2-OKS This study
pFusP26 X-3::PTEF1-ZhuJ-L1-ZhuI-L2-OKS This study
pFusP27 XI-2::PTEF1-L1-ZhuI This study
pFusP28 XI-2::PTEF1-ZhuI-L1 This study
pFusP29 XI-2::PTEF1-L2-ZhuI This study
pFusP30 XI-2::PTEF1-ZhuI-L2 This study
pFusP31 XI-2::PTEF1-L1-ZhuI-L2 This study
pFusP32 XI-2::PTEF1-L1-ZhuJ This study
pFusP33 XI-2::PTEF1-ZhuJ-L1 This study
pFusP34 XI-2::PTEF1-L2-ZhuJ This study
pFusP35 XI-2::PTEF1-ZhuJ-L2 This study
pFusP36 XI-2::PTEF1-L1-ZhuJ-L2 This study
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Table S4.3 List of S. cerevisiae strains used and constructed in this study. All strains except
the starting CEN.PK 113-5B strain were uracil prototroph. The Kl.URA3 marker was in X-3 if
only one insertion was done or in XI-2 if two gene insertions were done. All strains are derived
from the CEN.PK 113-5B.
Name Genotype Reference
Strains expressing OKS only
CEN.PK 113-5B MATa MAL2-8c SUC2 ura3-52 [2]
FusP-SC01 X-3::PTEF1-OKS This study
FusP-SC02 X-3::PTEF1-OKS-L1 This study
FusP-SC03 X-3::PTEF1-L1-OKS This study
FusP-SC04 X-3::PTEF1-OKS-L2 This study
FusP-SC05 X-3::PTEF1-L2-OKS This study
FusP-SC06 X-3::PTEF1-OKS XI-2::(Empty) This study
Strains expressing OKS and one cyclase
FusP-Sc07 X-3::OKS, XI-2::ZhuI This study
FusP-Sc08 X-3::OKS, XI-2::L1-ZhuI This study
FusP-Sc09 X-3::OKS, XI-2::ZhuI-L1 This study
FusP-Sc10 X-3::OKS, XI-2::L2-ZhuI This study
FusP-Sc11 X-3::OKS, XI-2::L1-ZhuI-L2 This study
FusP-Sc12 X-3::OKS-L1-ZhuI This study
FusP-Sc13 X-3::ZhuI-L1-OKS This study
FusP-Sc14 X-3::OKS-L2-ZhuI This study
FusP-Sc15 X-3::ZhuI-L2-OKS This study
FusP-Sc16 X-3::OKS, XI-2::ZhuJ This study
FusP-Sc17 X-3::OKS, XI-2::L1-ZhuJ This study
FusP-Sc18 X-3::OKS, XI-2::ZhuJ-L1 This study
FusP-Sc19 X-3::OKS, XI-2::L2-ZhuJ This study
FusP-Sc20 X-3::OKS, XI-2::L1-ZhuJ-L2 This study
FusP-Sc21 X-3::OKS-L1-ZhuJ This study
FusP-Sc22 X-3::ZhuJ-L1-OKS This study
FusP-Sc23 X-3::OKS-L2-ZhuJ This study
FusP-Sc24 X-3::ZhuJ-L2-OKS This study
Strains expressing OKS and two cyclases
FusP-SC25 X-3::PTEF1-OKS XI-2::PPGK1-ZhuJ;PTEF1-ZhuI This study
FusP-SC26 X-3::PTEF1-OKS XI-2::PTEF1-ZhuI-L1-ZhuJ This study
FusP-SC27 X-3::PTEF1-OKS XI-2::PTEF1-ZhuI-L2-ZhuJ This study
FusP-SC28 X-3::PTEF1-OKS XI-2::PTEF1-ZhuJ-L1-ZhuI This study
FusP-SC29 X-3::PTEF1-OKS XI-2::PTEF1-ZhuJ-L2-ZhuI This study
FusP-SC30 X-3::PTEF1-OKS-L1-ZhuI XI-2::PTEF1-ZhuJ This study
FusP-SC31 X-3::PTEF1-ZhuI-L1-OKS XI-2::PTEF1-ZhuJ This study
FusP-SC32 X-3::PTEF1-OKS-L2-ZhuI XI-2::PTEF1-ZhuJ This study
FusP-SC33 X-3::PTEF1-ZhuI-L2-OKS XI-2::PTEF1-ZhuJ This study
FusP-SC34 X-3::PTEF1-OKS-L1-ZhuJ XI-2::PTEF1-ZhuI This study
FusP-SC35 X-3::PTEF1-ZhuJ-L1-OKS XI-2::PTEF1-ZhuI This study
FusP-SC36 X-3::PTEF1-OKS-L2-ZhuJ XI-2::PTEF1-ZhuI This study
FusP-SC37 X-3::PTEF1-ZhuJ-L2-OKS XI-2::PTEF1-ZhuI This study
FusP-SC38 X-3::PTEF1-OKS-L1-ZhuI-L2-ZhuJ This study
FusP-SC39 X-3::PTEF1-OKS-L1-ZhuJ-L2-ZhuI This study
FusP-SC40 X-3::PTEF1-ZhuI-L1-OKS-L2-ZhuJ This study
FusP-SC41 X-3::PTEF1-ZhuJ-L1-OKS-L2-ZhuI This study
FusP-SC42 X-3::PTEF1-ZhuI-L1-ZhuJ-L2-OKS This study
FusP-SC43 X-3::PTEF1-ZhuJ-L1-ZhuI-L2-OKS This study
Strains not expressing OKS
FusP-SC44 XI-2::PTEF1-ZhuI This study
FusP-SC45 XI-2::PTEF1-ZhuJ This study
FusP-SC46 XI-2::PPGK1ZhuJ-PTEF1-ZhuI This study
FusP-SC47 X-3::(Empty) XI-2::PTEF1-ZhuI This study
FusP-SC48 X-3::(Empty) XI-2::PTEF1-ZhuJ This study
FusP-SC49 X-3::(Empty) XI-2::PPGK1ZhuJ/PTEF1-ZhuI This study
FusP-SC50 XI-2::PTEF1-L1-ZhuI This study
FusP-SC51 XI-2::PTEF1-ZhuI-L1 This study
FusP-SC52 XI-2::PTEF1-L2-ZhuI This study
FusP-SC53 XI-2::PTEF1-L1-ZhuI-L2 This study
FusP-SC54 XI-2::PTEF1-L1-ZhuJ This study
FusP-SC55 XI-2::PTEF1-ZhuJ-L1 This study
FusP-SC56 XI-2::PTEF1-L2-ZhuJ This study
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FusP-SC57 XI-2::PTEF1-L1-ZhuJ-L2 This study
FusP-SC58 X-3::(Empty) This study
FusP-SC59 XI-2::(Empty) This study
FusP-SC60 X-3::(Empty) XI-2::(Empty) This study
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Table S4.4 Averages of final OD600 of cultivations of strains expressing genetic constructs. The
standard deviations are given in parenthesis.
Strain Avg. OD600 (St. Dev)
FusP-Sc01 - WPavg 9.75 (0.47)
FusP-Sc02 9.53 (0.93)
FusP-Sc03 9.67 (0.18)
FusP-Sc04 9.63 (0.39)
FusP-Sc05 10.45 (1.55)
FusP-Sc06 9.32 (0.2)
FusP-Sc07 9.56 (0.35)
FusP-Sc08 9.41 (0.31)
FusP-Sc09 9.08 (0.89)
FusP-Sc10 9.12 (0.08)
FusP-Sc11 8.97 (0.12)
FusP-Sc12 8.83 (0.36)
FusP-Sc13 10.31 (0.12)
FusP-Sc14 10.24 (0.47)
FusP-Sc15 10.25 (0.29)
FusP-Sc16 10.52 (0.18)
FusP-Sc17 9.75 (0.41)
FusP-Sc18 8.4 (0.47)
FusP-Sc19 9.88 (0.11)
FusP-Sc20 9.73 (0.23)
FusP-Sc21 9.57 (0.22)
FusP-Sc22 9.83 (0.06)
FusP-Sc23 9.43 (0.59)
FusP-Sc24 10.27 (0.37)
FusP-Sc25 9.8 (0.07)
FusP-Sc26 9.49 (0.26)
FusP-Sc27 9.6 (0.11)
FusP-Sc28 9.52 (0.86)
FusP-Sc29 9.09 (0.38)
FusP-Sc30 9.72 (0.26)
FusP-Sc31 10.08 (0.21)
FusP-Sc32 9.32 (0.38)
FusP-Sc33 9.76 (0.52)
FusP-Sc34 9.72 (0.22)
FusP-Sc35 9.43 (0.5)
FusP-Sc36 9.63 (0.31)
FusP-Sc37 9.63 (0.37)
FusP-Sc38 9.61 (0.26)
FusP-Sc39 9.41 (0.21)
FusP-Sc40 9.75 (0.24)
FusP-Sc41 9.31 (0.18)
FusP-Sc42 10.4 (0.32)
FusP-Sc43 10.04 (0.14)
FusP-Sc44 10.19 (0.74)
FusP-Sc45 10.32 (0.35)
FusP-Sc46 7.83 (0.46)
FusP-Sc47 9.77 (0.2)
FusP-Sc48 9.59 (0.23)
FusP-Sc49 8.96 (0.07)
FusP-Sc50 6.36 (0.11)
FusP-Sc51 10.03 (0.2)
FusP-Sc52 10.36 (0.16)
FusP-Sc53 10.16 (0.08)
FusP-Sc54 10.32 (0.11)
FusP-Sc55 10.24 (0.18)
FusP-Sc56 10.29 (0.02)
FusP-Sc57 10.52 (0.08)
FusP-Sc58 10.72 (1.04)
FusP-Sc59 9.96 (0.2)
FusP-Sc60 10.16 (0.07)
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Table S4.5 The whole metabolomics dataset is available for download at:
https://files.dtu.dk/u/5NKLSHNSi0j20otL/Metabolomics%20dataset.xlsx?l
Figure S4.1 Calculated p-values when comparing the total level of quantified metabolites for
each strain. The t-test was done as a two-tailed test and assumed to be of unpaired with equal
variance type. Values highlighted in red are significant (P < 0.05).
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Figure S4.2 Calculated p-values when comparing the level of flavokermesic acid for each strain.
The t-test was done as a two-tailed test and assumed to be of unpaired with equal variance type.
Values highlighted in red are significant (P < 0.05).
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Figure S4.3 Calculated p-values when comparing the percentage of detected metabolite having
the C7-C12 folding pattern for each strain. The t-test was done as a two-tailed test and assumed
to be of unpaired with equal variance type. Values highlighted in red are significant (P < 0.05).
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Figure S4.4 Calculated p-values when comparing the percentage of all detected metabolites
being flavokermesic acid. The t-test was done as a two-tailed test and assumed to be of unpaired
with equal variance type. Values highlighted in red are significant (P < 0.05).
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Table S4.6 The whole proteomics dataset is available for download at:
https://files.dtu.dk/u/opOUcjUTlHWwk5Rx/Proteomics%20dataset.xlsx?l
The sequences added to the proteome search file:
>AaOKS
MSSLSNASHLMEDVQGIRKAQRADGTATVMAIGTAHPPHIFPQDTYADFYFRATNSEHKVELKKKFDRICKKTMIGKRYFNYDEEFLKKYPNITS
FDEPSLNDRQDICVPGVPALGAEAAVKAIAEWGRPKSEITHLVFCTSCGVDMPSADFQCAKLLGLRTNVNKYCVYMQGCYAGGTVMRYAKDLAEN
NRGARVLVVCAELTIIGLRGPNESHLDNAIGNSLFGDGAAALIVGSDPIIGVEKPMFEIVCAKQTVIPNSEDVIHLHMREAGLMFYMSKDSPETI
SNNVEACLVDVFKSVGMTPPEDWNSLFWIPHPGGRAILDQVEAKLKLRPEKFRATRTVLWDCGNMVSACVLYILDEMRRKSADEGLETYGEGLEW
GVLLGFGPGMTVETILLHSLPLM
>ZhuI
MRHVEHTVTVAAPADLVWEVLADVLGYADIFPPTEKVEILEEGQGYQVVRLHVDVAGEINTWTSRRDLDPARRVIAYRQLETAPIVGHMSGEWRA
FTLDAERTQLVLTHDFVTRAAGDDGLVAGKLTPDEAREMLEAVVERNSVADLNAVLGEAERRVRAAGGVGTVTA
> ZhuJ
MSGRKTFLDLSFATRDTPSEATPVVVDLLDHVTGATVLGLSPEDFPDGMAISNETVTLTTHTGTHMDAPLHYGPLSGGVPAKSIDQVPLEWCYGP
GVRLDVRHVPAGDGITVDHLNAALDAAEHDLAPGDIVMLWTGADALWGTREYLSTFPGLTGKGTQFLVEAGVKVIGIDAWGLDRPMAAMIEEYRR
TGDKGALWPAHVYGRTREYLQLEKLNNLGALPGATGYDISCFPVAVAGTGAGWTRVVAVFEQEEED
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Table S5.1 The AntiSMASH results are available for download at:
https://files.dtu.dk/u/qxzA2jycwNy5HMDZ/AntiSMASH_results.xlsx?l
Figure S5.1 The constructed phylogenetic tree is available for download at:
https://files.dtu.dk/u/mLoJLA86CSiKugkv/Phylogenetic_tree%28whole_dataset%29.pptx?l
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Table S5.2 List of strains in the subset used in this study. NCBI accession numbers are given
in parentheses.
NRRLa Otherb Species Geographic
origin
Source citation
2903 CBS
110244
F. austroamericanum Brazil NCAUR-MiSeq
5538 IMI 58289 F. fujikuroi Taiwan NCBI (HF679023) [3]
13374 FRC
R-5128
F. longipes New
Guinea
NCAUR-MiSeq [4]
13412 FRC Rd-
34
F. decemcellulare Dominican
Republic
NCAUR-Ion Torrent [4]
13444 - F. chlamydosporum Australia NCAUR-MiSeq [4]
20692 CBS
737.79
F. graminum Ethiopia NCAUR-MiSeq [4]
20693 CBS
720.79
F. heterosporum Netherlands NCAUR-MiSeq [4]
20956 CBS
123670
F. verticillioides USA Broad, MIPS [4]
26754 CBS
110254
F. acacia-mearnsii South
Africa
NCAUR-MiSeq This study
28387 F. commune Netherlands NCAUR-Ion Torrent
and MiSeq
[4]
31041 Li #95 F. virguliforme USA NCAUR-MiSeq [4]
31084 PH1 =
CBS
123657
F. graminearum USA Broad, MIPS [5]
34936 CBS
123668
F. oxysporum f. sp.
Lycopersici
Spain Broad, MIPS [4]
36148 CBS
109638
F. buxicola Belgium NCAUR-MiSeq [4]
45880 VanEtten
77-13-4
F. solani f. sp. pisi USA JGI [6]
53430 - F. sibiricum Russia NCAUR-MiSeq This study
54050 F. palustre USA NCAUR-MiSeq This study
54939 Fa5001 F. avenaceum Finland NCBI [4]
62612 CS3096 F. pseudogramin-
earum
Australia NCBI (NC_031954) [7]
62623 CS7071 F. culmorum Australia NCBI This study
62941 IMI
351954
Fusarium sp. Singapore NCAUR-MiSeq This study
- ET1 F. proliferatum Russia NCBI
(FJOF01000002)
[8]
a NRRL, ARS Culture Collection, Peoria, IL.
b CBS-KNAW, Centraalbureau voor Schimmelcultures—Fungal Biodiversity Center, Utrecht, Nether-
lands; FRC, Fusarium Research Center, The Pennsylvania State University, State College, PA and
IMI, CABI Biosciences, Egham, Surrey, England.
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Figure S5.2 Plot showing the identity of the different pgl2 genes from different species within
the Fusarium genus.
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Figure S5.3 Plot showing the identity of the different pgl3 genes from different species within
the Fusarium genus.
Figure S5.4 Plot showing the identity of the different pgl4 genes from different species within
the Fusarium genus.
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Figure S5.5 Plot showing the identity of the different pgl5 genes from different species within
the Fusarium genus.
Figure S5.6 Plot showing the identity of the different pgl6 genes from different species within
the Fusarium genus.
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Figure S5.7 Synteny of the genetic locus for the PGL1 cluster.
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Figure S5.8 Numbering of genes in the extra genes of species complexes buxicola, decemcellulare
and solani of investigated isolates.
Table S5.3 List of putative function for extra genes in species complexes buxicola, decemcellulare
and solani of investigated isolates. Numbering of genes are as in figure S5.8.
Gene Isolate Length
(AA)
PFAM Hit Domains Predicted func-
tion
1 F. buxicola 278 PF05572 Peptidase_M43
2 F. buxicola 250 - - -
3 F. buxicola 398 PF00891 Methyltransferase Methyltransferase
4 F. buxicola 447 PF07690 MFS transporter
5 F. buxicola 556 PF00324 AA_permease
6 F. decelcellulare 301 PF04479 RTA1 Membrane protein
7 F. decelcellulare 347 - - -
8 F. decelcellulare 786 PF00004 AAA ATPase
9 F. decelcellulare 728 PF06985 HET Heterokaryon in-
compability protein
10 F. decelcellulare 489 PF02458 Transferase Transferase
11 F. decelcellulare 510 PF00067 p450 Cytochrome P450
12 F. decelcellulare 334 PF10014 2OG-Fe_Oxy_2 Fe-dependant dioxy-
genase
13 F. decelcellulare 576 PF01053 Cys_Met_Meta_PP PLP-dependant
Cys/Met
metabolism
14 F. decelcellulare 352 PF00106 Short chain dehy-
drogenase
Short chain dehy-
drogenase
15 F. decelcellulare 460 - - -
16 F. decelcellulare 566 PF01494 FAD_binding_3 FMO
17 F. decelcellulare 544 PF00083 Sugar transporter Sugar transport
18 F. decelcellulare 343 PF00069 Pkinase Protein kinase
19 F. decelcellulare 619 - - -
20 F. decelcellulare 857 PF08407 +
PF01644
Chitin_synth_1 Chitin synthase
21 F. decelcellulare 461 PF00232 Glyco_hydro_1 Glycoside hydrolase
22 F. decelcellulare 896 PF05592 +
PF08531
Bacterial rhamnosi-
dase
Glycoside hydrolase
23 F. decelcellulare 427 PF07690 MFS transporter MFS transporter
24 F. decelcellulare 482 PF07632 DUF1593 Unknown
25 F. virguliforme 503 PF13520 AA_permease_2 Amino acid perme-
ase
26 F. virguliforme 361 - - -
27 F. virguliforme 1269 PF00445 +
PF01565
Ribonuclease_T2 +
FAD_binding_4
FAD-binding RNase
28 F. virguliforme 238 - - -
29 F. virguliforme 550 PF02129 +
PF08530
X-Pro dipeptidyl-
peptidase
Protease
30 F. virguliforme 289 PF06985 HET Heterokaryon in-
compability protein
31 F. virguliforme 458 - - -
32 F. virguliforme 564 PF06985 HET Heterokaryon in-
compability protein
33 F. virguliforme 398 - - -
34 F. virguliforme 1131 - - -
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35 F. virguliforme 832 PF13625 +
PF04851 +
PF16203
Helicase_C_3
+ ResIII +
ERCC3_RAD25_C
Helicase
36 F. virguliforme 291 - - -
37 F. virguliforme 104 - - -
38 F. virguliforme 315 PF00106 Short chain dehy-
drogenase
Short chain dehy-
drogenase
39 F. virguliforme 409 PF07690 MFS transporter MFS transporter
40 F. virguliforme 889 PF05592 +
PF08531
Bacterial rhamnosi-
dase
Glycoside hydrolase
41 F. solani 338 PF00962 Adenosine/AMP
Deaminase
Adenosine deami-
nase
42 F. solani 703 PF04082 Fungal TF Transcription factor
43 F. solani 596 PF13561 Enoyl-(Acyl carrier
protein) reductase
Enoyl reductase
44 F. solani 286 PF08240 +
PF00107
Alcohol dehydroge-
nase + Zinc binding
dehydrogenase
Dehydrogenase
45 F. solani 731 PF13561 Enoyl-(Acyl carrier
protein) reductase
Enoyl reductase
46 F. solani 538 PF00083 Sugar transporter Sugar transport
47 F. solani 342 PF13489 Methyltransferase Methyltransferase
48 F. solani 378 PF01370 Epimerase NADH dehydroge-
nase (Ubiquinone)
49 F. solani 165 - - -
50 F. solani 248 - - -
51 F. solani 550 PF02129 +
PF08530
X-Pro dipeptidyl-
peptidase
Protease
52 F. solani 667 PF04082 Fungal TF Transcription factor
53 F. solani 332 PF05544 Proline racemase Proline racemase
54 F. solani 477 PF07690 MFS transporter MFS transporter
55 F. solani 350 - - -
56 F. solani 396 PF11951 Fungal_trans_2 Fungal TF
57 F. solani 344 PF00106 Short chain dehy-
drogenase
Short chain dehy-
drogenase
58 F. solani 439 PF07690 MFS transporter MFS transporter
59 F. solani 896 PF05592 +
PF08531
Bacterial rhamnosi-
dase
Glycoside hydrolase
60 Fusarium sp.
62941
377 PF01370 Epimerase NADH dehydroge-
nase (Ubiquinone)
61 Fusarium sp.
62941
170 - - -
62 Fusarium sp.
62941
247 - - -
63 Fusarium sp.
62941
179 - - -
64 Fusarium sp.
62941
551 PF02129 +
PF08530
X-Pro dipeptidyl-
peptidase
Protease
65 Fusarium sp.
62941
660 PF04082 Fungal TF Transcription factor
66 Fusarium sp.
62941
403 PF05544 Proline racemase Proline racemase
67 Fusarium sp.
62941
850 PF07690 MFS transporter MFS transporter
68 Fusarium sp.
62941
539 PF00083 Sugar transporter Sugar transport
69 Fusarium sp.
62941
506 PF00232 Glycoside hydrolase Glycoside hydrolase
70 Fusarium sp.
62941
896 PF05592 +
PF08531
Bacterial rhamnosi-
dase
Glycoside hydrolase
71 Fusarium sp.
62941
358 - - -
72 Fusarium sp.
62941
439 PF07690 MFS transporter MFS transporter
73 Fusarium sp.
62941
345 PF00106 Short chain dehy-
drogenase
Short chain dehy-
drogenase
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